CA3217132A1 - The polarity and specificity of sars-cov2 -specific t lymphocyte responses as a biomarker of disease susceptibility - Google Patents

Abstract

The application pertains to biomarkers for assessing whether an individual is likely to resist to an infection by a SARS-CoV-2 virus or is susceptible to SARS-CoV-2.

Description

The polarity and specificity of SARS-CoV2 -specific T lymphocyte responses as a biomarker of disease susceptibility FIELD OF THE INVENTION
The present invention relates to the field of antiviral vaccination. More particularly, the invention provides immunogenic compositions for vaccination against SARS-CoV-2 and methods for in vitro determining if an individual is likely to resist to an infection by SARS-CoV-2.
BACKGROUND OF THE INVENTION
The emergence and spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus disease 2019, have resulted in devastating morbidities and socioeconomic disruption. The development of community protective immunity relies on long-term B and T cell memory responses to SARS-CoV-2. This can be achieved through viral infection [1] or by vaccination [2-4].
Reports on rapidly decreasing spike- and nucleocapsid-specific antibody titers post-COVI D-19 infection [5] or reduced neutralizing capacity of vaccine-induced antibodies against viral escape variants compared to the ancestral SARS-CoV-2 strain [6,7] have shed doubts on the importance of humoral immunity as a standalone response. In contrast, T cell immunity was identified as an important determinant of recovery and long-term protection against SARS-CoV-1, even 17 years after infection [8-11].
The TH1 versus TH2 concept suggests that modulation of the relative contribution of TH1 or TH2 cytokines regulates the balance between immune protection against microbes and immunopathology [12-14]. TH1 cells (as well as cytotoxic T cells with a similar cytokine pattern referred to as Tc1 cells) produce I FNy, IL-2, and TNFa, promote macrophage activation, antibody-dependent cell cytotoxicity, delayed type hypersensitivity, and opsonizing and complement-fixing IgG2a antibody production [12]
Therefore, TH1/Tc1 cells drive the phagocyte-dependent host response and are pivotal for antiviral responses [13,14]. In contrast, TH2 (and Tc2) cells produce IL-4, IL-5, IL-10 and IL-13, providing optimal help for both humoral responses and mucosal immunity, through the production of mast cell and eosinophil growth and differentiation factors, thus contributing to antiparasitic and allergic reactions. Naïve T cell differentiation to distinct TH fates is guided by inputs integrated from TCR affinity, 0025 expression, costimulatory molecules, and cytokines [15].
SARS-CoV-2-specific T cell immunity plays a key role during acute COVI D-19, and up to eight months after convalescence [16-20]. Indeed, functional T cell

2 responses remain increased in both frequency and intensity up to six months post-infection [5]. They are mainly directed against spike, membrane and nucleocapsid proteins, and have been studied in greater detail by single cell sequencing in a limited number of patients [21]. Memory TH 1/Tc1 T cells specific for SARS-CoV-2 and follicular T helper cells (TFH) cells have been detected in mild cases [21]. However, cases of reinfection have been reported [22], raising questions on the clinical significance of T cell polarization and peptide repertoire specificities against current viral variants. Moreover, pioneering reports suggest that, before SARS-CoV-2 became prevalent (i.e., before 2020), some individuals exhibit immune responses, mainly among CD4+ T cells, against SARS-CoV-1 nucleocapsid (NC) and ORF1a/b, or common cold coronaviruses (CCC) spike and nucleocapsid proteins that are cross-reactive with SARS-CoV-2 [9,23-25]
However, the relevance of CCC or SARS-CoV-1-specific memory T cells for effective protection against the current pandemic remains questionable [21,26]. The current study was designed to correlate T cell responses to clinical protection against COVID-19, in healthy individuals and cancer patients, who are more susceptible to severe infections, and by extension to reinfection and breakthrough infection post-vaccination.
In the Example 1 below, the inventors studied SARS-CoV-2 ¨specific T cell responses in 382 cancer-bearing or cancer-free subjects, and prospectively followed up 227 COVID-free individuals to understand which T cell polarity and peptide repertoire may convey resistance to COVI D-19. They found that a SARS-CoV-2-specific IL-2/1L-5 lymphokine ratio<1 conferred susceptibility to COVID-19 infection or reinfection in both health care workers (HCVV) and cancer patients, coinciding with defective TH1/Tc1 recognition of the receptor binding domain (RBD) of the spike protein, likely affecting viral evolution by selecting for new antigenic variants. Moreover, T
cell immunity against the S1-RBD reference strain tended to decrease with time and in cancer patients, and crossreacted to some degree with the RBD sequences of viral variants of concern.
SUMMARY OF THE INVENTION
In the Example 1 below, the inventors characterized the polarity and specificity of circulating SARS-CoV-2-specific T cell responses against whole virus lysates and 186 unique peptides derived from the SARS-CoV-1 or SARS-CoV-2 ORFeomes to determine T cell immune correlates with spontaneous (crossreactive), virus-elicited or vaccine-induced protection against COVI D-19 infection or reinfection in healthy individuals and in a more vulnerable population composed of cancer patients.
Irrespective of the presence of malignant disease, a high ratio between the prototypic T helper 1 (TH1)/ T cytotoxic type 1 (Tc1) cytokine, interleukin-2 (1L-2), and the prototypic

3 T helper 2 (TH2) cytokine, interleukin-5 (1L-5), released from SARS-CoV-2-specific memory T cells measured in early 2020, among SARS-CoV-2-negative persons, was associated with low susceptibility of these individuals to develop PCR-detectable SARS-CoV-2 infection in late 2020 or 2021. Of note, T cells from individuals who recovered after SARS-CoV-2 reinfection spontaneously produced elevated levels of IL-5 and secreted the immunosuppressive TH2 cytokine interleukin-10 in response to SARS-CoV-2 lysate, suggesting that TH2 responses to SARS-CoV-2 are maladaptive.
Moreover, individuals susceptible to SARS-CoV-2 infection, reinfection or breakthrough infection post-vaccination exhibited a selective deficit in the TH1/Tc1 peptide repertoire affecting the highly mutated receptor binding domain (RBD) amino acids (331-525) of the spike protein. The inventors thus deduced that a SARS-CoV-2-specific IL-2/1L-5 lymphokine ratio<1 conferred susceptibility to COVI D-19 infection or reinfection in both health care workers (HCVV) and cancer patients, coinciding with defective TH1/Tc1 recognition of the receptor binding domain (RBD) of the spike protein, likely affecting viral evolution by selecting for new antigenic variants.
Current vaccines triggered anti-S1-RBD specific TH1/Tc1 responses in most healthy subjects, albeit with reduced efficacy in cancer patients. T cell immunity against the S1-RBD reference strain tended to decrease with time and in cancer patients, and crossreacted to some degree with the RBD sequences of viral variants of concern.
T cell immunity against the RBD sequences of viral variants of concern was reduced in vaccinees independently of age, gender and cancer. These findings indicate that COVI D-19 protection relies on TH1/Tc1 cell immunity against SARS-CoV-2 S1-RBD, which in turn likely drives the phylogenetic escape of the virus.
The inventors then found that the most important response for being protected against a circulating strain of SARS-CoV-2 is a TH1 response against the RBD
(amino acids 331-525 of the spike protein) of said circulating strain. For example, a high TH1 response against the S1-RBD of the reference (Wuhan) strain was not only insufficient to protect against infection by the omicron strain, but it could even facilitate this infection.
The next generation of COVID-19 vaccines should elicit high-avidity TH1/Tc1 (rather than TH2)-like T cell responses against the RBD domain of current and emerging viral variants, while booster vaccinations should be guided by prior T cell assays.
According to a first aspect, the present invention thus pertains to a method for in vitro determining whether an individual is likely to resist to an infection by SARS-CoV-2, comprising:

4 (i) generating dendritic cells (DC) from monocytes obtained from said individual;
(ii) loading said DC with a SARS-CoV-2 lysate or SARS-CoV-2 antigens;
(iii) contacting peripheral blood lymphocytes (PBL) from said individual with the DC obtained in step (ii), in appropriate conditions to activate said PBL;
(iv) following the PBL activation, measuring the expression of at least one cytokine secreted by Th1 cells, selected from the group consisting of IL-2, IFkly and TNFa, and measuring the expression of at least one cytokine secreted by Th2 cells, selected from the group consisting of IL-5, IL-4, IL-9, IL-10 and IL-13; and (v) from the results of step (iv), assessing the Th1/Th2 polarization of SARS-CoV-2-specific memory T cell response in said individual, wherein a Th1 polarization indicates that the individual is likely to resist to an infection by SARS-CoV-2, and a Th2 polarization indicates that the individual is susceptible to an infection by SARS-CoV-2.
The invention also pertains to another method for in vitro determining whether an individual is likely to resist to an infection by SARS-CoV-2, comprising:
(i) incubating T lymphocytes from said individual with a mix of antigenic peptides from SARS-CoV-2, under conditions appropriate to stimulate Th1 and/or Th2 lymphocytes specific for said peptides; and (ii) assessing the presence of Th1 and/or Th2 lymphocytes;
wherein the presence of Th1 lymphocytes specific for said peptides indicates that the individual is likely to resist to an infection by SARS-CoV-2, and/or the absence of Th1 lymphocytes and/or the presence of Th2 lymphocytes specific for said peptides indicates that the individual is susceptible to an infection by SARS-CoV-2.
A method for monitoring the efficacy of a vaccination against SARS-CoV-2 in an individual, comprising performing any of the above methods with a biological sample from said individual, is also part of the present invention.
Another aspect of the invention is also the use of one of the above methods for in vitro assessing the susceptibility or resistance status of an individual after vaccination, to monitor the efficacy of a vaccination against SARS-CoV-2 in an individual or in a population.
The invention also relates to an immunogenic composition comprising, in one or several polypeptides, the epitopes present in a sequence corresponding to amino acids 331 to 525 of a SARS-CoV-2 spike protein, as well as, optionally, the epitopes present in a sequence corresponding to amino acids 1 to 165 of a SARS-CoV-2 spike protein.

A nucleic acid molecule encoding the above-defined polypeptides is also part of the invention, as well as an immunogenic composition comprising the same.
The present invention also relates to a vaccine comprising an immunogenic composition as described above, as well as a pharmaceutically acceptable

5 excipient and/or adjuvant.
Another aspect of the present invention is an immunogenic composition comprising a polypeptide comprising or consisting of the sequence LDSKVGGNY
(SEQ
ID No: 262), or a nucleic acid encoding the same, for use in the treatment of cancer.
BRIEF DESCRIPTION OF THE DRAWINGS
Fiaure Leaends Figure 1. SARS-CoV-2 TH1/Tc1 responses in COVID-19 and unexposed individuals.
A. Graphical representation of the prospective patient cohorts used for the study (refer to Table 1 to 3). B. First experimental in vitro stimulation assay of peripheral blood lymphocytes (PBL) using crosspresentation of viral lysates by autologous dendritic cells (DC). Twelve plex flow cytometric assay to monitor cytokine release in replicates.
C. Mean fold changes (Log2, F.C) between SARS-CoV-2-specific cytokine secretions of acute COVID-19 patients or convalescent COVID-19 individuals and controls (also refer to SIC). D. Ratios of cytokine secretion between PBL stimulated with DC pulsed with SARS-CoV-2 (or the other CCC lysates) versus VeroE6 (or versus CCC respective control cell lines), at the acute or convalescent phases of COVID-19. One typical example is outlined in Figure S1A of Fahrner etal., 2022 [100]. Each dot represents the mean of replicate wells for one patient (Controls, n=304; Convalescent COVID-19, n=54;
Acute COVID-19, n=24). Asterisks indicate statistically significant differences in comparison to the control group determined using two-sided Wilcoxon-Mann-Whitney test (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). E. Spearman correlations between SARS-CoV-2-specific IL-2 release and anti-NC IgG antibody titers (Controls, n=63;
Convalescent, n =16). F. Spearman correlations between SARS-CoV-2-specific IL-release and anti-NC IgG antibody titers (Controls, n=63; Convalescent, n=16).
Figure 2. Unexposed individuals susceptible to COVID-19 exhibited a SARS-CoV-2 specific TH2 profile during the first surge of the pandemic.
A-B. Upper scheme: Outline of the prospective collection of blood samples used to identify COVID-19 resistant (light grey) versus susceptible (black) cancer patients (A, upper panel, Table 1, Tables 4&5) and pie chart indicating the absolute numbers (and %) of patients reported as contact (resistant) or infected (susceptible) or unexposed (grey)

6 during one-year follow-up (B). Lower scheme: Outline of the prospective collection of blood samples used for the comparison of T cell responses in the cohort of cancer-free individuals who lived in the same household with family members tested positive for COVI D-19 during the 2020 lock down (Table 4). C. Number of positive cytokines released by SARS-CoV-2-specific PBL during the crosspresentation assay (Figure 1B) in each group (Unexposed, n=159; Resistant, n=48; Susceptible, n=22). D-E.
SARS-CoV-2-specific IL-2 (left panel) and IL-5 (right panel) secretion contrasting resistant (light grey) versus infected (black) cancer cases. Each dot represents the ratio (D) of the replicate wells in one individual and the box plots indicate medians, 25th and 75th percentiles for each cancer patient subset. The bar plots (E) represent the percentage of positive patients (resist., n=41; suscept., n=19). Fisher exact test to compare the number of cytokine positive patients across groups (*p<0.05). F. SARS-CoV-2-specific IL-2/1L-5 ratios (means+SEM) in the different subsets of healthy and cancer individuals presented in panel A. Refer to Figure 7 for the waterfall plots to visualize variations in the percentages of individuals with IL-2/IL-5 ratios > or < 1 according to subject category.
All group comparisons were performed using two-sided Wilcoxon-Mann-Whitney test and asterisks indicate statistically significant differences. G. CCC (0C43 and 229E)-specific IL-2 ratio (left panel) or IL-5 secretion ratio (right panel) contrasting contact (resistant, light grey dots, n=34) versus infected (susceptible, black dots, n=11) cases.
H. Spearman correlations between 0C43 and SARS-CoV-2-specific IL-2 (left panel) and IL-5 (right panel) secretions in 156 controls. I. Anti-spike IgG titers (means+SEM) specific of seasonal betacoronaviruses in contact (resist., light grey dots, n=34) versus infected (suscept., black dots, n=11) cases. J-K. SARS-CoV-2-specific T cell reactivity monitored by IL-5 and IFNy-ELISA (J) or IFNy ELISpot (K) before and after Dupilumab in 9 patients diagnosed with atopic dermatitis. Each line represents the mean of two experimental replicates that are shown for n=3 samples before Dupilumab, and for n=7 samples after Dupilumab, including 7/9 in COVID-19 convalescence, only one patient had paired samples pre- and post-Dupilumab. Wilcoxon signed rank test for paired comparisons of clustered data (J) or linear mixed model (K) were used to compare experimental groups.
L. Scheme detailing the two groups of cancer-free individuals from the same hospital with opposite clinical phenotypes (multi-exposed individuals (n=12) versus patients reinfected with SARS-CoV-2 (n=17) patients) (K, left panel). Results of the crosspresentation assay against SARS-CoV-2 for IL-10 (K, right panel) and IL-2. IL-5 levels at baseline and after TCR cross-linking are depicted in the middle panel. Each dot represents the mean of two replicates for one patient. All group comparisons were performed using two-sided Wilcoxon-Mann-VVhitney test and asterisks indicate statistically significant differences (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).

7 Figure 3. Peptide recognition patterns in all distinct subsets of individuals:

repertoire breadth of peptide does not predict resistance to COVID-19.
A. Experimental setting for the 185 peptide-based in vitro stimulation assays.
B-C.
Percentages of positive peptides in individuals from the pre-COVI D19 era (n=24) versus contemporary controls (n=97) (B, right panel) and in cancer (n=111) versus cancer free contemporary individuals (n=10) (B, left panel) and in uninfected (control (contemporary), n=97) versus convalescent (recovery, n=27) (C, left panel) and resistant individuals (non-infected contact cases (n=44) versus susceptible (infected, n=18) individuals (C, right panel). Group comparisons were performed using two-sided VVilcoxon-Mann-Whitney test and asterisks indicate statistically significant differences (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).
Figure 4. Spike Receptor Binding Domain (S1-RBD)-directed TH1/Tc1 recall responses predict resistance to COVID-19.
A.Volcano plot showing statistical significance (p values) and magnitude of change in odd ratios of IFNy secretion in response to SARS-CoV-1 (sarbecovirus) and SARS-CoV-2 peptides belonging to distinct viral proteins (each scatterplot) between susceptible versus resistant individuals. B-D. Percentages of patients recognizing at least one of the 11 S1-RBD peptides in the I FNy ELISA of the peptide IVS assay across patients' groups described in Figure 2A (B) or convalescent versus reinfected patients (C) or vaccinees experiencing breakthrough infection (D). E. Percentages and absolute numbers of mutations contained in our S1-RBD peptide list reported in the current SARS-CoV-2 variants (refer to Table S12 of Fahrner et al , 2022). The difference of the probability of mutation in S1-RBD region and in other regions was evaluated using logistic regression (Odd Ratio=0.21, 95% confidence interval [0.06; 0.68], p=0.01). F, H. High-throughput screening T cell assay using the Enzyme Linked Fluorescent Assay technique in an automatic platform monitoring IFNy levels in whole blood samples from several independent cohorts of HCW (F) or cancer patients (H) with or without COVID-19 history (F), pre- and/or per (after 1 immunization, Day 21) and/or post vaccination (Day 90, Day 180) using different peptide pools (Table 12,). Monitoring of IFNy release (F, H lower panels) and percentages of individuals with I FNy levels > threshold of detection (upper panels). G. Influence of covariates (refer to Subtables S13a and S13b of Fahrner et al., 2022 for statistics). Specimen were not systematically paired in the kinetic study. The log10 normalized IFNy secretions for all peptide stimulation were pooled to model simultaneously their dynamics from the first vaccine to day 180 using linear mixed effect regression adjusted for the patient age, sex, cancer status, COVID history, and vaccine schedule (cf statistical method section for more details). The Forest plot depicts the impact of the different variables on the PEPwtRBD IFNy secretion levels (a positive or

8 negative coefficient indicating increase or decrease of IFNy !Wm!
respectively) (G).
I. Paired analysis of the differential magnitude of TH1/Tc1 reactivity against PEPwtRBD
versus PEPmutReD in 343 cancer-free HCW vaccinees with no history of COVI D-19. Each line represents one patient sample. Group comparisons were performed using two-sided paired Wlcoxon-Mann-Whitney test and asterisks indicate statistically significant differences (*p<0.05, **p<0.01, "p<0.001, ****p<0.0001).
Figure 5. Detailed SARS-CoV-2 and CCC-specific cytokine release for convalescent COVID-19 patients compared with unexposed individuals.
A. Percentage and number of patients in each cohort (Pre-COVI D19 era (yes (+)/no(-)), Cancer (yes (+)/no(-) and COVID-19 (yes (+)/no(-)) who had a SARS-CoV-2-specific cytokine release (for the 5 statistically significant cytokines at the convalescent phase) compared with VeroE6 (Control, n=304; Convalescent, n=54). B-C. ldem as in Figure 1D comparing frequencies of patients with CoV-2NeroE6 ratios>2 for the most relevant cytokines in cancer versus cancer-free control individuals, taking into account cancer staging (C). Asterisks indicate statistically significant differences of SARS-CoV-2-specific cytokine release proportions between two groups determined using Fisher exact test (*p<0.05).
Figure 6. TH1/Tc1 differentiation patterns in susceptible versus resistant individuals.
A-B. Unsupervised hierarchical clustering of SARS-CoV-2-specific cytokine release.
Heatmap of cytokine release in the crosspresentation assay performed during the first surge of the pandemic in unexposed individuals (n=60), aligning cytokines in the two subject categories, susceptible (persons who got infected during the second or the third surge of the pandemic) versus resistant (contact) individuals. Group comparisons were performed using a two-sided VVilcoxon-Mann-Whitney test. C. Dynamic study of the stability of the TH1/TH2 profile in individuals that were followed up at two time points.
Ratio of cytokine release at the acute and convalescent phase (left panel) and corresponding IL-2/IL-5 ratio (right panel) in 5 cancer patients. Two-sided VVilcoxon-Mann-Whitney test did not reveal significant difference between both time points.
D. Validation cohort of 2A with 8 additional HCW from Hospices Civils de Lyon (HCL) and 10 cancer patients from Gustave Roussy (D). E. Percentages of SARS-CoV-2 specific TH1 or TH2 cell responses determined by dual Elispot assay (CoV2/VeroE6 >1.5 increase in I FNr(left) or IL-5 (middle) SFC respectively). Calculation of the IFNy+
/IL-5+ SFC ratio per individual in VeroE6 or SARS-CoV-2 condition, and percentages of patients with an increased (>2) ratio in the SARS-CoV-2 condition, in both Resist versus Suscep. Groups (right panel). Fisher's exact test to compare the number of patients positive for each category between groups (*p<0.05, "p<0.01).

9 Figure 7. Waterfall plots indicating the IL-211L-5 ratio in all patient or individual groups.
Waterfall plot between IL-2 and IL-5 ratio of cytokine release in the Figure 1B IVS assay in all patients during the first surge of the pandemic depicting cancer (grey) versus cancer free (black) COVID-19+ convalescent patients (D), resistant (grey) versus susceptible (black) (A), locked down (or unknown) subjects (B, n=301) and healthy individuals in contact with their COVID-19-F family members (C). Each bar represents one patient.
Proportion of patients exhibiting an IL-2/IL-5 ratio superior or inferior to 1 is indicated in each panel. Clinical conditions are annotated as 0, +, ++, +++ for asymptomatic, mild, moderate, and severe COVID-19 severity, respectively. Refer to Figure 2F where percentages are compared inbetween groups.
Figure 8. Crosspresentation assays using viral variants.
A. Percentage and number of patients in Fig2L right panel who had a SARS-CoV-2-specific IL-2 release. Of note, only 4 reinfected patients could be tested because DC
could not be differentiated into monocytes in the others to allow the crosspresentation assay. B. Cytokine ratio in the crosspresentation assay detailed in Figure 1B, using the original strain IHUMI846 (early 2020 episode) (CoV-2 in (A)), versus the Danish mink (B.1.160, 20A.EU2, GH) and North African (B1.367, 20C, GH) strains in 25 control individuals. Statistical comparisons were performed using paired two-sided VVilcoxon-Mann-Whitney test and the asterisks indicate statistically significant differences (*p<0.05, **p<0.01, ***p<0. 001, ****p<0. 0001).
Figure 9. Logistic regression analyses identifying cohort -specific fingerprints of T cell repertoires.
A. Statistically significant peptide signatures in the peptide-based IVS assay (Figure 3A) using a multivariable logistic regression analysis adjusted for period (pre-COVI D-19 era or contemporary patients), COVI D-19 history and cancer (refer to Tables 2 and 3). The left column shows variables, and the x axis indicates the significant peptides (pval<0.05).
The magnitude of the log (Odd Ratio) is indicated in the red/blue color code while that of the p-value is represented by the circle size. B-C. Log10 of the p value of the Fisher exact test comparing two groups of 101 individuals, based on their reactivity to PEP
= wtRBD
(yes/no) for each H LA allele (B), followed by selection of the most significant allele with its relative proportion among RBD reactive or areactive vaccinees (C).

DETAILED DESCRIPTION
According to a first aspect, the present invention pertains to a method for in vitro determining whether an individual is likely to resist to an infection by SARS-CoV-2, comprising:
5 (i) generating dendritic cells (DC) from monocytes obtained from said individual;
(ii) loading said DC with a SARS-CoV-2 lysate or SARS-CoV-2 antigens;
(iii) contacting peripheral blood lymphocytes (PBL) from said individual with the DC
obtained in step (ii), in appropriate conditions to activate said PBL;
(iv) following the PBL activation, measuring the expression of at least one cytokine

10 secreted by Th1 cells, selected from the group consisting of IL-2, IFNy and TN Fa, and measuring the expression of at least one cytokine secreted by Th2 cells, selected from the group consisting of IL-5, IL-4, IL-9, IL-10 and IL-13; and (v) from the results of step (iv), assessing the Th1/Th2 polarization of SARS-CoV-2-specific memory T cell response in said individual, wherein a Th1 polarization indicates that the individual is likely to resist to an infection by SARS-CoV-2, and a Th2 polarization indicates that the individual is susceptible to an infection by SARS-CoV-2.
An individual "susceptible" to an infection by SARS-CoV-2 is one having little resistance to such an infection, and therefore capable of being infected.
In the above method, a "SARS-CoV-2 lysate" preferably refers to a lysate of a SARS-CoV-2 circulating strain, against which the resistance status of the individual is sought, or a lysate of a strain genetically close to said circulating strain.
Similarly, "SARS-CoV-2 antigens" preferably refers to antigens of a SARS-CoV-2 circulating strain, against which the resistance status of the individual is sought, or antigens of a strain genetically close to said circulating strain.
According to a particular embodiment, the SARS-CoV-2 antigens comprise or consist of a SARS-CoV-2 Spike protein or a fragment thereof comprising the receptor binding domain (RBD) of the Spike protein (corresponding to amino acids 331-525 of the spike protein of the reference Wuhan strain). Preferably, the Spike RBD present in the antigen(s) used for loading the dendritic cells is identical to that of the circulating strain, or has at least 80%, preferably at least 90% and more preferably at least 95% identity with the RBD
of the Spike protein of the circulating strain.
According to a particular embodiment of the above method, the expressions of IL-2 and IL-5 are measured in step (iv), and the ratio 1L2/IL-5 is calculated in step (v). A ratio I L2/1L5>1 indicates that the individual is likely to resist to an infection

11 by SARS-CoV-2, and I L2/I L51 indicates that the individual is susceptible to an infection by SARS-CoV-2.
According to another embodiment, the present invention relates to a method for in vitro determining whether an individual is likely to resist to an infection by SARS-CoV-2, comprising:
(i) incubating T lymphocytes from said individual with a mix of antigenic peptides from SARS-CoV-2, under conditions appropriate to stimulate Th1 and/or Th2 lymphocytes specific for said peptides; and (ii) assessing the presence of Th1 and/or Th2 lymphocytes;
wherein the presence of Th1 lymphocytes specific for said peptides indicates that the individual is likely to resist to an infection by SARS-CoV-2, and/or the absence of Th1 lymphocytes and/or the presence of Th2 lymphocytes specific for said peptides indicates that the individual is susceptible to an infection by SARS-CoV-2.
While the experimental part illustrates this method with an incubation time of several days, the skilled person can of course modify the protocol to shorten this incubation time and/or automate the whole process, for example by using techniques disclosed in W02018/202864 and in references cited therein.
In the above method, the "mix of antigenic peptides from SARS-CoV-2"
preferably comprises peptides comprising epitopes of the RBD of the Spike protein of a circulating strain, or epitopes able to trigger an immune reaction cross-reacting with the RBD of a SARS-CoV-2 circulating strain, against which the resistance status of the individual is sought.
According to a particular embodiment, the mix of antigenic peptides comprises at least five peptides of 9 to 50 aminoacids, preferably 12 to 25 aminoacids, from a sequence consisting of aminoacids 331 to 555 of a SARS-CoV-2 spike protein (preferably identical or having at least 80%, at least 90% and preferably at least 95%
identity with the aminoacids 331 to 555 of the SARS-CoV-2 spike protein of a circulating strain). As already mentioned, in the present text, the aminoacid positions are those of the proteins of the reference strain (Wuhan), which are disclosed in GenBank (M N908947.3).
According to another particular embodiment, the mix of antigenic peptides used to perform the above method comprises:
at least five peptides of 9 to 50 aminoacids, preferably 12 to 25 aminoacids, from a sequence consisting of aminoacids 331 to 555 of a SARS-CoV-2 spike protein;
and - at least one, preferably at least two or at least three peptides of 9 to aminoacids, preferably 12 to 25 aminoacids, from a SARS-CoV-2 nucleocapsid protein.

12 As described in the experimental part below, the inventors identified the subregions of the spike proteins which are of particular importance in the immune response against the virus. Thus, according to another particular embodiment, the mix of antigenic peptides used to perform the above method comprises:
- at least five peptides of 9 to 50 aminoacids, preferably 12 to 25 aminoacids, from a sequence consisting of aminoacids 361 to 555 of a SARS-CoV-2 spike protein, wherein at least one or two of said peptides are preferably from a sequence consisting of aminoacids 361 to 495 of a SARS-CoV-2 spike protein and at least one or two of said peptides are preferably from a sequence consisting of aminoacids 466 to 555 of a SARS-CoV-2 spike protein; and at least two, preferably at least 3 peptides of 9 to 50 aminoacids, preferably to 25 aminoacids, from a sequence consisting of aminoacids 1 to 135 of a SARS-CoV-2 spike protein.
According to yet another particular embodiment, the mix of antigenic peptides used to perform the above method comprises:
at least one, preferably at least two or at least three peptides of 9 to 50 aminoacids, preferably 12 to 25 aminoacids, from a sequence consisting of aminoacids 1 to 270 of a SARS-CoV-2 nucleocapsid protein; and/or at least one, preferably at least two or at least three peptide of 9 to 50 aminoacids, preferably 12 to 25 aminoacids, from a sequence consisting of aminoacids 331 to 419 of a SARS-CoV-2 nucleocapsid protein; and/or - one peptide of 9 to 50 aminoacids, preferably 12 to 25 aminoacids, from a SARS-CoV-2 ORF3a_AB protein, preferably consisting of or encompassing a sequence consisting of aminoacids 244 to 258 of said SARS-CoV-2 ORF3a_AB protein;
and/or - at least two peptides of 9 to 50 aminoacids, preferably 12 to 25 aminoacids, from a sequence consisting of aminoacids 856 to 1050 of a SARS-CoV-2 spike protein.

According to yet another particular embodiment, the mix of antigenic peptides used to perform the above method comprises:
at least one peptide of 9 to 50 aminoacids, preferably 12 to 25 aminoacids, from a sequence consisting of aminoacids 1 to 165 of a SARS-CoV-2 spike protein;
and/or at least one peptide of 9 to 50 aminoacids, preferably 12 to 25 aminoacids, from a SARS-CoV-2 ORF10 protein; preferably from a sequence consisting of aminoacids 1 to 22 of a SARS-CoV-2 ORF10 protein and/or at least one peptide of 9 to 50 aminoacids, preferably 12 to 25 aminoacids, from a SARS-CoV-2 ORF8 protein, preferably from a sequence consisting of aminoacids 1 to 36 or 99 to 121 of a SARS-CoV-2 ORF8 protein.

13 When performing the above method, step (i) can be performed by incubating T lymphocytes with the mix of antigenic peptides from SARS-CoV-2 in the presence of IL-2 and IL-15 to stimulate Th1 and/or Th2 lymphocytes specific for said peptides; in step (ii), the presence of Th1 lymphocytes can then be assessed by measuring the production of IFNy and/or the presence of Th2 lymphocytes can be assessed by measuring the production of at least one cytokine selected from IL-5, IL-4, IL-6, IL-9 IL-10 and IL-13.
Alternatively, the stimulation of Th1 and/or Th2 lymphocytes in step (i) can be done by incubating T lymphocytes with the mix of antigenic peptides from SARS-CoV-2 in the presence of low doses of IL-2 or IL-15, or PMA/ionomycine, or low dose of anti CD3/anti 0D28 antibodies to sensitize the TCR, in addition to IL-4 and/or anti-1L12 antibodies; then, in step (ii), the presence of Th2 lymphocytes can be assessed by measuring the production of at least one cytokine selected from IL-5, IL-9 IL-10 and IL-13.
According to a particular embodiment, the above method can be performed using at least one recipient that contains a mix of peptides which are common to all known strains of SARS-CoV-2 or induce cross-reactive immunity.
Alternatively or additionally, the above method is performed using at least one recipient that contains a mix of peptides which encompass the RBD region of circulating strain(s) of SARS-CoV-2 or induce cross-reactive immunity against this region in circulating strain(s).
According to a particular embodiment of the above method, the mix of peptides is dispatched in several recipients for performing the method, wherein at least one recipient contains a mix of peptides which are specific for one or more SARS-CoV-2 variant(s). The skilled person can thus establish a detailed profile of the individual or of a population, for example to assess the prevalence or the dynamics of a given strain.
According to a particular embodiment of the above method, the mix of peptides is dispatched in several recipients for performing the method, wherein at least one recipient contains a mix of peptides which are common to all known strains of SARS-CoV-2 or induce cross-reactive immunity, and at least another recipient comprises a mix of peptides which are specific for one or more SARS-CoV-2 variant(s).
When the above method is performed with a recipient that contains a mix of peptides which are common to all known strains of SARS-CoV-2 or induce cross-reactive immunity, detection of Th1 lymphocytes in said recipient indicates that the individual is likely to resist to an infection by any SARS-CoV-2 strain.
Conversely, when the method is performed with a mix of peptides comprising only peptides present in the proteins of a given variant strain of

14 SARS-CoV-2, the result indicates whether the individual is likely to resist to an infection by this variant strain of SARS-CoV-2.
According to a particular embodiment of the above method, the Th1 response is assessed using a first mix of peptides comprising at least 3, 4, 5, 6 or more peptides relevant for assessing Th1 response against SARS-CoV-2 and the Th2 response is assessed using a second mix of peptides comprising at least 3, 4, 5, 6 or more peptides relevant for assessing Th2 response against SARS-CoV-2.
The skilled person can chose the peptides present in the first and/or second mixes of peptides so that they comprise at least one peptide described in Table 12. According to a particular embodiment, several peptides are selected amongst those of Table 12. These two mixes of peptides can be identical or partially or totally different.
According to a particular embodiment, the first and second mixes of peptides are present in separate recipients/tubes.
When performing the above method, the presence of Th1 lymphocytes can be assessed in step (ii) by measuring the production of IFNy in the recipient comprising the first mix of peptides and the presence of Th2 lymphocytes can be assessed by measuring the production of at least one cytokine selected from IL-5 in the recipient comprising the second mix of peptides.
In the absence of Th1 after incubation of the T lymphocytes with a mix of peptides covering a sequence comprising amino acids 331 to 525 and/or amino acids 329 to 521 and/or amino acids 391 to 555 of a SARS-CoV-2 spike protein (under conditions appropriate to stimulate Th1), the skilled person performing the method can deduce that the individual is susceptible to an infection by SARS-CoV-2 and its variants.
The same interpretation can be deduced if the results show the presence of a Th2 response combined to the absence or weak presence of Th1 after incubation of the T lymphocytes with a mix of peptides covering a sequence comprising amino acids 331 to 525 and/or amino acids 329 to 521 and/or amino acids 391 to 555 of a SARS-CoV-2 spike protein indicates that the individual is susceptible to an infection by SARS-CoV-2 and its variants (under conditions appropriate to stimulate Th1/Th2).
Conversely, the presence of Th1 after incubation of the T lymphocytes with a mix of peptides covering a sequence comprising amino acids 331 to 525 and/or amino acids 329 to 521 and/or amino acids 391 to 555 of a SARS-CoV-2 spike protein indicates that the individual is likely to resist to an infection by SARS-CoV-2 and its variants, at least to an infection by a SARS-CoV-2 strain having a RBD
sequence with a high level of identity (at least 80%, 90%, 95% or 99%) with the sequences used to perform the method.

The inventors identified that the most important target for a protective Th1 response is that of the RBD of the spike protein. If this region is not tested or elicits a poor Th1 response, the presence of Th1 after incubation of the T lymphocytes with a mix of peptides comprised in a sequence consisting of amino acids 1 to 135 of a SARS-CoV-5 2 spike protein indicates that the individual is likely to resist to an infection by SARS-CoV-2 and its variants, only if a Th1 response has also been obtained against another part of the virus, e.g. against peptides of the nucleocapsid.
According to another of its aspects, the present invention pertains to a method for monitoring the efficacy of a vaccination against SARS-CoV-2 in an individual, 10 comprising performing a method as those described above with a biological sample from said individual (after vaccination).
This method can advantageously be used to assess the efficacy of a vaccine for inducing a protective immune response against one or several new variant(s). For example, using peptides specific for said new variant(s) to stimulate Th1

15 and/or Th2 lymphocytes after vaccination (prime or boost) of the individual with a vaccine based on the Wuhan strain, a skilled person can assess whether the individual has become resistant to said new variant(s) thanks to this vaccination_ Doing so in a representative cohort would provide information useful for dynamically establishing a correct vaccination policy in a population, depending of the population (age, ...) and the time (circulating and/or emerging strains).
Of course, at the individual level, this method can be used to monitor the efficacy of a vaccination against SARS-CoV-2 in an individual.
Another aspect of the present invention is an immunogenic composition comprising, in one or several polypeptides, the epitopes present in a sequence corresponding to amino acids 331 to 525 of a SARS-CoV-2 spike protein; such an immunogenic composition can additionally comprise, in the same or in different polypeptides, the epitopes present in a sequence corresponding to amino acids 1 to 165 of a SARS-CoV-2 spike protein.
According to a particular embodiment such an immunogenic composition comprises a first polypeptide sequence comprising amino acids 331 to 525 of a SARS-CoV-2 spike protein, and a second polypeptide sequence comprising amino acids 1 to 165 of a SARS-CoV-2 spike protein, wherein said first and second polypeptide sequences are in the same polypeptide molecule or in separate polypeptides which are distinct from a natural spike protein.
According to an example of such an immunogenic composition, the first polypeptide sequence consists of amino acids 331 to 525 of a SARS-CoV-2 spike

16 protein, and/or the second polypeptide sequence consists of amino acids 1 to 165 of a SARS-CoV-2 spike protein.
According to another example of such an immunogenic composition, the first polypeptide sequence consists of amino acids 331 to 600 of a SARS-CoV-2 spike protein or a fragment thereof, and/or the second polypeptide sequence consists of amino acids 1 to 270 of a SARS-CoV-2 spike protein or a fragment thereof.
As already mentioned, the above amino acid positions are those of the reference Wuhan strain, it being clearly understood that the immunogenic composition can comprise sequences originating from one or several other SARS-CoV-2 strain, for example from circulating variant(s) of concern.
In addition to the polypeptides mentioned above, an immunogenic composition according to the invention can further comprise a polypeptide sequence comprising amino acids 1 to 270 of a SARS-CoV-2 nucleocapsid protein, and/or a polypeptide sequence comprising amino acids 244 to 258 of a SARS-CoV-2 ORF3a_AB
protein, and/or a polypeptide sequence comprising amino acids 29 to 92 of a SARS-CoV-2 OR F8 protein, and/or a polypeptide sequence comprising amino acids 1 to 36 of a SARS-CoV-2 ORF8 protein, and/or a polypeptide sequence comprising amino acids 22 to 38 of a SARS-CoV-2 ORF10 protein, wherein said additional polypeptide sequence(s) are in the same polypeptide molecule as the first and/or second polypeptide sequences or are in one or several separate polypeptide(s).
As shown in Example 2, the inventors also tested tumor infiltrating lymphocytes (TIL) from patients in the pre-pandemic time, and during the pandemic, to identify potential T-cell cross-reactivity between SARS-CoV-2 and self or viral proteins. By doing so, they identified cross-reactivity with SARS-CoV-1 but not with other circulating Coronaviral species, as well as a possible cross-reactivity to non-mutant or mutant human 'self proteins'. TIL are an interesting source to screen for potential autoimmunity in viral targets because they invade tissues.
Positive reactivity against SARS-CoV-2 peptides, based on the cytokine production pattern, can thus indicate an increased risk for autoimmune diseases upon exposure to the viral pathogen, or an increased pathogenicity upon viral infection due to an overt immune response (unproductive inflammation in the lung and other organs). To avoid such reaction and possible resulting organ-specific damage (such as myocarditis or damage of olfactory receptors for example), immunogenic compositions designed for being administered to humans should thus be devoid of sequences which could be recognized by T-cells also recognizing non-mutant human tissue.

17 Hence, according to a particular embodiment, the immunogenic composition according to the invention does not comprise the peptide sequence LVRDLPQGFSALE (SEQ ID No: 377).
According to another particular embodiment, the immunogenic composition according to the invention does not comprise the peptide sequence DVRVVLDFI (SEQ ID No: 178).
According to another particular embodiment, the immunogenic composition according to the invention does not comprise the peptide sequence LLNKHIDAY (SEQ ID No: 275).
According to another particular embodiment, the immunogenic composition according to the invention does not comprise the peptide sequence IELCVDEAG (SEQ ID No: 305).
According to another particular embodiment, the immunogenic composition according to the invention does not comprise the peptide sequence MKFLVFLGI (SEQ ID No: 308).
According to another particular embodiment, the immunogenic composition according to the invention does not comprise the peptide sequence MKFLVFLGIITTV (SEQ ID No:378).
Of course, the immunogenic compositions according to the invention can be administered as polypeptide(s), or in the form of a nucleic acid molecule encoding the same. Such a nucleic acid molecule encoding the polypeptide(s) present in immunogenic compositions defined above are thus also part of the present invention, as well as an immunogenic composition comprising the same such as, for example, a viral vector comprising the same.
According to a preferred embodiment, the nucleic acid molecule according to the invention is a RNA molecule.
Another aspect of the present invention is a vaccine composition against SARS-CoV-2. In a particular embodiment, such a vaccine composition comprises an immunogenic composition as any one of those described above, as well as a pharmaceutically acceptable excipient and/or adjuvant.
Preferred adjuvants are those that favor a Th1 response. Examples of adjuvants which are appropriate for being included in a vaccine composition according to the invention thus include TLR4 agonists, TLR3 ligands/ agonists, TLR7-8 agonists and TLR9 agonists.
More particularly, a vaccine composition according to the invention can advantageously comprise at least one adjuvant selected from the group consisting of lipopolysaccharides, MPL: 3-0-desacy1-4'-monophosphoryl lipid A derived from

18 Salmonella minnesotta LPS, poly A :U, poly I :C, IMIQUIMOD, CpG DNA and CpG
ODNs.
Surprisingly, the inventors also identified a sequence in the spike protein of SARS-CoV-2 that shares antigenic sites with an antigen that is specific for certain forms of cancers. Due to this antigenic mimicry, an infection by SARS-CoV-2 could elicit an immune response ameliorating the patients' antitumor response.
The present invention thus pertains to an immunogenic composition comprising a polypeptide comprising a sequence selected amongst LDSKVGGNY (SEQ

ID No: 262), NSNNLDSKV (SEQ ID No: 263) and NSNNLDSKVGGNY (SEQ ID No:
379), or a nucleic acid encoding the same, for use in the treatment of cancer.
According to a preferred embodiment, such an immunogenic composition is used in the treatment of a cancer overexpressing Tensin-1.
Such an immunogenic composition according to the invention is particularly useful for immunotherapy of a pancreas adenocarcinoma or a colon adenocarcinoma.
Other characteristics of the invention will also become apparent in the course of the description which follows of the experimental assays which have been performed in the framework of the invention and which provide it with the required experimental support, without limiting its scope.

19 EXAMPLES
Example 1: The polarity and specificity of SARS-CoV2 -specific T lymphocyte responses determine disease susceptibility Material and methods Patient and cohort characteristics. All clinical studies were conducted after written informed consent in accordance with Good Clinical Practice guidelines and the provisions of the Declaration of Helsinki. Cohorts' and subsets' characteristics are detailed in Tables 1 to 8, 10 and 14, and Figure 1A. Two cohorts of cancer patients (from the pre-COVID-19 era and from the COVID-19 era) and three cohorts of healthy volunteers (from the pre- COVI D-19 era and from the COVI D-19 period including three cohorts of vaccinees (HCL, GR, cancer/cancer free) were exploited to set up the translational research analyses. Peripheral blood mononuclear cells (PBMC) were provided by Gustave Roussy Cancer Campus (Villejuif, France) and IHU
Mediterranee Infection (Marseille, France) (see Blood analyses section). The type of ancillary studies is detailed in Table 1.
Contemporary clinical studies (COVID-19 era): 1/ ONCOVID clinical trial and regulatory approvals.
Principles. The protocol NCT04341207 is available on the clinicaltrials.gov website.
Gustave Roussy Cancer Center sponsored the trial named 'ONCOVID and collaborated with the academic authors on the trial design and on the collection, analysis, and interpretation of the data. Sanofi provided trial drugs. Protocol approval was obtained from an independent ethics committee (ethics protocol number EudraCT No: 2020-001250-21). For details, refer to previous report [32]. Samples for translational research. PMBCs were isolated less than 8 hours after the blood collection (at patient inclusion and at every hospital visit) and kept frozen at-80 C. 2/PROTECT-Coy clinical trial and regulatory approvals. Principles. IHU Mediterranee Infection sponsored the trial named 'PROTECT-Coy' and collaborated with the academic authors on the trial design and on the collection, analysis, and interpretation of the data.
Protocol approval was obtained from an independent ethics committee (ethics protocol number ANSM
No:
2020-A01546-33). The trial was conducted in accordance with Good Clinical Practice guidelines and the provisions of the Declaration of Helsinki. All patients provided written informed consent. Subjects. PROTECT-Coy eligible subjects were members of the same family/home composed of two or more people and selected from the microbiology laboratory register on SARS-Cov-2 tests performed between March 23 and April 10, 2020. Trial design. Members of the same family/home who had at least one (a)symptomatic COVID-19 + case (RT-qPCR <35 Ct values for SARS-CoV-2 on nasopharyngeal swabs) and at least one member with negative RT-qPCR for SARS-CoV-2 (35 Ct) were screened. A telephone interview was conducted in order to confirm and complete the list of family circles in connection with the positive case.
The compliant 5 subjects finally selected were invited to come back to the IHU
Mediterranee Infections hospital where they were included in the trial and had a blood test. 3/ COVID-SER
clinical trial and regulatory approvals. Principles. At the "Hospices Civils de Lyon", France was conducted the trial named COV1D-SER. Protocol approval was obtained from an independent ethics committee (the national review board for biomedical 10 research, Comae de Protection des Personnes Sud Mediterranee, ID-RCB-2020-A00932-37). The clinical study was registered on ClinicalTrial.gov (NCT04341142). For details, refer to Mouton et al. [43]. Written informed consent was obtained from all participants and the study. Blood sampling was performed before vaccination and 4 weeks after receiving 1 or 2 doses of vaccine for naive and convalescent health care 15 workers respectively. According to French procedures, a written non-opposition to the use of donated blood for research purposes was obtained from healthy volunteers. The donors' personal data were anonymized before transfer to our research laboratory_ We obtained approval from the local ethical committee and the French ministry of research (DC-2008-64) for handling and conservation of these samples. Human biological

20 samples and associated data were obtained from NeuroBioTec (CRB HCL, Lyon France, Biobank BB-0033-00046) and Virginie Pitiot. 4/ COV3AP-HP clinical trial and regulatory approvals. Principles BioMerieux S.A is the promotor of the trial "COV3AP-HP" approved by the local ethical committee (number N ID-RCB : 2021-A00304-37).
The trial was conducted in accordance with Good Clinical Practice guidelines and the provisions of the Declaration of Helsinki at Gustave Roussy and Cochin Institute, France.
All subjects provided written informed consent. 5/ Dupilumab for atopic dermatitis translational study. This trial was conducted at the Department of Dermatology, Center of Excellence in Eczema Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai New York, NY, USA with Regeneron sponsorship after ethical committee approval (STUDY-20-00682-MOD001).
Clinical studies from the Pre-COVID-19 era: 1/ Series of patients with cancer:
This cohort is composed of different IGR clinical trials. Patients were included and blood was collected and banked between 1999 and 2018 (Pre-COVID-19 era). Clinical studies have been described in previous reports [29,31,77] (CALEX protocol, n1 ID RCB

A01074-49, date 29 February 2008). (Study code Dex2 : N0T01159288, date 19 December 2005) (Study code LUD 99 003 : N-CSET : 99/090/752, date 1 December 1999) (Phase I IMAIL-2 trial approved by the Kremlin Bic6tre Hospital Ethics Committee

21 [no 07-019] and the Agence Frangaise de Securite Sanitaire des Produits de Sante [no A70385-27; EudraCT N :2007-001699-35 in 2007). 2/ Series of patients without cancer: Peripheral blood was obtained from healthy volunteers at the Etablissement Francais du Sang (EFS, Paris France, n 18EFS031 date 24 September 2018).
Blood analyses. Blood samples (for serum and PBL) were drawn from patients enrolled in the different cohorts presented in the cohort description section above.
Whole human peripheral blood was collected into sterile vacutainer tubes. Anti-SARS-CoV-2 immunoglobulins measurements. Serum was collected from whole blood after centrifugation at 600 g for 10 min at room temperature and transferred to -80 C freezer to await analysis. Serological analysis SARS-CoV-2 specific IgA, IgM and IgG
antibodies were measured in 119 serum samples from 87 patients with The Maverick TM SARS-CoV-2 Multi-Antigen Serology Panel (Genalyte Inc. USA) according to the manufacturer's instructions. The MaverickTM SARS-CoV-2 Multi-Antigen Serology Panel (Genalyte Inc) is designed to detect antibodies to five SARS-CoV-2 antigens: nucleocapsid, Spike S1 RBD, Spike S1S2, Spike S2 and Spike S1 or seasonal HCoV -NL-63 nucleocapsid, -0C-43, -229E and -HK-U1 Spike in a multiplex format based on photonic ring resonance technology. This system detects and measures with good reproducibility changes in resonance when antibodies bind to their respective antigens in the chip. The instrument automates the assay. Briefly, 10p1 of each serum samples were added in a sample well plate array containing required diluents and buffers. The plate and chip are loaded in the instrument. First the chip is equilibrated with the diluent buffer to get baseline resonance.
Serum sample is then charged over the chip to bind specific antibodies to antigens present on the chip. Next, chip is washed to remove low affinity binders.
Finally, specific antibodies of patients are detected with anti-IgG or -IgA or -IgM secondary antibodies. Isolation of peripheral blood mononuclear cells (PBMCs) from fresh blood sampling. Venous blood samples (10m1 to 30m1) were collected in heparinized tubes (BD Vacutainer0 LH 170 U.I., Dutscher, UK). On the same day, blood was processed in a biosafety level 2 laboratory at Gustave Roussy Institute, Villejuif, France, or in IHU Mediterranee Infection, Marseille, France. Peripheral blood mononuclear cells (PBMCs) were freshly isolated by LSM, Lymphocyte Separation Medium (Eurobio Scientific, France) density gradient centrifugation according to manufacturer's instructions. (Leucosep tubes, Greiner; Blood', Bio&SELL). PBMCs were then collected, washed once with phosphate-buffered saline solution (PBS) and aliquoted in 1m1 of cryopreservation medium (CryoStor0, STEMCELLS Technologies, USA) in cryovials (two cryovials per patient). Cryovials (CryotubeTM vials ThermoFisher Scientific, Denmark) were conserved for 24h at -80 C in a cryo-freezing container

22 (Mr.Frostirm,Thermo Fisher Scientific) before storage in liquid nitrogen.
Serum and serologies. Specific anti-SARS-CoV-2 IgG antibodies were detected by the Liaison XL
automated chemiluminescent immunoassay (CLIA) (Diasorin Inc., Saluggia, Italy) according to the manufacturer's recommendations. Seroneutralization was performed as already described [78].
Reagents: culture media, cytokines, ELISA and multiplex assays. PBMC
isolation.
Blood samples were collected in heparinized tubes BD Vacutainer0 LH 170 U.I., from Dutscher (catalog reference: 367526), diluted in PBS 1X purchased from Eurobio Scientific (catalog reference: CS3PBS01-01) and transferred in LeucosepTm 50mL
purchased from Greiner Bio-One (catalog reference: 227290). Blood was centrifuged using MF48-R Centrifuge from AWEL Industries (catalog reference: 20023001).
PBMC
were collected in Centrifuge tube 50mL TPP from Dutscher (catalog reference:
91050), washed with PBS 1X, resuspended in CryoStor CS10 purchased from STEMCELLTm technologies (catalog reference: 5100-0001) and transferred in CryotubeTM
vials from ThermoFisher Scientific (catalog reference: 377267). Samples were finally conserved for 24h at -80 C in a cryo-freezing container MrFrostyTM from Thermo Fisher Scientific before storage in liquid nitrogen. Crosspresentation assay or peripheral blood lymphocyte stimulation with autologous monocyte derived- dendritic cells (DC).
Frozen PBMCs were thawed, washed and resuspended in RPM! Medium 1640 (1X) purchased from GIBCO (catalog reference: 31870-025). Counting and viability were evaluated using ViCELLTM XR Cell Viability Analyzer from Beckman Coulter (catalog reference: AV13289).To separate adherent and non-adherent cell populations, PBMC
were transferred in 6 or 24 well flat bottom Sterile tissue culture testplate TPP purchased from Dutscher (catalog reference: 92006 / 92024) and cultured in complex medium (Complex Medium 1) containing human AB serum (catalog reference: 201021334), purchased from Institut de Biotechnologies Jacques Boy France), RPM! Medium (1X) (catalog reference: 31870-025), Sodium Pyruvate (catalog reference: 11360-039), Penicillin /Streptomycin (catalog reference: 15140-122), L-Glutamine (200mM) (catalog reference: 25030-024) HEPES Buffer Solution (catalog reference: 15630-056), MEM
NEAA (catalog reference: 1140-035), purchased from GIBCO/ThermoFisher Scientific.
The Non-adherent fraction was cultured in another complex medium (Complex Medium 2) containing human AB serum, lscove's Modified Dulbecco's Medium (catalog reference: 13390), from Sigma-Aldrich, Sodium Pyruvate (catalog reference:
11360-039), Penicillin/Streptomycin (catalog reference: 15140-122), L-Glutamine (200mM) (catalog reference: 25030-024) HEPES Buffer Solution (catalog reference: 15630-056), MEM
NEAA (catalog reference: 1140-035) from GIBCO/ThermoFisher Scientific and

23 Recombinant Human IL-2 (PHAR000306) from Gustave Roussy Institute pharmacy.
The adherent fraction was differentiated into monocyte derived- dendritic cells (mo-DC) in a mo-DC differentiating media constituted with Complex Medium 1 supplemented with Recombinant Human GM-CSF Premium purchased from Miltenyi (catalog reference:
130-093-867) and human IFNa-2b (Introna) purchased from MSD (France) (catalog reference: PHAR008943). For activation and maturation, DCs were stimulated with LPS
purchased from Invivogen (catalog reference: ) and GM-CSF purchased from Miltenyi Biotec (catalog reference: 130-093-867). PBL and mo-DC were finally co-cultured into 96 well V bottom Sterile NuncTm plate, VWR purchased from Dutscher (catalog reference: 92097). For positive control, PBL were stimulated with DynabeadsTm Human T-Activator CD3/CD28 purchased from GIBCO / ThermoFisher Scientific (catalog reference: 11131D). All cell cultures were performed at 37 C, 5% CO2 into Heraue incubator purchased from Kendro Laboratory Products, ThermoFisher Scientific (catalog reference: BB 6220) And supernatants were transferred into 96 well V bottom Sterile NuncTM plate, VWR purchased from Dutscher (catalog reference: 734-0491) and frozen.
Peptide-based assay. 96 well V bottom Sterile NUflCTM plate were coated with peptides at 2pg/mL in RPM! Medium 1640 (1X) (catalog reference. 31870-025) supplemented with 1% Penicillin/Streptomycin (catalog reference: 15140-122) and conserved at -80 C.
PBMCs were then thawed and plated in plate containing peptides in RPM! Medium (1X) (catalog reference: 31870-025) supplemented with 1%
Penicillin/Streptomycin (catalog reference: 15140-122) supplemented with Recombinant Human IL-15 Premium grade from Miltenyi biotec (catalog reference: 130-095-765) and Recombinant Human IL-2 (PHAR000306) from Gustave Roussy Hospital. For positive, PBMC were stimulated with functional grade CD3, OKT3 purchased from ThermoFisher Scientific (catalog reference: 16-0037-85). Cell cultures were then supplemented with human AB
serum (catalog reference: 201021334) purchased from Institut de Biotechnologies Jacques Boy (France) and cultured at 37 C, 5% CO2. Cytokines monitoring. Supernatants from cultured cells from Crosspresentation assay were monitored using the MACSPlex Cytokine 12 Kit human purchased from Miltenyi Biotec (catalog reference: 130-099-169).
Acquisitions and analyses were performed on CytoFLEX S purchased from Beckman Coulter (catalog reference: B75442)/FACSAria Fusion purchased from BDbiosciences and FlowJo Software from Treestar respectively. Whereas Supernatants from cultured cells from peptide-based assay were monitored using ELISA tests purchased from BioLegend: ELISA MAXTM Deluxe Set Human I FN-y (catalog reference: 430104) ELISA
MAXTM Deluxe Set Human IL-17 (catalog reference: 433914) and ELISA MAXTM
Deluxe Set Human IL-9 (catalog reference: 434705).

24 Viral studies. Biosafety levels for in vitro experiments. Frozen PBMCs from patients with a confirmed negative RT-qPCR for SARS-CoV-2 genome at the time of blood drawing were processed in a biosafety level 2 laboratory at Gustave Roussy Institute, Villejuif, France. All samples from patients with positive RT-qPCR were processed in a biosafety level 3 laboratory at Henri Mondor Hospital, Creteil, France. When a patient was sampled at different timepoints, samples were processed together in the same laboratory. RT-qPCR analysis. SARS-CoV-2 diagnostic testing of clinical nasopharyngeal swabs or other samples by RT-qPCR was conducted from 14 March to 23 March 2020 at an outside facility using the Charite protocol. From the 23th March 2020 testing was performed internally at the Gustave Roussy. The cycle thresholds were collected only for assays performed at Gustave Roussy. Nasopharyngeal swab samples were collected using flocked swabs (Sigma Virocult) and placed in viral transport media.
SARS-CoV-2 RNA was detected using one of two available techniques at Gustave Roussy: the GeneFinder COVID-19 Plus RealAmp kit (ELITech Group) targeting three regions (RdRp gene, nucleocapsid and envelope genes) on the ELITe InGenius (ELITech Group) or the multiplex real-time RT-PCR diagnostic kit (the Applied Biosystems TaqPath COVI D-19 CE-IVD RT-PCR Kit) targeting three regions (ORF1ab, nucleocapsid and spike genes) with the following modifications. Nucleic acids were extracted from specimens using automated Maxwell instruments following the manufacturer's instructions (Maxwell RSC simplyRNA Blood Kit; AS1380;
Promega).
Real-time RT-PCR was performed on the QuantiStudio 5 Dx Real-Time PCR System (Thermo Fisher Scientific) in a final reaction volume of 20 1j1, including 5 pl of extracted nucleic acids according to the manufacturer instruction. Viral lysates and their production. SARS-CoV-2 IHUMI2, IHUMI845, IHUMI846, IHUMI847 (early 2020 episode), IHUMI2096 (20A.EU2, B.1.160) and IHUMI2514 (20C, B.1.367) [25]
IHUMI3076 (201/501Y.V1, B.1.1.7), IHUMI3147 (20H/501Y.V2, B.1.351) and (20J/501Y.V3, P.1) strains were isolated from human nasopharyngeal swab as previously described [25] and grown in Vero E6 cells (ATCC CRL-1586) in Minimum Essential Medium culture medium (MEM) with 4% fetal calf serum (FCS) and 1%
L-glutamine. Influenza strains H1N1 (0022641132) and H3N2 (8091056304) were isolated then produced from human nasopharyngeal swab in MDCK cells (ATCC CCL-34) in MEM with 10% FCS and 1% L-glutamine. All these clinical isolates were characterized by whole viral genome sequencing from culture supernatants.
Coronavirus 0C43 (ATCC vr-1558) was grown in HCT8 cells (ATCC CCL-244) in RPM! with 10%
FCS. Coronavirus 229E (ATCC vr-740) was grown in MRC5 cells (ATCC CCL-171) in MEM with 10% FCS. All reagents for culture were from ThermoFisher Scientific and all cultures were incubated at 37 C under 5% CO2 without antibiotics. All viral strains were produced in 125 cm2 cell culture flasks. When destruction of cell monolayer reached approximately 80%, between 2 to 7 days according to cell line and viral strain, culture supernatant was harvested. After low -speed centrifugation to remove cells and debris (700 x g for 10 min.) supernatants were filtered through 0.45 then 0.22 pm pore-sized 5 filters. These viral suspensions were then inactivated for 1 hour at 65 C
before use.
BaTches of scrapped control uninfected cells were rinsed twice in PBS, and then finally resuspended in 5 ml of PBS at 5.105 cells/ml. All cells and antigens were tested negative for Mycoplasma before use.
In vitro stimulation assays. Crosspresentation assay or peripheral blood 10 lymphocyte stimulation with autologous monocyte derived- dendritic cells (DC).
Frozen PBMCs were thawed, washed and resuspended in RPM! 1640 media (GIBCO).
Viability and count were evaluated using a Vi-Cell XR Cell Counter (Beckman Coulter, Brea). PBMC were then cultured in RPM! 1640 supplemented with 10% human AB
serum, 1mM Glutamine, 1% sodium pyruvate, 1% HEPES, 1% penicillin/streptomycin at 15 a cell density of 0.5M cells/cm2 for 2 hours at 37 C, 5% CO2 and separated into adherent and non-adherent cell populations. Non-adherent cells, containing Peripheral Blood Lymphocytes (PBL), were collected and cultured 4 days at 37 C, 5% CO2 in IMDM
medium (Sigma-Aldrich, UK), supplemented with 10% human AB serum (Institut de Biotechnologies Jacques Boy, France), 1mM Glutamine (GIBCO/ThermoFisher 20 Scientific, UK) 1% Sodium Pyruvate (GIBCO/ThermoFisher Scientific, UK), 1% HEPES
(GIBCO/ThermoFisher Scientific, UK), 1%
penicillin/streptomycin (GIBCO/ThermoFisher Scientific, UK) and 200 Ul/mL rhIL-2 (Miltenyi, Germany).
The adherent cell population was cultured for 3 days, at 37 C, 5% CO2, in a mo-DC
differentiating media containing RPM! 1640 supplemented with 10% human AB
serum,

25 1mM Glutamine, 1% sodium pyruvate, 1% HEPES, 1% penicillin /streptomycin, 1000U1/mL rhGM-CSF (Miltenyi) and 250U1/mL human IFNa-2b (Introna, MSD
France).
At day 3, adherent cells were slowly detached by pipetting after 20 minutes of incubation at 4 C and 20.000 cells were seeded in 96 well round bottom plate and were pulsed, or not (control condition), overnight, at 37 C, 5% CO2, with 1/10 heat inactivated viral lysates, or their respective control (see viral lysates production section).
Spinoculation (800g for 2h, Centrifuge 5810R, Eppendorf, Germany) was next performed to ensure synchronized capture of the viral particles by mo-DCs. For activation and maturation, adherent cells were stimulated with LPS (10 ng/mL, Thermofisher) and GM-CSF
(1000U1/mL). After 6h, mo-DCs were washed twice to remove LPS from the media and 100 000 PBL/well were seeded onto mature mo-DCs. PBL alone served as negative control, and PBL stimulated with anti-CD3 and anti-CD28 microbeads (1pL/mL, Dynabeads T-Activator, InVitrogen) as a positive control. moDC-PBL co-culture was

26 incubated at 37 C, 5% CO2 for 48h and supernatants were harvested and stored at -20 C.
Multiplex Cytokine Analysis or bead-based multiplex assays. moDC-PBL co-culture supernatants were analyzed using bead-based multiplex kit assays (MACSplex cytokine 12 human, Miltenyi) according to the manufacturer protocol. Briefly, 50uL of supernatant were used with a MACSPLEX Cytokine12 Capture Beads (Miltenyi, France) to measure the concentration of 12 cytokines (GM-CSF, IFN-a, IFN-y, IL-10, IL-12, IL-17A, IL-2, IL-4, IL-5, IL-6, IL-9, TNF-a). Bead fluorescence was acquired on a CytoFLEX
flow cytometer (Beckman Coulter) for samples processed at Gustave Roussy Institute and on a FACSAria Fusion (Becton Dickinson) for samples processed in the biosafety level 3 laboratory at Henri Mondor Hospital. FlowJo (Treestar, Ashland, OR, USA) software was used for analysis. Positivity threshold determination for cytokine concentration using multiplex assays and commercial ELISA assays. For multiplex assays (or ELISA), a 4 parameter logistic regression was fitted for each cytokine based on the APC
mean fluorescent intensity (or Optical Density) of standard dilution samples using nlpr(v0.1-7). This model was then used to calculate the concentration of each sample of unknown concentration For multiplex assays, a ratio was computed for each cytokine using the cytokine concentration measured in response to each virus (SARS-CoV-2, HCoV-229E, HCoV-0C43) divided by the median concentration of their respective biological controls (Vero 81, MRC5, HCT8). A positivity threshold was set up based on the ratio for each cytokine. A ratio of above 1.5 minimum was requested to consider the supernatant "positive" for a cytokine. VVhen necessary, a higher threshold was set up as such, median cytokine concentration of the biological controls + 2 times the standard deviation of the biological control concentrations divided by the median concentration.
For ELISA assays, a ratio was computed as the concentration of the sample divided by the mean concentration of the negative controls.
ELISpot assay. The enumeration of antigen-specific I FNy and IL-5 producing T
cells was performed using the ImmunoSpot human IFNy/IL-5 double-color enzymatic ELISPOT kit (Cellular Technology Limited (CTL), Germany). Peripheral blood lymphocytes were stimulated with autologous monocyte derived- dendritic cells loaded with SARS-CoV-2 lysates or their respective controls (see cross presentation assay section). After 48 hours, cells were resuspended in serum-free testing medium (CTL, Germany) containing 1 mM GlutaMAX (Gibco) and 1% penicillin/streptomycin (GIBCO) at a final volume 200 pL/well and seeded in a 96-well nitrocellulose plate coated with human IFNy and IL-5 capture antibody. Plates were incubated for 18h at 37 C
in 5%
CO2. ELISPOT assays were then performed according to manufacturer's instructions.
Spots were counted by CTL ImmunoSpot Analyzer using ImmunoSpot software.

27 Flow cytometric analyses. Sample preparation. Cells from the crosspresentation assays (PBL+DC loaded with viral lysates or VeroE6 supernatants) were stained for viability with Zombie Aqua (BioLegend Cat#423102) for 20 min at +4 C, then washed in staining buffer (PBS 1X, BSA 2%, 2mM EDTA). Then, cells were stained with a panel of antibodies (as indicated in table for supplementary methods below) for 20 min at room temperature in staining buffer with Brillant Strain Buffer (BD, Cat#563794).
Cells were then washed, fixed and permeabilized (Foxp3/Transcription Factor Staining Buffer Set eBiosciences Cat#00-55-23-00) for 40 min at +4 C before being stained with intracellular antibodies for 30 min at +4 C. Data Acquisition. Samples were acquired on a BD
LSRFortessaTM X-20 Flow Cytometer. Data analysis. Analysis was performed with F I owJ o software (Tree Star).
Table for supplementary methods:
Channel Target Clone Reference Company PE-Cy7 CCR4/CD194 1G1 557864 BD
FITC CXCR3/CD183 G025H7 353704 BioLegend PE-CF594 4-1BB/CD137 4B4-1 309826 BioLegend BioLegend BV421 Ki67 356 562899 BD

PE 1-bet eBio4B10 12-5825-82 eBiosciences Whole-transcriptome RNA-sequencing. PBL from eleven resistant and 7 susceptible patients as well as 8 and 10 patients for whom crosspresentation assays revealed an IL-2/1L-5 ratio > and <1 respectively were used for the RNA sequencing of PBLs at 48 his after incubation with DC loaded with viral lysates. Cells from 18 wells post-stimulation with SARS-CoV-2 or VEROE6 were analyzed. The RNA integrity (RNA Integrity Score 7.0) was checked on the Agilent 2100 Bioanalyzer (Agilent) and quantity was determined using Qubit (Invitrogen). SureSelect Automated Strand Specific RNA Library Preparation Kit was used according to manufacturer's instructions with the Bravo Platform.
Briefly, to 100 ng of total RNA sample was used for poly-A mRNA selection using oligo(dT) beads and subjected to thermal mRNA fragmentation. The fragmented mRNA samples

28 were subjected to cDNA synthesis and were further converted into double stranded DNA
using the reagents supplied in the kit, and the resulting dsDNA was used for library preparation. The final libraries were bar-coded, purified, pooled together in equal concentrations and subjected to paired-end sequencing (2 x 100 bp) on Novaseq-sequencer (Illumina) at Gustave Roussy.
Peptide-based assays.
Rationale of peptide selection and peptide synthesis (Refers to Table 9).
Peptide selection and synthesis: the peptides from the spike and nucleocapsid proteins were selected by dividing the sequences of the SARS-CoV-2 spike protein (RefSeq ID
0HD43416.1) and of the nucleocapsin protein (RefSeq ID 0HD43423.2) in non-overlapping 15 amino acid segments. The peptides from the membrane protein were selected by dividing the sequence of 2 potential immunogenic regions of the SARS-CoV-2 (RefSeq QHD43422.1) membrane protein in overlapping 15 amino acid segments.
The peptides from the ORF8 and ORF10 proteins were selected by dividing the sequences of the SARS-CoV-2 ORF8 protein (RefSeq ID QH D43422.1) and of the ORF10 protein (RefSeq ID QHI42199.1) in overlapping 15 amino acid segments. The peptides from ORF3 and some for ORF8 were selected based on a previous study79. The SARS-CoV-1peptides were peptides found to be immunogenic in previous reported studies [11,54,80,81,82,83,84]. The peptides were synthesized by peptides&elephants GmbH
(Berlin, Germany). The peptide pools for the controls for Influenza, EBV and CMV were acquired from peptides&elephants GmbH (Berlin, Germany) order numbers LB01774, LB01361 and LB01232 respectively.
186-Single peptide in 96 well plates. Lyophilized peptides were dissolved in sterile water and used at 2pg/mL in RPM! 1640 glutamax media (GIBCO) supplemented with 1% penicillin/streptomycin (GIBCO). 185 single peptides were plated in duplicates in 96 well round bottom TPP treated culture plates. Peptide plates were then stored at -80 C
until use. The day of the experiment, peptide plates were thawed at room temperature.
Frozen PBMCs were thawed, washed and resuspended in RPM! 1640 media (GIBCO).
Viability and count were evaluated using a Vi-Cell XR Cell Counter (Beckman Coulter, Brea). PBMCs were then plated in RPM! 1640 glutamax media (GIBCO) supplemented with 1% penicillin/streptomycin (GIBCO), with 200U1/mL rhl L-2 (Miltenyi) and 200U1/mL
rhIL-15 (Miltenyi) at a cell density of 10x103 cells and incubated with each peptide at 37 C, 5% CO2. PBMCs were stimulated with 60 ng/mL OKT-3 antibody (ThermoFisher Scientific, clone OKT3) or with 10pg/mL phytohemagglutinin as positive controls and

29 PBMCs alone served as negative controls. After 6 hours, 20pL of human AB serum was added to each well and plates were incubated at 37 C, 5% CO2 for 6 additional days. On day 7, supernatants were harvested and frozen at -80 C. Concentration of IFNy, IL-9, IL-5 and IL-17A in the culture supernatant was determined using a commercial ELISA
kit (ELISA Max Deluxe set human IFN-y, Biolegend).
Peptide pools and COVID IGRA Biornerieux assay utilized for the COVID-SER
clinical trial vaccinees [43]. Fresh blood collected in heparanized tubes was stimulated for 22 hours at 37 C under 5% of CO2 with peptide pools targeting RBD (46 peptides) (bioMerieux,France) diluted in I FA solution (bioMerieux, France). The IFA
solution was used as a negative control and a mitogen was used as a positive control. The peptides (15-mer) encompassed the whole RBD protein sequence and overlapped by 5-residues.
The concentration of IFNy in the supernatant was measured using the VIDAS
automated platform (VIDASO IFNy RUG, bioMerieux). The positivity range was 0.08 -8 IU/mL
and I FA positivity thresholds were defined at 0.08 IU/mL. The IFNy response was defined as positive when the IFNy concentration of the test was above threshold and the negative control was below threshold or when the IFNy concentration of the test minus IFNy concentration of the negative control was above threshold. All positive controls were IU/mL. Peptide pools and high throughput screening T cell assay with COVID
IGRA
Biomerieux assay utilized for the COV3AP-HP clinical trial vaccinees [43].
Same process but using different peptides pools that are detailed in Figure 5C of Fahrner et al., 2022 and Table 12.
Generating TH2 cell lines.
Generatinq SARS-CoV-2 lysates specific clones. 10 million peripheral blood lymphocytes from a healthy donor with history of SARS-CoV-2-specific IL-5 release (refer to Figure 10) were stimulated with autologous monocyte derived-dendritic cells loaded with SARS-CoV-2 lysates (see cross presentation assay section). After 18 hours, cells were harvested and CD137+ cells were isolated using CD137 MicroBead Kit, human (Miltenyi, France) according to manufacturer's instructions. Limiting dilution of CD137+
cells was performed by seeding 100pL of CD137 positive cellular suspension at a 10 cells/mL concentration in 96 round botom well plates in sterile conditions.
Feeder cells were generated by isolating CD14 positive cells using CD14 MicroBead Kit, human (Miltenyi, France). Isolated feeder cells were co-cultured with CD137 positive cells at a 1000:1 ratio and cultivated in IMDM medium (Sigma-Aldrich, UK), supplemented with 10% human AB serum (Institut de Biotechnologies Jacques Boy, France), 1mM
Glutamine (G I BCO/ThermoFisher Scientific, UK), 1% Sodium Pyruvate (GIBCO/ThermoFisher Scientific, UK), 1% HEPES (GIBCO/ThermoFisher Scientific, UK), 1% penicillin/streptomycin (GIBCO/ThermoFisher Scientific, UK), supplemented with 100U1/mL IL-7 (Miltenyi,France) and 100U1/mL IL-15 (Miltenyi,France).
Medium was changed every 2-3 days. Clones were screened for IFN-y and IL-5 secretion by 5 quantification of the accumulation of these cytokines in supernatants between day 7 and day 13 using commercial ELISA kits. 93 clones of interest were identified and screened for specificity against SARS-CoV-2 lysates by quantifying I FN-y and IL-5 secretion after restimulation with autologous monocyte- derived dendritic cells loaded with SARS-CoV-2 lysate or its respective control at day 21. Three rounds of IVS were performed over 10 3 weeks. Clones were starved in a cytokine free media two days before restimulation.
Six SARS-CoV-2 specific cell lines could be identified and their MHC-I/MHC-class II
recognition dependency was assessed by monitoring IFN-y and IL-5 production after stimulation with autologous monocyte derived- dendritic cells loaded with SARS-CoV-2 lysate or its respective control in the presence or absence of neutralizing anti-H LA-ABC
15 and HLA-DR, DP, DO antibodies (W6/32 &amp; T039) at day 28. Flow cytometric determination of CD4, CD8, T-bet, GATA3 was performed on the IL-5 producing SARS-CoV-2 specific cell lines according to methods already reported [32]
Generatino Spike 25- specific cell lines.
20 PBMC from an healthy donor with previous history of breakthrough COVID-19 infection after complete vaccination were stimulated using 186 peptides spaning the ORFeome of SARS-CoV-2 (Figure 3A). I FNy and IL-5 were monitored in supernatants after 7 days of culture using commercial ELISA kits to identify IL-5 -restricted reactivity. One Spike 25 -specific IL-5 producing (but IFNy negative) T cell line was identified and further 25 expanded using monocyte derived -dendritic cells (DC) pulsed with Spike 25 for one week (at a concentration of 1 pg/mL in RPMI supplemented with 10% human AB
serum (Institut de Biotechnologies Jacques Boy, France), 1mM Glutamine (GIBCO/ThermoFisher Scientific, UK), 1% Sodium Pyruvate (GIBCO/ThermoFisher Scientific, UK), 1% penicillin/streptomycin (GIBCO/ThermoFisher Scientific, UK),

30 IL-2 200U1/mL (Miltenyi) and IL-15 (Miltenyi). After the 3rd week, the T
cell line was restimulated with Spike 25 -loaded DC in the presence or absence of neutralizing anti-HLA-ABC and HLA-DR, DP, DQ antibodies (W6/32; T039) in duplicate wells to monitor cytokine release using the 12 plex assay and stained with CD3, CD4, CD8, GATA3, T-bet, -specific antibodies to assess phenotypical characteristic by flow cytometry (refer to flow cytometric analyses).

31 Statistical analyses. All calculations, statistical tests, and data visualization were performed using R v4Ø3. All analyses were performed on independent samples, excepting when the presence of replicates is mentioned. The associations between continuous variables were evaluated using Spearman correlation. Group comparisons were performed using non-parametric test with the wilcox.test R function: the Wilcoxon-Mann-Whitney test for independent samples, and the VVilcoxon signed rank test for paired samples. When the number of replicates was unbalanced between the individuals, the Wilcoxon signed rank test for paired comparisons of clustered data was performed with the clusVVilcox.test function of the R package clusrank. The comparison of categorical data was performed using the Fisher exact test with the fisher.test R
function. Hierarchical clustering was performed with the package hclust, using the Euclidean distance. Linear and logistic regressions were performed with respectively the Im and the glm R base functions. A peptide set enrichment analysis was performed with the R package fgsea (version 1.14.0), using as statistic the t-value of the coefficient of univariable linear regressions of the logarithm-normalized IL-2 secretion on the different peptides. All hypothesis tests (including those of regression coefficients) were two-sided and considered as statistically significant when p<0.05 Graphical illustrations were drawn using the standard R packages dedicated to the data visualization (ggp10t2, ggpubr, corrplot, complexheatmap, circlize, and Hmisc). RNA -seq data analysis. Quality control were made on raw FastQ files with FastQC (v0.11.9) [85]. Quality reports were gathered with MultiQC (v1.9) [86]. Abundance estimation was performed with Salmon (v0.9.0) [87] using GENCODE (GRCh38, v34) annotation [88]. Quantification results were aggregated with tximport (v1.14.0), and differential gene analysis was performed with DESeq2 (v1.30.0), according to the Soneson et al. [89] procedure. The whole pipeline was powered by both Snakemake [90] and SnakemakeWrappers. Gene set enrichment analysis on DESeq2 results was performed with GSEA software (v4.1.0, pre-ranked based on Wald test statistic, 1000 permutations, weighted enrichment statistic) and immunologic signature gene sets coming from MSigDB (C7, v7.4) [91].
Multivariate analyses of peptide pool -specific T cell responses according to co-variates (Figure 4, Subtables S13a and S1 3b of Fahrner et a/., 2022). We pooled the 10g10 normalized IFNy secretion measurements obtained with the three peptide pools to model simultaneously their dynamics from the first shot of vaccine using linear mixed effect regression adjusted for the patient age, sex, cancer status (yes/no), COVID history, and vaccine schedule.
To identify the differences between the dynamics of each panel, we adjusted the model for the peptide pool (representing baseline differences), and added interaction terms between the peptide pool and each covariable (including the time since the first vaccine).
The intra-patient and intra-panel correlation were considered by adding patient-peptide

32 random effect for the intercept. A statistically significant interaction indicates that the covariable has an impact on the peptide-specific IFNy measurement that is statistically different from its impact on the reference peptide pool (Subtables S1 3a and S1 3b of Fahrner et al., 2022).

n >
o u, r., , ,i ,-u, r., r., o r., `.' "

N, ,i N
o N
N
Table 1. Overview of all subgroups and cohorts.
=-.) t..) z .&.
c, ,-, CROSS-COHORTS
PEPTIDES
Presentation*
NAME Cancer Covid Vaccinees 7 day-long 22hr ex Elisa ELISPOT IVS (Single vivo peptide)** (Pool)***
Yes No Yes No Yes No ONCOVID x x x x x x x x PROTECT-CoV x x x x HCW-HCL x x x x x x x x CoV3APHP x x x x x x x x Re-infected (2nd covid) x x x x x Breakthrough infection x x x x x Dupilumab x x * Refer to Figure 1B
** Refer to Figure 3A
*** Refer to Figure 5C of Fahrner et al., 2022 t r) Refer to Figure 60 m ot t..) N
N

I¨, (o) CA

(?.
Table 2. Characteristics of cancer patients and healthy individuals (ONCOVID
and others) Controls Acute COVID-19 Convalescent P.value*
P.value #
(n=320) (n=40) COVID-19 (n=69) 2000 - Nov. 2002 7 2 Nov. 2002 - 2018 61 19 Years <0.01 <0.01 Unknown 2 1 Median 61 63 Age (years) 0.13 0.02 [Range] [18-89] [20-90]
[21-85]
Male 124 45 22 55 Gender Female 150 55 18 45 0.31 41 59 0.05 Unknown 46 Yes 257 80 40 100 Malignancy <0.01 <0.01 No 63 20 0 0 Refers to available samples described in table S1 * : statistical analyses between controls and aAcute COVID-19;
#: statistical analyses between controls and convalescent (,) Table 3. Clinical characteristics of vaccinated cancer patients.
Vaccinated cancer patients (n=92) Median 57 Age (years) [Range] [20-86]
n %
Male 34 Gender Female 57 Unknown 1 Solid tumors 73 Type of cancer Hematologic tumors 18 Unknown 1 Localized 10 Locally advanced 18 Cancer spread Metastatic 62 Unknown 2 Patients under cancer All 87 treatment before sampling (windows of 2 months) Unknown 1 Chemotherapy 45 I mmunotherapy 30

33 Cancer treatment Radiotherapy 5 Others 28 Unknown 1 Table 4. Characteristics of family members during the 2020 lockdown (PROTECT-CoV).
Contact Convalescent Total P.value (n=22) (n=29) Median 46 39 49 Age (years) 0.69 [Range] [17-75] [17-75] [20-62]
n % n % n %
Male 26 51 13 59 13 Gender 0.40 Female 25 49 9 41 16 Number of contacts per case within the family <0.01 >12 0 0 5 Number of SARS-CoV-2 positive individuals in the family <0.01 Household size <0.01 Household living space (m2) <70 7 32 6 0.16 >100 12 55 12 Number of rooms in the household 0.22 Number of individuals using personal protective equipment Number of individuals respecting barriers gestures Table 5. Characteristics of contact (resistant) and infected (susceptible) cancer patients and corresponding swimmer plot.
Susceptible Resistant (n=54) P.value (n=22) Median 54 53 Age (years) 0.9 [Range] [19-81] [22-80]
n % n oh Male 17 31 11 50 Gender 0.2 Female 37 69 11 50 Yes 54 100 22 100 Malignancy 1.0 No 0 0 0 0 Solid tumors 52 96 19 86 Type of cancer 0.1 Hematologic tumors 2 4 3 14 Localized 25 46 4 18 Cancer spread Locally advanced 8 15 5 23 0.07 Metastatic 21 39 13 59 Table 6. Characteristics of contact (resistant) and infected (susceptible) cancer patients and corresponding swimmer plot.
Resistant (n=9) Susceptible P.value (n=9) Median 50 44 Age (years) 0.452 [Range] [28-71] [28-82]
n % n oh Male 4 44 2 22 Gender 1.000 Female 5 56 7 78 Yes 5 56 3 33 Malignancy 1.000 No 4 44 6 67 Solid tumors 5 100 3 100 Type of cancer 1.000 Hematologic tumors 0 0 0 0 Localized 1 20 1 33 Cancer spread Locally advanced 0 0 1 33 1.000 Metastatic 4 80 1 33 Results 1.1.
Effector and memory T cell responses against coronaviruses during COVID-19 infection We conducted a cross-sectional analysis of the functional T cell responses across several cohorts of healthy individuals and cancer patients enrolled during the first surge of the pandemic (Figure 1A, Figure 2A) with the final aim of determining T cell correlates with clinical protection against COVID-19 diagnosed until March 2021 (Tables 1-6) [27]. First, we focused on the quality of SARS-CoV-2-specific T cell responses detected in 215 cancer patients who stayed COVID-19-free between mid-March and September 2020, that we compared to 24 and 28 cancer patients in the acute and convalescence phase of SARS-COV-2 infection respectively (Tables 2&3, Figure 1A). In parallel, we analyzed 22 COVID-19-free healthy volunteers (HV) from distinct families at the same time as their family members who were in convalescent phase for COVID-19 (n=26) (Figure 2A, Table 4). A third cohort of 67 individuals from the pre-COVID-19 era (leukocytes frozen between 1999 and 2018) were either HV
from the blood bank (n=38) or cancer patients (n=29) recruited in the context of clinical trials (Figure 1A) [28-31].
T cell responses directed against viral lysates from the reference SARS-CoV-2 strain IHUMI846 (CoV-2) isolated in early 2020 or two endemic common cold coronaviruses (CCC), 0C43 and 229E, were evaluated by an in vitro stimulation assay (IVS, Figure 1B). Autologous monocyte derived-dendritic cells (DC) were differentiated for each individual and pulsed with heat-inactivated viral lysates before exposure to LPS.
The specific viral lysates were compared to supernatants from cell lines permissive for viral replication (such as VeroE6 for SARS-CoV-2, Figure S1A of Fahrner etal., 2022).
Peripheral blood lymphocytes (PBL) were then stimulated for 48hrs by viral lysate-loaded DC (Figure 1B). The cytokines accumulating in the supernatants were analyzed by means of a 12-plex flow cytometry-based bead assay (Figure S1A of Fahrner et al., 2022). In this crosspresentation assay, SARS-CoV-2-related cytokine release from PBL
depended on MHC class I and MHC class II molecules, as shown using specific neutralizing antibodies (Figure SIB of Fahrner et al., 2022). We calculated the ratio of cytokine release by dividing interleukin concentrations following exposure to viral lysates by those obtained with the respective control supernatants, to ascribe the specificity of the reactivity to SARS-CoV-2 or to common cold coronaviruses (CCC) antigens for each subject. First, we characterized the intensity and the quality of PBL
responses elicited at the acute phase of SARS-CoV-2 infection (day of symptom onset and/or first positive qPCR of the oropharyngeal swab and/or serology), between mid-March and mid-May 2020 in 24 interpretable tests performed on COVID-19+ subjects compared to a cohort of 304 controls (Tables 2&3). Robust SARS-CoV-2 specific IL-2 and I FNy release, most likely caused by TH1/Tc1 cells, and the secretion of IL-4, IL-5 and IL-10, most likely mediated by TH2/Tc2 effector T cells, were detectable (Figure 1C, Figure 1D).
Of note, COVID-19 infection did not reactivate CCC-specific T cell responses (Figure 1D, Figure S2A of Fahrner etal., 2022). We next examined the polarization of SARS-CoV-2-specific memory T cell responses between May and September 2020 in 54 convalescent COVI D-19 individuals (median time lapse between PCR negative and T cell assay: 85 days, range: 13-106 days) compared with contemporary controls (Figure 1A, Figure 1C-D, Figure SIC, S2A-B of Fahrner etal., 2022, Figure 5, Tables 2&3). A mixed SARS-CoV-2-specific memory TH1/TH2 response was observed in most convalescent subjects within the next 2-3 months after acute infection.
Differences in memory T cell responses between unexposed controls and COVID-19+ individuals could not be attributed to age, gender or cancer status as they were still statistically significant for IL-2, IL-5 and TNF-a in a separate analysis matching 51 convalescent patients to 51 control patients using a propensity score adjusting for age, gender and cancer status (Figure SIC of Fahrner etal., 2022). More specifically, SARS-CoV-2 -specific IL-2 and IL-5 secretion levels were comparable in cancer and cancer-free COVID-19 patients during the recovery phase. Flow cytometric analyses of SARS-CoV-2-reactive T
cells revealed central memory (TCM) TH1 (CD3+CD4+CD45RA-CCR7ET-bet+GATA3-CD69+Ki67-) and effector/effector memory (TEM) Tc1 (CD3+CD8+CD45RA-CCR7-T-bet+CD25+Ki67+) phenotypes (Figure S1D of Fahrner et al., 2022). Of note, SARS-CoV-2 specific IL-2 release at recovery correlated with an increase in the frequency of circulating non-activated TFH cells (Figure S1E of Fahrner et al , 2022) 32.
In some of these patients, we performed double-color IFNy/IL-5 ELISpot assays which were consistent which ELISA-based cytokine measurements (Figure S3B of Fahrner et al., 2022). Moreover, the frequency of IFNy-secreting cells correlated with the percentage of CD4+T-bet+TEM, and the frequency of IL-5-secreting cells was associated with the proliferation of CD8+CCR4+T-bet- in the crosspresentation assay (Figure S3C of Fahrner et al., 2022). Finally, SARS-CoV-2 specific IL-2 secretion was the only parameter correlating with anti-SARS-CoV-2 nucleocapsid (NC) antibody titers (reported to be stable for 8 months 5) but not with IgG and IgA antibodies targeting the Si domain of the SARS-CoV-2 spike protein including the RBD (Figure 1E-F).
As previously described [21,23,24,33,34], contemporary COVID-19 negative subjects also harbored spontaneous (cross-reactive) SARS-CoV-2 specific-polyfunctional TH1/Tc1 memory responses that appear to pre-exist in cancer patients and healthy individuals whose blood was drawn in the pre-COVI D-19 era, including prior to outbreaks of SARS-CoV-1 and MERS (Figure S2A-B of Fahrner et al., 2022 and Figure 2A). The unsupervised hierarchical clustering considering 12 cytokines monitored in 358 subjects did not segregate pre-COVID-19 from contemporary unexposed individuals nor convalescent patients (Figure S2A of Fahrner etal., 2022).

Preexisting frequencies of SARS-CoV-2-specific IL-2 and IL-5' T cell responses were comparable (about 15%) in individuals with or without cancer, with no impact of the cancer staging (Figure 5B-C).
Hence, while TH1 and TH2 cell responses were elicited during the acute phase of COVID-19, preexisting and SARS-CoV-2-induced memory responses leading 10 to IL-2 and IL-5 release were similarly detectable in healthy subjects and cancer patients.
1.2.
Clinical relevance of the IL-2/1L-5 ratio to predict COVID-19 infection We next determined the clinical significance of these memory T cell responses monitored in unexposed individuals during the first surge of COVID-19 (mid-March to mid-May 2020) to decipher the nature of memory T cells contributing to susceptibility or resistance to the successive surges of this viral pandemic in fall 2020 and winter 2021. We phoned 229 patients to discover that 22 individuals had developed COVI D-19 infections (diagnosed by qPCR or serology) with different degrees of severity according to WHO criteria (Figure 2A, Table 5). Indeed, about one third of the initially D-19-free individuals became contact cases (n=70) and 29% among these contact cases were diagnosed with COVI D-19 infection by specific RT-qPCR or serology (n=22, Figure 2B, Tables 5&6). The unsupervised hierarchical clustering of the T cell secretory profiles in these 70 individuals failed to correctly segregate resistant (contact) from susceptible (infected) cases (Figure 6A). In addition, the polyfunctionality of T cell responses failed to segregate the two categories of cancer patients (Figure 2C, Figure 6B). However, IL-2 and IL-5 secreted by memory T cells responding to SARS-CoV-2 correlated with resistance and susceptibility to SARS-CoV-2, respectively (Figure 2D-E). Indeed, the levels of IL-2 in the recall response and the proportions of individuals exhibiting IL-2 polarized T cell memory responses were both associated with resistance 30 to COVID-19 (Figure 2D, p=0.01, two-sided VVilcoxon-Mann-Whitney test, Figure 2E, p=0.049, Fisher exact test). In contrast, IL-5 levels in recall responses were associated with increased susceptibility to COVID-19 (Figure 2D, p=0.057, two-sided Wilcoxon-Mann-Whitney test). Of note, the intra-individual variability of the spontaneous SARS-CoV-2 -specific recall TH1 or TH2 responses were negligible over time (Figure 60).

Next, we analyzed the clinical significance of the ratio between SARS-CoV-2-specific IL-2 and IL-5 release. Indeed, the IL-2/1L-5 recall response ratio was significantly higher in cancer patients who were SARS-CoV-2-resistant (Figure 2F) and in convalescent patients (Figure 7A). The vast majority (15 out of 19) of cancer patients doomed to be infected with SARS-CoV-2 exhibited an IL-2/1L-5 ratio with the two severe COVID-19 cases displaying an IL-2/1L-5 ratio <10 (Figure 7B). Moreover, the transcription profile of PBL in the crosspresentation assays leading to IL-2/1L-5 ratios>
versus <1 performed in 18 patients (8 with an IL-2/IL-5 ratio>1 and 10 with an ratio < 1) was enriched in genes expressed in TH1/Tc1 (e.g. IFNy & GRZMB) versus TH2/Tc2 (e.g. CXCR5 & CD79A), respectively (Figure S3D of Fahrner etal., 2022). In contrast, CCC-specific T cell reactivities did not allow to discriminate susceptible from resistant individuals (Figure 2G), although IL-5 (not IL-2) stood out as the strongest correlate between SARS-CoV-2 and 0C43-specific T cell responses among 156 individuals (Figure 2H). Of note, titers of IgG antibodies directed against the spike of the seasonal betacoronaviruses 0C43 and HKU1 (but not the alphacoronavirus 229E
and NL63) were higher in individuals susceptible to SARS-CoV-2 compared to resistant individuals (Figure 21).
The SARS-CoV-2-specific IL-2/1L-5 recall response ratio was also clinically significant in the cohort of cancer-free individuals that were locked down together with their COVID-19-positive family members (Figure 2A, Table 4, Figure 7C-D). Individuals who did not get infected harbored IL-2/1L-5 ratios>1 reaching mean values comparable to those achieved in convalescent individuals (Figure 2F, Figure 7A) at higher frequencies than the overall population (Figure 7C). We next utilized the double-color IFNy/IL-5 ELISpot assay to enumerate cytokine-producing T cells in blood from cancer patients (n=8) and HCW (n=10) drawn in March 2020 and followed up for 12 months for the COVID-19 diagnosis (Figure 6D, Figure 21 of Fahrner et al., 2022, Table 6). While 6 out 9 resistant subjects (who did not develop COVID-19) exhibited a SARS-CoV-2 specific 2 fold increase in IFNy+/IL-5+ spot ratios, none of the 9 susceptible subjects (who developed asymptomatic or mild COVID-19) did so (Figure 6E).
Of note, Dupilumab, a monoclonal antibody blocking IL-4Ra signaling that reduces the severity of COVID-19 in rodents and patients with allergy [35], improved the IFNy/IL-5 balance of the SARS-CoV-2-specific response in a group of 9 patients suffering from atopic dermatitis (Table 7). Thus, injections of Dupilumab inhibited SARS-CoV-2-specific IL-5 release but stimulated SARS-CoV-2-specific IFNy secretion (Figure 2J, K).

n >
o u, r., , .,=1 r., o r., L.' ' :8 Table 7. Characteristics of atopic dermatitis patients treated (or not) with dupilumab during the pandemic. N

N
Allergic patients (n=9) t...) i=-.) Severity Other Date of Date of t,.) SUBJECT COVID-19 Type of Date of z Age Gender of the atopic Treatment blood COVID-19 COVID-19 .6.
# Allergy Start symptoms Allergy conditions sampling diagnosis 56 Female Atopic Moderate None Dupilumab 25/05/2017 22/06/2020 Control NA NA

Dermatitis 27 Male Atopic Moderate Food Dupilumab 21/11/2017 07/07/2020 Control NA NA
2 Dermatitis allergies, seasonal allargies 46 Male Atopic Severe None Dupilumab 06/03/2019 25/06/2020 Convalescent 29/03/2020 Unk Dermatitis 54 Male Atopic Moderate Food Dupilumab Unk/03/2019 15/07/2020 Acute Asymptomatic, No 4 Dermatitis allergies tv 56 Male Atopic Severe Seasonal Dupilumab 23/03/2018 21/08/2020 Convalescent Unk/03/ 2020 Unk Dermatitis allergies, history of asthma 6 30 Male Atopic Severe None Dupilumab Unk/04/2017 07/01/2021 Acute 07/01/2021 No Dermatitis 27 Female Atopic Moderate Food No systemic NA
27/07/2020 Acute 27/07/2020 No 7 Dermatitis allergies, treatment seasonal allergies

34 Female Atopic Moderate Seasonal No systemic NA 16/11/2020 Acute 16/11/2020 Yes 8 Dermatitis allergies treatment It r) 9 41 Female Atopic Moderate Seasonal No systemic NA Sample 1: Acute 21/01/2021 No .t.!
Dermatitis allergies treatment 21/01/2021 tt ot Sample 2:
o t=-) w NA: not applicable o --, Unk: unknown o c.) un Table 8. Characteristics of multi-contact and re-infected cancer-free individuals.
Re-infected (n=17) Multi-exposed P.value cases (n=12) Median 37 48 Age (years) 0.08 [Range] [16-78] [28-69]
n % n %
Male 7 41 6 50 Gender 0.72 Female 10 59 6 50 Yes 5 31 -Comorbidities No 11 69 - --Unknown 1 - - -Asthma 3 60 Obesity 2 40 - -Type 2 Type of 2 40 - -diabetes _ cornorbidities Cancer 20 - -HIV* 1 20 - -H BP** 2 40 - -<03 2 17 - -Time to reinfection 03 - 06 7 58 - -(mo.) >06 3 25 -Unknown 5 - - -B.1.177 1 - - -B.1.160 6 - - -Second surge 9.1.351 1 - - --variants 9.1.1.7 2 - - -Unknown 7 - - -Refers to eligible patients described in Table Si *Human Immunodeficiency Virus **High Blood Pressure Given that 15-25% of individuals exhibit a TH2/Tc2 memory response to SARS-CoV-2 (Figure 7D), we wondered whether such individuals would be at higher risk to get reinfected by SARS-CoV-2 variants. Hence, we analyzed PBMCs in a series of individuals (n=17) who were diagnosed with COVID-19 during the first surge of the SARS-CoV-2 pandemic and then were reinfected with viral variants prevailing during the later outbreak occurring in fall 2020 or winter 2021, comparing them to HCW
who, in spite of multi-exposure and multiple oropharyngeal PCR tests, remained SARS-CoV-2-negative (n=12) (Table 8, Figure 2L). Surprisingly, monocytes could be differentiated into DC only in 4 out of 17 reinfected patients. Unstimulated PBL from reinfected and re-convalescent subjects spontaneously secreted much higher levels of IL-5 than did PBL
from multi-exposed cases, reaching similar ranges as those obtained after TCR
crosslinking (Figure 2L, middle panel). After specific restimulation with SARS-CoV-2 lysates, IL-10 was markedly increased in recall responses from reinfected but not multi-exposed cases (Figure 2L, right panel), and IL-2 was undetectable (Figure 8A).
In this small cohort of multi-contact individuals, the recognition pattern of the United Kingdom (UK) (IHUMI3076, B.1.1.7), South Africa (IHUMI3147, B.1.351) and Brazil (IHUMI3191, P.1)[25] strains were rather variable, some individuals losing the TH1/Tc1 or acquiring a TH2/Tc2 profile, depending on the strain (Figure S4A of Fahrner et al., 2022).
We next compared the immunogenicity of the lysates derived from the original SARS-CoV-strain (IHUM1846) with that of the Danish (IHUMI2096, 20A.EU2, B.1.367, GH) and North African (IHUM12514, 20C, B.1.160, GH) strains isolated at the end of 2020 [25]. Of note, T cells lost their capacity to produce IL-2 in response to the IHUMI2096 and viral variants while IL-17 release tended to increase (p=0.0857, Figure 8B).
We conclude that an imbalanced TH1/Tc1 versus TH2/Tc2 polarity of SARS-CoV-2 specific-memory T cell responses determines susceptibility to infection, an IL-2/1L-5 ratio >1 indicating resistance to COVID-19.
1.3. Defects in the Th1 repertoire residing in SARS-CoV-2 RBD in susceptible individuals In hosts affected by viral infections or cancer, the breadth of T cell epitope recognition is a prerequisite for protective immunity [36-38]. We analyzed the diversity of SARS-CoV-2 T cell responses by single peptide mapping using 186 peptides with 9 to 51 amino acids corresponding to 146 non-overlapping or poorly overlapping epitopes of the SARS-CoV-2 ORFeome (among which 25 epitopes were shared with SARS-CoV-1), encompassing membrane, nucleocapsid, spike, ORF3a, ORF8 and ORF10 proteins, plus 41 epitopes covering the SARS-CoV-1 ORFeome of immunological relevance (among which 8 epitopes were shared with SARS-CoV-2), as well as a series of positive controls, namely epitopes from influenza virus, Epstein Barr virus (EBV) and cytomegalovirus (CMV), phytohemagglutinin (PHA), and anti-CD3c (OKT3) antibody (Table 9). IFNy responses against the 186 peptides were evaluated in 148 individuals (121 unexposed individuals, 27 convalescent COVID-19-positive patients, 18 reinfected patients). To enable the detection of low-frequency SARS-CoV-2 peptide-specific T cells, we used an in vitro 7 day-long, IL-2+IL-15 enriched IVS assay in the presence of each individual peptide (Figure 3A). We chose to monitor IFNy, a proxy for TH1/Tc1 responses, as opposed to IL-2, in the 7 day- coculture supernatants by ELISA
because recombinant human IL-2 was already added to the IVS assay to maintain T cell viability (Figure 3A). The overall recognition patterns of these peptides across various patient populations, and their individual frequencies are detailed in Figure 3B, 3C
and S5 of Fahrner et at., 2022. About 10% convalescent individuals recognized more than 15%
of our peptide selection within the SARS-CoV-2 ORFeome. T cell responses in 5 unexposed patients, in particular in the pre-COVID-19 era, covered large specificities, as suggested by previous reports [9,21,24] (Figure 3B, right panel and Figure 3C of Fahrner et al., 2022). In accord with the literature [9,24], the T cell repertoire of convalescent COVID-19 patients was larger than that of unexposed individuals, mainly directed against spike, membrane, and nucleocapsid (NC) and, to a lower extent, against 10 ORF3a, ORF8, and ORF10 (Figure 3B, 3D left panel). The breadth of the peptide recognition coverage tended to be reduced in cancer patients compared with others (Figure 3B left panel, Figure 3B of Fahrner et al., 2022). In a limited number of individuals, we measured not only IFNy but also IL-5, IL-9 and IL-17 by ELISA.
The recognition profile specific to the spike (and more specifically the RBD) as well as ORF8 15 was more geared toward TH1/Tc1 (IFNy) than TH2 (IL-5), TH9 (IL-9) or TH17 (IL-17) production (Figure S6A-C of Fahrner et al., 2022). The membrane- and NC-specific repertoire was strongly TH17 oriented (Figure S6B of Fahrner et al., 2022).
Using logistic regression analyses, we determined the TH1/Tc1 peptide recognition fingerprint significantly associated with each patient category (Figure 9A).
20 The hallmark repertoire of the pre-COVID-19 era consisted in a stretch of peptides covering part of the SARS-CoV-1 genome (spike, membrane, ORF3a, NC), some peptide residues sharing high or complete homology with SARS-CoV-2, as well as numerous ORF8 sequences (Table 9). Of note, the recognition pattern of these SARS-CoV-1 epitopes highly correlated with responses directed against ORF8 peptides. In 25 contrast, the COVID-19-associated blueprint encompassed many nucleocapsid peptides (NC_1 (residues 1-15), NC_6-7 (residues 76-105, NC_8 (residues 106-120) sharing 93%
and 100% homology with 0C43 and HKU1, respectively, the HLA-A2- restricted nonamer (RLNQLESKV) NC_226-234 from SARS-CoV-1 (sharing high structural homology with the SARS-CoV-2 epitope RLNQLESKM) and another SARS-CoV-1 NC
30 nonamer peptide (NC_345-361), three peptides residing in ORF8, two epitopes belonging to the RBD region ("SPIKE29") found at high frequency across subjects (23.5%), as well as a peptide from the C terminal portion of spike ("SPIKE84", residues 1246-1260) (Figure 9A). Cancer patients tended to lack some specificities, yet with no prototypical signature (Figure 9A).

n >
o 1. .
r . , , ,11 .j ir 1 :1 o Table 9. SARS-CoV-1 and CoV-2 orfeome peptide list: sequences and positions.
N

N
N
Similar SARS- SARS- SARS- i=-.) Peptide SARS-CoV-2 z Peptide name SEQ ID Virus Protein sequence in SEQ ID CoV-2 last CoV-1 CoV-1 .6.
sequence 1st pos SARS-CoV-2 pos 1st pos last pos 1--, MFVFLVLLPLVS
Spike1 1 SARS-CoV-2 Spike 1 15 SQC
VNLTTRTQLPP
Spike2 2 SARS-CoV-2 Spike 16 30 AYTN
SFTRGVYYPDK
Spike3 3 SARS-CoV-2 Spike 31 45 VFRS
SVLHSTQDLFLP
Spike4 4 FFS SARS-CoV-2 Spike NVTWFHAIHVS
Spike5 5 SARS-CoV-2 Spike 61 75 GTNG
TKRFDNPVLPF
Spike6 6 SARS-CoV-2 Spike 76 90 NDGV
YFASTEKSNIIR
Spike7 7 SARS-CoV-2 Spike GWI
a, FGTTLDSKTQS
Spike8 8 SARS-CoV-2 Spike 106 120 LLIV
NNATNVVIKVCE
Spike9 9 FQF SARS-CoV-2 Spike CNDPFLGVYYH
Spike10 10 SARS-CoV-2 Spike 136 150 KNNK
SWMESEFRVYS
Spike11 11 SARS-CoV-2 Spike SANN
It CTFEYVSQPFL
n 5pike12 12 SARS-CoV-2 Spike MDLE
t.J.
tt GKQGNFKNLRE
It Spike13 13 SARS-CoV-2 Spike 181 195 r.) FVFK
o r.) NIDGYFKIYSKH
w Spike14 14 SARS-CoV-2 Spike TPI
o --, NLVRDLPQGFS
o Spike15 15 SARS-CoV-2 Spike 211 225 c.) un ALEP

n >
o 1. .
r . , , ,11 .j ir 1 :1 LVDLPIGINITRF

Spike16 16 SARS-CoV-2 Spike QT
o LLALHRSYLTPG
r..) Spike17 17 SARS-CoV-2 Spike 241 255 i=-.) DSS
t,.) o SGINTAGAAAYY
.6.
Spike18 18 SARS-CoV-2 Spike 256 270 1--, VGYL
QPRTFLLKYNE
Spike19 19 SARS-CoV-2 Spike 271 285 NGTI
TDAVDCALDPL
Spike20 20 SARS-CoV-2 Spike 286 300 SETK
CTLKSFTVEKGI
Spike21 21 SARS-CoV-2 Spike 301 315 YQT
SNFRVOPTESIV
Spike22 22 SARS-CoV-2 Spike 316 330 RFP
NITNLCPFGEVF SARS-CoV-1+ SARS-Spike23 23 NAT CoV-2 Spike RFASVYAINNRK
Spike24 24 SARS-CoV-2 Spike RISN
.r.
-...1 CVADYSVLYNS
Spike25 25 SARS-CoV-2 Spike 361 375 ASFS
TFKCYGVSPT K
Spike26 26 SARS-CoV-2 Spike 376 390 LNDL

Spike27 27 SARS-CoV-2 Spike 391 405 RGD
EVRQIAPGQTG
Spike28 28 SARS-CoV-2 Spike 406 420 KIAD
YNYKLPDDFTG
Spike29 CVIA 29 SARS-CoV-2 Spike INNSNNLDSKV
n Spike30 30 SARS-CoV-2 Spike 436 450 t.J.
GGNYN
tt YLYRLFRKSNLK
It Spike31 31 SARS-CoV-2 Spike 451 465 r.) PFE
o 6.) RDISTEIYQAGS
Spike32 32 SARS-CoV-2 Spike o TPC
i--, o NGVEGFNCYFP
c.) Spike33 33 SARS-CoV-2 Spike 481 495 un LQ SY

n >
o 1. .
r . , , ,11 .j ir 1 :1 GFQPTNGVGY

Spike34 34 SARS-CoV-2 Spike QPYRV

VVLSFELLHAPA
r..) Spike35 35 SARS-CoV-2 Spike 511 525 i=-.) TVC
t,.) z GPKKSTNLVKN
.6.
Spike36 36 SARS-CoV-2 Spike 526 540 1¨

KCVN
FNFNGLTGTGV
Spike37 37 SARS-CoV-2 Spike LTES
NKKFLPFQQFG
Spike38 38 SARS-CoV-2 Spike RDIA
DTTDAVRDPQT
Spike39 39 SARS-CoV-2 Spike LEIL
DITPCSFGGVS
Spike40 40 SARS-CoV-2 Spike VITP
GINTSNOVAVL
Spike41 41 SARS-CoV-2 Spike YQDV
NCTEVPVAIHAD
Spike42 42 SARS-CoV-2 Spike OLT
PTWRVYSTGSN
Spike43 43 SARS-CoV-2 Spike URN
oo RAGCLIGAEHV
Spike44 44 SARS-CoV-2 Spike NNSY
ECDIPIGAGICA
Spike45 45 SARS-CoV-2 Spike SYQ
TQTNSPRRARS
Spike46 46 SARS-CoV-2 Spike VASQ
SIIAYTMSLGAE
Spike47 47 NSV SARS-CoV-2 Spike 691 705 AYSNNSIAIPTN
n Spike48 48 SARS-CoV-2 Spike 706 720 t.J.
FTI
tt SVTTEILPVSMT
It Spike49 49 SARS-CoV-2 Spike 721 735 r.) KTS

6.) VDCTMYICGDS
Spike50 50 SARS-CoV-2 Spike a, TECS
i¨

=, NLLLQYGSFCT SARS-CoV-1 + SARS-ca Spike51 CoV-2 51 Spike 751 765 733 747 un QLNR

n >
o 1. .
r . , , ,11 .j ir 1 :1 ALTGIAVEQDKN
Spike52 52 SARS-CoV-2 Spike TQE

VFAQVKQIYKTP
r..) Spike53 53 SARS-CoV-2 Spike 781 795 i=-.) PIK
t,.) z .6.
DFGGFNFSQILP
Spike54 54 SARS-CoV-2 Spike 796 810 1--, DPS
KPSKRSFIEDLL
Spike55 55 SARS-CoV-2 Spike FNK
VTLADAGFIKQY
Spike56 56 SARS-CoV-2 Spike GDC
LGDIAARDLICA
Spike57 57 SARS-CoV-2 Spike QKF
NGLTVLPPLLTD
Spike58 58 SARS-CoV-2 Spike EMI
AQYTSALLAGTI
Spike59 59 SARS-CoV-2 Spike 871 885 TSG
VVIFGAGAALQI SARS-CoV-1+ SARS-Spike60 60 PFAM CoV-2 Spike -1.
QMAYRFNGIGV SARS-CoV-1 + SARS-Spike61 61 TQNV CoV-2 Spike 901 915 883 897 LYENQKLIANQF
Spike62 62 SARS-CoV-2 Spike NSA
IGKIQDSLSSTA
Spike63 63 SARS-CoV-2 Spike 931 945 SAL
GKLQDVVNQNA SARS-CoV-1 + SARS-Spike64 64 Spike QALN CoV-2 TLVKQLSSNFG SARS-CoV-1 + SARS-Spike65 AISS CoV-2 65 Spike VLNDILSRLDKV SARS-CoV-1+ SARS-n Spike66 66 EAE CoV-2 Spike 976 990 958 972 t.!
tt Val DRLITGRLQ SARS-CoV-1 + SARS-1-1:
Spike67 67 Spike 991 1005 973 987 r.) SLQ CoV-2 r.) TYVTQQLIRAAE SARS-CoV-1+ SARS-O--Spike68 68 Spike 1006 1020 988 1002 a, IRA CoV-2 i--=, SANLAATKMSE SARS-CoV-1+ SARS-c.) Spike69 CoV-2 69 Spike 1021 1035 1003 1017 un CVLG

n >
o 1. .
r . , , ,11 .j ir 1 :1 QSKRVDFCGKG SARS-CoV-1 + SARS-Spike70 70 YHLM CoV-2 Spike SFPQSAPHGW
r..) Spike71 71 SARS-CoV-2 Spike 1051 1065 i=-.) FLHV
t,.) z TYVPAQEKNFT
.6.
Spike72 72 SARS-CoV-2 Spike 1066 1080 1--, TAPA
ICHDGKAHFPR
Spike73 73 SARS-CoV-2 Spike 1081 1095 EGVF
VSNGTHWFVTQ
Spike74 74 SARS-CoV-2 Spike 1096 1110 RNFY
EPQIITTDNTFV
Spike75 75 SARS-CoV-2 Spike 1111 1125 SGN
CDVVIGIVNNTV
Spike76 76 SARS-CoV-2 Spike 1126 1140 YDP
LQPELDSFKEEL SARS-CoV-1+SARS-Spike77 77 DKY CoV-2 Spike FKNHTSPDVDL SARS-CoV-1+SARS-Spike78 78 GDIS CoV-2 Spike GINASWNIQKE SARS-CoV-1+SARS-Spike79 79 IDR CoV-2 Spike LNEVAKNLNES SARS-CoV-1 + SARS-Spike80 80 Spike LIDL CcV-2 QELGKYEQYIK SARS-CoV-1 + SARS-Spike81 81 Spike WPVVY CoV-2 IWLGFIAGLIAIV
Spike82 82 SARS-CoV-2 Spike 1216 1230 MV
TIMLCCMTSCC
Spike83 SCLK 83 SARS-CoV-2 Spike It GCCSCGSCCKF
n Spike84 84 SARS-CoV-2 Spike 1246 1260 t.J.
DEDD
tt SEPVLKGVKLH SARS-CoV-1 + SARS-It Spike85 85 CcV-2 Spike 1261 1273 1243 1255 r.) YT

6.) MSDNGPQNQR
Nucleocapsidi 86 SARS-CoV-2 Nucleocapsid a, NAPRI
i--, =, TFGGPSDSTGS
c.) Nucleocapsid_2 87 SARS-CoV-2 Nucleocapsid 16 30 un NQNG

n >
o 1. .
r . , , ,11 .j ir 1 :1 ERSGARSKQRR
Nucleocapsid_3 PQGL 88 SARS-CoV-2 Nucleocapsid b.) PNNTASINFTAL SARS-CoV-1+ SARS-i=-.) Nucleocapsid_4 TQHG CoV-2 89 Nucleocapsid 46 60 47 61 t,.) z .6.
KEDLKFPRGQG
Nucleocapsid_5 90 SARS-CoV-2 Nucleocapsid 61 75 1--, VPIN
TNSSPDDQIGY
Nucleocapsid_6 YRRA 91 SARS-CoV-2 Nucleocapsid TRRIRGGDGKM
Nucleocapsid_7 92 SARS-CoV-2 Nucleocapsid 91 105 KDLS
PRINYFYYLGTG
Nucleocapsid_8 93 PEAG SARS-CoV-2 Nucleocapsid 106 120 LPYGANKDGIIIN
Nucleocapsid _9 94 SARS-CoV-2 Nucleocapsid 121 135 VAT
EGALNTPKDHI SARS-CoV-1+ SARS-Nucleocapsid_l 0 95 GTRN CoV-2 Nucleocapsid PANNAAIVLQLP
Nucleocapsidi 1 96 SARS-CoV-2 Nucleocapsid QGT
v, TLPKGFYAEGS SARS-CoV-1+ SARS-Nucleocapsid_12 97 RGGS CoV-2 Nucleocapsid QASSRSSSRSR
Nucleocapsid_13 NSSR 98 SARS-CoV-2 Nucleocapsid NSTPGSSRGTS
Nucleocapsid_14 99 FARM SARS-CoV-2 Nucleocapsid 196 210 AGNGGDAALAL
Nucleocapsid 15 100 SARS-CoV-2 Nucleocapsid 211 225 LLLD
RLNQLESKMSG
Nucleocapsid_16 KGQQ 101 SARS-CoV-2 Nucleocapsid 1-o QQGQTVTKKSA SARS-CoV-1+ SARS-n Nucleocapsid_17 102 AEAS CoV-2 Nucleocapsid 241 255 242 256 t.J.
tt It KKPRQKRTATK
r.) Nucleocapsid_18 103 SARS-CoV-2 Nucleocapsid AYNV
6.) TQAFGRRGPEQ SARS-CoV-1+ SARS--cB
Nucleocapsid_19 104 TQGN CoV-2 Nucleocapsid 271 285 272 286 o, --, =, FGDQELIRQGT
c.) Nucleocapsid_20 105 SARS-CoV-2 Nucleocapsid 286 300 un DYKH

n >
o 1. .
r . , "
,11 .j ir 1 :1 WPQIAQFAPSA SARS-CoV-1 + SARS-Nucleocapsid_21 106 SAFF CoV-2 Nucleocapsid w b.) GMSRIGMEVTP SARS-CoV-1 + SARS-Nucleocapsid_22 107 SGTW CoV-2 Nucleocapsid 316 330 317 331 i=-.) z .6.
LTYTGAI KLDDK
Nucleocapsid_23 108 SARS-CoV-2 Nucleocapsid 331 345 1--, DPN
F KDQVI LLN K H I
Nucleocapsid_24 109 SARS-CoV-2 Nucleocapsid 346 360 DAY
KTFPPTEPKKD SARS-CoV-1 + SARS-Nucleocapsid_25 110 KKKK CoV-2 Nucleocapsid 361 375 362 ADETQALPQRQ
Nucleocapsid_26 111 SARS-CoV-2 Nucleocapsid KKQQ
TVTLLPAADLDD
Nucleocapsid 27 112 SARS-CoV-2 Nucleocapsid FS K
QLQQSMSSADS
Nucleocapsid_28 113 SARS-CoV-2 Nucleocapsid TQA
MADSNGTITVE
Membrane_1 114 SARS-CoV-2 Membrane 1 15 ELKK
ITVE ELK KLLEQ
v, Membrane_2 115 SARS-CoV-2 Membrane VVNL
K KLLEQWNLVI
Membrane_3 116 SARS-CoV-2 Membrane GFLF
EQWNLVIGFLFL
Membrane_4 117 SARS-CoV-2 Membrane TWI
LLESELVIGAVIL
Membrane _5 118 SARS-CoV-2 Membrane RG
IGAVILRGHLRIA
Membrane_6 119 SARS-CoV-2 Membrane GH
1-io HLRIAGHHLGR
n Membrane_7 120 SARS-CoV-2 Membrane 148 162 t.J.
CDI K
tt LLN KHIDAYKTF SARS-CoV-1 + SARS-It r..) SARS 2016.05.006 CoV-2 Nucleocapsid 6.) PLQASLPFGWL PIQASLPFGW
O--SARS_10.1128_1 122 SARS-CoV-1 0 RF3a 188 36 50 36 50 o, VIGV LIVGV
i--, =, NYNYKYRYLRG NYNYLYRLFR
c.) SARS_10.1128_2 123 SARS-CoV-1 Spike KLRPF KSNLKPF

n >
o 1. .
r . , , ,11 .j ir 1 :1 AGCLIGAEHVD
AGCLIGAEHV
SARS_10.1128_3 124 SARS-CoV-1 Spike TSYECDI
NNSYECDI t,.) r..) GETALALLLLDR
GDAALALLLL
SARS_10.1128_4 125 SARS-CoV-1 Nucleocapsid 191 215 229 216 230 i=-.) LNQ DRLNQ
z .6.
GHLRMAGHSLG
GHLRIAGHHL
SARS_10.1128_5 126 SARS-CoV-1 Membrane 192 147 161 146 160 1--, RCDI GRCDI
NFNGLTGTGVL
NFNGLTGTGV im SARS_10.1128_6 127 SARS-CoV-1 TPSSKRF Spike LTESNKKF
'''''' DIPIGAGICASY
DIPIGAGICAS
SARS_10.1128_7 128 SARS-CoV-1 HTVSLL Spike SWFITQRNFFS
HWFVTQRNF
SARS_10.1128_8 129 SARS-CoV-1 Spike PQM YEPQII
SARS-CoV-1 + SARS-SARS_HLA-A*02:01_1 FIAGLIAIV 130 CoV-2 Spike SASS-CoV-1 + SARS-SARS_HLA-A*02:01_2 LITGRLQSL 131 CoV-2 Spike SARS-CoV-1 + SARS-SARS_HLA-A*02:01_3 RLNEVAKNL 132 CoV-2 Spike u, SARS_HLA-A*02:01_4 ILPDPLKPT 133 SARS-CoV-1 Spike SARS-CoV-1+SARS-SARS_HLA-A*02:01_5 WFLHVTYV 134 CoV-2 Spike SARS_HLA-A*02:01_6 KLPDDFMGCV 135 SARS-CoV-1 Spike KLPDDFTGCV 197 424 433 411 420 SARS-CoV-1+SARS-SARS_HLA-A*02:01_7 VLNDILSRL 136 CoV-2 Spike SASS-CoV-1 + SARS-SARS_HLA-A*02:01_8 LLLDRLNQL 137 CoV-2 Nucleocapsid SARS_HLA-A*02:01_9 RLNQLESKV 138 SARS-CoV-1 Nucleocapsid RLNQLESKM 198 226 234 227 235 SARS-CoV-1+SARS-SARS_HLA-A*02:01_10 GMSRIGMEV 139 CoV-2 Nucleocapsid 316 324 317 325 1-io n WLTYHGAIKLD
WLTYTGAIKL tJ.
SARS_HLA-A*02:01_11 140 SARS-CoV-1 Nucleocapsid 199 330 346 331 347 tt DKDPQF
DDKDPNF It r.) QFKDNVILLNKH
NFKDQVILLN o SARS_HLA-A*02:01_12 141 SARS-CoV-1 Nucleocapsid 200 345 361 346 362 t,.) IDAYK
KHIDAYK t,.) O--MASGGGETALA
MAGNGGDAA 0, --, SARS_HLA-A*02:01_13 LLLLDRLNQLES 142 SARS-CoV-1 Nucleocapsid LALLLLDRLN 201 210 234 211 235 =, c.) KV QLESKM
un n >
o 1. .
r . , "
,11 .j ir 1 :1 TWLTYHGAIKLD
TWLTYTGAIK N
SARS_HLA-A*02:01_14 DKDPQFKDNVIL 143 SARS-CoV-1 Nucleocapsid LDDKDPNFKD 202 329 353 330 354 cc L QVILL
r..) i=-.) SARS_HLA-A*02:01_15 GETALALLLL 144 SARS-CoV-1 Nucleocapsid GDAALALLLL 203 215 224 216 225 z .6.
LVIGFLFLAWIM
LVIGFLFLTWI
1--, SARS_HLA-A*02:01_16 LLQFAYSNRNR 145 SARS-CoV-1 Membrane CLLQFAYANR 204 22 45 21 44 F NRF
VLAAVYRINIM/
VLAAVYRINWI
SARS HLA-A*02:01 17 TGGIAIAMACIV 146 SARS-CoV-1 Membrane TGGIAIAMACL 205 66 92 65 91 GLMW VGLMW
ILLNVPLHGTI
ILLNVPLRGTIVT
SARS_HLA-A*02:01_18 147 SARS-CoV-1 Membrane LTRPLLESEL 206 RPLMESELVIG
VIG
IGNYKLNTDHA
IGNYKLNTDH
SARS_HLA-A*02:01_19 GSNDNIALLV 148 SARS-CoV-1 Membrane GHLRMAGHPLG
GHLRIAGHHL
SARS_HLA-A*02:01_20 149 SARS-CoV-1 Membrane RCDI GRCDI
PLQASLPFGWL
PIQASLPFGW 50 v, SARS_HLA-A*02:01_21 150 SARS-CoV-1 ORF3a 188 36 50 36 -i.
VIGV LIVGV
DVNCTEVPVA
DVNCTDVSTAIH
SARS_01026-X 151 SARS-CoV-1 Spike ADQLTPAWR
R
KDKKKKADET
KDKKKKTDEAQ
SARS_01025-8_1 152 SARS-CoV-1 Nucleocapsid QALPQRQKK 209 370 389 371 390 PLPQRQKKQ
Q
QRQKKQPTVTL
QRQKKQQTV
SARS_01025-8_2 LPAADMDDFSR 153 SARS-CoV-1 Nucleocapsid TLLPAADLDD 210 384 406 385 407 Q FS KQ
1,0 n NAFNCTFEYISD
SARS_HLA-DR0401_1 154 SARS-CoV-1 Spike 155 172 t.J.
AFSLDV
tt It YISDAFSLDVSE
r.) SARS HLA-DR0401 2 155 SARS-CoV-1 KSGNFK Spike t-) YLRHGKLRPFE
O--SARS_HLA-DR0401_3 156 SARS-CoV-1 Spike 442 459 0, RDISNVP
i--=, RPFERDISNVPF
c.) SARS_HLA-DR0401_4 157 SARS-CoV-1 Spike 449 465 SPDGK

n >
o 1. .
r . , , ,11 .j ir 1 :1 MADSNGTITV
MADNGTITVEEL
N
EELKKLLEQW cc SARS_3726.20051 KQLLEQWNLVI 158 SARS-CoV-1 Membrane NLV1GFLFLTW 211 1 32 1 31 GFLFLAWI
i=-.) I
z .6.
LMESELVIGAVII
LLESELVIGAV
1--, SARS_3726.2005_2 RGHLRMAGHPL 159 SARS-CoV-1 Membrane ILRGHLRIAGH 212 133 162 132 161 GRCDIK HLGRCDIK
NNNAATVLQLP
ANNAAIVLQL
SARS_5314.20041 QGTTLPKGFYA 160 SARS-CoV-1 Nucleocapsid PQGTTLPKGF 213 152 175 153 176 EGSR YAEGSR
KTFPPTEPKK
KTFPPTEPKKD
DKKKKADETQ
KKKKTDEAQPL
ALPQRQKKQ
SARS_5314.2004_2 PQRQKKQPTVT 161 SARS-CoV-1 Nucleocapsid QTVTLLPAAD
LLPAADMDDFS
LDDFSKQLQQ
RQLQNSM
SM
MKFLVFLGIITTV
ORF8_1 162 SARS-CoV-2 ORF8 AA
v, GIITTVAAFHQE
v, ORF8_2 163 SARS-CoV-2 ORF8 8 22 CSL
AFHQECSLQSC
ORF8_3 164 SARS-CoV-2 ORF8 15 29 TQHQ
LQSCTQHQPYV
ORF8_4 165 SARS-CoV-2 ORF8 22 36 VDDP

ORF8_5 166 SARS-CoV-2 ORF8 29 43 HFYS
PCPIHFYSKWYI
ORF8_6 167 SARS-CoV-2 ORF8 RVG
It SKWYIRVGARK
n ORF8_7 168 SARS-CoV-2 ORF8 43 57 tJ..
SAPL
tt GARKSAPLIELC
It ORF8 J3 169 SARS-CoV-2 ORF8 50 64 r.) VDE

LIELCVDEAGSK
ORF8_9 170 SARS-CoV-2 ORF8 SPI
0, --, EAGSKSPIQYIDI
=, c.) ORF8_10 171 SARS-CoV-2 ORES

GN

n >
o u , r . , , ir 1 ', IQYIDIGNYTVS
ORF8_11 172 SARS-CoV-2 ORF8 71 85 t..) CLP

w NYTVSCLPFTIN
b.) ORF8_12 173 SARS-CoV-2 ORF8 78 92 i=-.) CQE
w o .&.
PFTINCQEPKLG
c, ORF8_13 174 SARS-CoV-2 ORF8 85 99 1¨
SLV
EPKLGSLWRC
ORF8_14 175 SARS-CoV-2 ORF8 92 106 SFYE
WRCSFYEDFL
ORF8_15 176 SARS-CoV-2 ORF8 99 113 EYHD
EDFLEYHDVRV
ORF8_16 177 SARS-CoV-2 ORF8 106 120 VLDF
ORF8_17 DVRWLDFI 178 SARS-CoV-2 ORF8 MGYINVFAFPFT
ORF10_1 179 SARS-CoV-2 ORF10 IYS
vl AFPFTIYSLLLC
(:), ORF10_2 180 SARS-CoV-2 ORF10 8 22 RMN
SLLLCRMNSRN
ORF10_3 181 SARS-CoV-2 ORF10 15 29 YIAQ
NSRNYIAQVDV
ORF10_4 182 SARS-CoV-2 ORF10 22 36 VNFN
ORF10_5 QVDWNFNLT 183 SARS-CoV-2 ORF10 29 38 GNYTVSCSPFTI
ORF8_A 184 SARS-CoV-2 ORF8 77 91 NCQ
GNYTVSCLPFTI
ORF8_BC 185 SARS-CoV-2 ORF8 77 91 NCQ
VQIHTIDGSSGV
ORF3a_AB 186 SARS-CoV-2 ORF3a 244 258 It VNP
r) VQIHTIDVSSGV
-.., ORF3a_C 187 SARS-CoV-2 ORF3a 244 258 m VNP
ot w t,) SARS-CoV-2 Refseq ID: QHD43416.1 (Spike); QHD43423.2 (nucleocapsid);
QH043419.1 (membrane); QHD43417.1 and QHZ00380.1 -`,-(0rf3a); QHD43422.1 (0r18); QHI42199.1 (Orf10); SARS-CoV-1 Refseq ID:
AAP41037.1 (Spike); AAP41047.1 (nucleocapsid); o, ,-, =, AYV99779.1 (membrane); AYV99776.1 (0rf3a); (0rf8); (Orf10) (,) u, Next, we investigated the ORFeome peptide repertoire associated with SARS-CoV-2-specific IL-2 (supposedly protective) memory responses in 118 unexposed individuals by means of linear regression analysis (Figure 4B of Fahrner et a/., 2022, left panel). Among the 9 peptides associated with a positive contribution to IL-2 secretion, one nonamer (KLPDDFMGCV in SARS-CoV-1 genome and KLPDDFTGCV in the SARS-CoV-2 genome) resided in the RBD region that constitutes the binding site for its cellular receptor angiotensin-converting enzyme 2 (ACE2) 39 while, conversely among the 13 peptides associated with a hole in the TH1 response, 5 resided within the RBD of the spike glycoprotein. More specifically, there was a statistically significant enrichment of RBD-related peptides within this TH1/Tc1 hole (Figure 4B of Fahrner et al., 2022, right panel).
In order to validate the clinical significance of the TH1/Tc1 repertoire hole and the assumption that a defect in the TH1/Tc1 recognition pattern of the RBD
sequence could be a risk factor for COVID-19, we annotated the presence of at least one positive peptide selected from the RBD region spanning aminoacid 331-525 residues (called "SPIKE23" to "SPIKE35" in Table 9), versus other regions of the Orfeome in each of the 83 individuals who were comprehensively explored in the peptide-based IVS assay, resistant (contact) individuals, 14 infected persons (susceptible) as well as 32 controls (unexposed lockdown and/or unknown) using the I FNy ELISA (Figure 4A). The Volcano plot assigning significant odd ratios of TH1/Tc1 reactivities to different SARS-CoV1/CoV2 aminoacid sequences between susceptible versus resistant individuals, highlighted that anti-S1-RBD TH1/Tc1 reactivity best correlated with resistance to infection (Figure 4A). In accordance with the immunodominance of S1-RBD, the other signatures indicated by our logistic regression analysis (Figure 9A), namely the convalescent or the pre-COVID-19 era -related blueprints were not significantly associated with COVID-19 resistance (Figure 4E-F of Fahrner et at., 2022). While susceptible individuals exhibited a significant defect in the RBD-related TH1/Tc1 repertoire (Figure 4B), up to 25% of the resistant individuals harbored robust TH1/Tc1 responses to the 331-525 aminoacid residues of RBD
(Figure 4B, p=0.049, Fisher exact test). Secondly, the RBD-specific TH1/Tc1 responses were almost undetectable in patients who got infected twice with SARS-CoV-2 (Table 8), while they could be measured in 50% convalescent COVID-19 patients (Figure 40, p=0.011, Fisher exact test) in accordance with a recent report highlighting the immunodominance of the S346-365 region (corresponding to our "SPIKE24" epitope) in convalescent individuals [40].
Thirdly, patients diagnosed with COVID-19 breakthrough infections more than one month after complete vaccination (Table 10) harbored a major defect in S1-RBD-specific TH1/Tc1 cell responses (Figure 4D). Of note, neutralizing antibody titers were above the detection limit in 66% of COVID-19 patients infected once versus 40% of reinfected patients. In contrast, in vaccinees experiencing breakthrough infection, IgG antibody titers against trimeric Spike assessed within 2 months post-2nd vaccine were comparable to levels measured in unaffected vaccinees (Figure S6D of Fahrner et al., 2022). Thus the cellular anti-S1-RBD TH1fTc1 response might be a better predictor of protection against SARS-CoV-2 infection than the humoral response against trimeric Spike.
Table 10. Characteristics of vaccinees experiencing a breakthrough infection.
Breakthrough infection p value No (n=20) Yes (n=9) Median 48 67 Age (years) 0.004 [Range] [21-77] [51-88]
n % n %
Male 4 20 6 67 Gender 0.032 Female 16 80 3 33 Yes 7 35 1 11 Malignancy 0.372 No 13 65 8 89 Yes 0 0 1 11 Obesity No 0 0 8 89 -Unknown 20 0 0 0 Yes 0 0 3 33 Asthma No 0 0 6 67 -Unknown 20 0 0 0 Days from second Median 41 vaccination and [Range] NA [9-69] -COVID-19 first symptoms Unknown 2 COVID-19 variant Alpha NA 9 100 -IFNy and IL-5 T cell responses to S1-RBD peptides were evaluated in 81 patients. Less than 10% individuals harbored S1-RBD-specific TH2/Tc2 responses (Table 11). Long-lived TH2 clones could be derived from two patients exhibiting robust spontaneous or breakthrough C0VID19-induced SARS-CoV-2 or SPIKE25 -specific IL-release (Figure S7A-F of Fahrner et al., 2022). Of note, there was a robust concordance of the polarization status of patients between the two (cross-priming and peptide-based) IVS assays (p=2.2e-16 for the TH 1/Tc1 cytokines IL-2 and I FNy release; p <le-16 for the TH2/Tc2 factor IL-5, McNemar test).

Table 11. Peptide-specific T cell polarisation determined by IL-5 or IFN-y quantification.
SARS-CoV-2 protein n*
IL-5-/IFNy- IL-5* /IFNy- IL-5-/IFNy* IL-5*/IFNy* P.value Resistant 20 3 1 1 Membrane _____________________________ 35 0.76 Susceptible 10 0 0 0 Resistant 17 3 7 3 Nucleocapsid _________________________ 42 0.58 Susceptible 9 0 3 0 :.?: Resistant 15 0 9 4 g 51 36 ______________________________________________________________________ 0.34 E Susceptible 7 0 1 0 E
Resistant 15 3 10 0 .0¨

= S1-RBD 36 __________________________________________________________________ 0.06 o Susceptible 8 0 0 0 a) c al Resistant 8 0 7 1 g S2 23 ______________________________________________________________________ 0.75 o_ Susceptible 5 0 2 0 ci) Resistant 11 0 5 0 ORF8 22 ______________________________ 1.00 Susceptible 4 0 2 0 Resistant 15 0 1 0 ORF10 23 _____________________________ 0.53 Susceptible 6 0 1 0 Resistant 14 0 1 0 0RF3a 22 _____________________________ 1.00 Susceptible 7 0 0 0 >.
_______________________________________________________________________________ __ :.= Peptide pool Vaccinated n IL-5-/IFNy- IL-5-VIFNy- IL-51IFNy* IL-54/IFNy* P.value c E No 15 6 2 6 1 E PEPorf 0.003 ¨

Yes 30 3 0 26 1 a a) No 15 12 0 3 0 =
lo PEPwtRBD
0.020 c 68 30 0 38 0 ¨
6 Yes c No 15 14 0 1 0 ¨
<a Ls PEPmutRBD
0.167 as Yes 30 20 1 9 0 >
"The numbers correspond to the enumeration of patients who were positive for at least one of the epitopes of each protein listed in Table 9.
Given that immunoselection may drive antigenic drift of viruses as well as the evolution of viral phylogeny, we analyzed the coincidence of mutations (mutations occurring in at least 75% of emergent variant or predicted to decrease antibody neutralizing activity) in the SARS-CoV-2 ORFeome41 with T cell memory patterns of clinical significance (Table S12 of Fahrner etal., 2022). Significantly higher mutation frequencies were detected within the S1-RBD-specific TH1 response (62%) compared with other regions of the SARS-CoV-2 orfeome (25.5%) (odds ratio = 0.21, 95% confidence interval [0.06;
0.68], p=0.01, Figure 4E).

During the course of this study, SARS-CoV-2 mRNA and DNA vaccines were approved by FDA and EMA based on reports that they prevent COVI D-19 infection with an efficacy of >90%.3,42 Using a simple 22hr-whole blood stimulation assay allowing the quantitative measurement of IFNy using the Enzyme Linked Fluorescent Assay technique 5 in an automated platform (VIDASO IFNy RUO, 43 we analyzed RBD-specific T
cell reactivities before and/or after dual vaccination with BNT162b2 mRNA
(BioNTech/Pfizer) and/or AZD1222 adenovirus (Astrazeneca) in 233 unexposed HCW and 92 cancer patients, as well as in 69 convalescent individuals before and/or after one vaccine.
Firstly, using a pool of 42 overlapping peptides spanning the S1-RBD sequence, we observed 90%
10 reactivity in naive (cancer-free, no COVID-19 infection) HCW (n=70) 3 weeks after the second immunization, as well as in convalescent patients (n=14) after the sole vaccination (not shown). Secondly, we reduced the S1-RBD 42 peptide pool to our collection of 11 non overlapping peptides ("PEP,,tRBD") (Figure 50 of Fahrner et al., 2022, Tables 9 and 12).
PBL reactivities to both of these peptide pools were MHC class I and class II
dependent 15 (Figure S8 of Fahrner et al., 2022). As a positive control of memory responses against SARS-CoV-2 [44], we used a pool of eighteen 15-mer epitopes "PEPorf"
comprising not only different stretches of overlapping S1-RBD peptides but also peptides spanning Spike S1 and S2, membrane and nucleocapside sequences (Figure 5C of Fahrner et a/., 2022, Table 12). At day 90 post-vaccine initiation, 75% of HCW (with no history of COVI D-19 nor 20 cancer) mounted PERARBD -specific TH1/Tc1 responses while >90% responded to PEPorf, reaching similar levels as individuals with a history of COVID-19 or one course of vaccination with an impact of gender and time of sampling (Figure 4F, upper panel, Table 13). The magnitude of PEP
= wtRBD -specific IFNy release post-vaccination was maintained up to day 180 in both patient subsets (Figure 4F, lower panel).
Multivariate 25 analyses confirmed that administration of two vaccines or COVID-19 infection followed by one vaccine elicited significant TH1/Tc1 immune responses against S1-RBD
independently of age, gender, cancer and time of sampling (Figure 4G). Of note, the titers of IgG S1-RBD
antibodies poorly correlated with PEP
= wtRBD- specific T cell IFNy secretions in 176 HCW
vaccinees without a history of COVID-19 (Figure 5G of Fahrner et al., 2022, R=0.17, 30 p=0.025).

Table 12. Epitope sequences for PEPOrf, PEPwtRBD, PEPmut RBD, PEPovRBD.
SARS-CoV-2 Peptide Seq position Peptide sequence ID No Virus Protein pools name 1st last PEPorf SASFSTFKCYGVSPT 215 SARS-CoV-2 Spike 371 385 PEPorf YKLPDDFTGCVIAWN 216 SARS-CoV-2 Spike 423 437 PEPorf NNLDSKVGGNYNYLY 217 SARS-CoV-2 Spike 439 453 PEPorf SKVGGNYNYLYRLFR 218 SARS-CoV-2 Spike 443 457 PEPorf YLYRLFRKSNLKPFE 31 SARS-CoV-2 Spike 451 465 PEPorf SNLKPFERDISTEIY 219 SARS-CoV-2 Spike 459 473 PEPorf CTFEYVSQPFLMDLE 12 SARS-CoV-2 Spike 166 180 PEPorf NIDGYFKIYSKHTPI 14 SARS-CoV-2 Spike 196 210 PEPorf LMDLEGKQGNFKNLR 220 SARS-CoV-2 Spike 176 190 PEPorf NFSQILPDPSKPSKR 221 SARS-CoV-2 Spike 801 815 PEPorf NLLLQYGSFCTQLNR 51 SARS-CoV-2 Spike 751 765 PEPorf LLWPVTLACFVLAAV 222 SARS-CoV-2 Membrane 56 70 PEPorf CLVGLMWLSYFIASF 223 SARS-CoV-2 Membrane 85 99 PEPorf RGHLRIAGHHLGRCD 224 SARS-CoV-2 Membrane 146 160 PEPorf YRINWITGGIAIAMA 225 SARS-CoV-2 Membrane 71 85 PEPorf KEITVATSRTLSYYK 226 SARS-CoV-2 Membrane 166 180 PEPorf LLESELVIGAVILRG 118 SARS-CoV-2 Membrane 133 147 PEPorf PSGTWLTYTGAIKLD 227 SARS-CoV-2 Nucleocapsid 326 340 PEPwtRBD CVADYSVLYNSASFS 25 SARS-CoV-2 Spike 361 375 PEPwtRBD TFKCYGVSPTKLNDL 26 SARS-CoV-2 Spike 376 390 PEPwtRBD CFTNVYADSFVIRGD 27 SARS-CoV-2 Spike 391 405 PEPwtRBD EVRQIAPGQTGKIAD 28 SARS-CoV-2 Spike 406 420 PERAARBD YNYKLPDDFTGCVIA 29 SARS-CoV-2 Spike 421 435 PEPwtRBD WNSNNLDSKVGGYN 228 SARS-CoV-2 Spike 436 450 PEPwtRBD YLYRLFRKSNLKPFE 31 SARS-CoV-2 Spike 451 465 PEPwtRBD RDISTEIYQAGSTPC 32 SARS-CoV-2 Spike 466 480 PEPwtRBD NGVEGFNCYFPLQSY 33 SARS-CoV-2 Spike 481 495 PEPwtRBD GFQPTNGVGYQPYRV 34 SARS-CoV-2 Spike 496 510 PEPwtRBD VVLSFELLHAPATVC 35 SARS-CoV-2 Spike 511 525 PEPmutRBD CVADYSFLYNSASFS 229 SARS-CoV-2 Spike 361 375 PEPmutRBD EVRQIAPGQTGNIAD 230 SARS-CoV-2 Spike 406 420 PEPmutRBD EVRQIAPGQTGTIAD 231 SARS-CoV-2 Spike 406 420 PEPmutRBD WNSKNLDSKVGGNYN 232 SARS-CoV-2 Spike 436 450 PEPmutRBD WNSNKLDSKVGGNYN 233 SARS-CoV-2 Spike 436 450 PEPmutRBD YRYRLFRKSNLKPFE 234 SARS-CoV-2 Spike 451 465 PEPmutRBD RDISTEIYQVGSTPC 235 SARS-CoV-2 Spike 466 480 PEPmutRBD RDISTEIYQAGNTPC 236 SARS-CoV-2 Spike 466 480 PEPmutRBD RDISTEIYQAGSKPC 237 SARS-CoV-2 Spike 466 480 PEPmutRBD NGAEGFNCYFPLQSY 238 SARS-CoV-2 Spike PEPmutRBD NGVKGFNCYFPLQSY 239 SARS-CoV-2 Spike PEPmutRBD NGVQGFNCYFPLQSY 240 SARS-CoV-2 Spike PEPmutRBD NGVEGFNCYFPLRSY 241 SARS-CoV-2 Spike PEPmutRBD GFQPTYGVGYQPYRV 242 SARS-CoV-2 Spike PEPovRBD SASFSTFKCYGVSPT 243 SARS-CoV-2 Spike 371 385 PEPovRBD YKLPDDFTGCVIAWN 244 SARS-CoV-2 Spike 423 437 PEPovRBD NNLDSKVGGNYNYLY 245 SARS-CoV-2 Spike 439 453 PEPovRBD SKVGGNYNYLYRLFR 246 SARS-CoV-2 Spike 443 457 PEPovRBD YLYRLFRKSNLKPFE 31 SARS-CoV-2 Spike 451 465 PEPovRBD SNLKPFERDISTEIY 247 SARS-CoV-2 Spike 459 473 PEPovRBD LLWPVTLACFVLAAV 248 SARS-CoV-2 Membrane 56 70 PEPovRBD CLVGLMWLSYFIASF 249 SARS-CoV-2 Membrane 85 99 PEPovRBD RGHLRIAGHHLGRCD 250 SARS-CoV-2 Membrane 146 160 Spike28_a2 EVRQIAPGQTGPIAD 251 SARS-CoV-2 Spike 406 420 Spike23 NITNLCPFDEVFNAT 252 SARS-CoV-2 Spike 331 345 Spike25 CVADYSVLYNLASFS 253 SARS-CoV-2 Spike 361 375 Spike25 CVADYSVLYNSALFS 254 SARS-CoV-2 Spike 361 375 Spike25 CVADYSVLYNSASFF 255 SARS-CoV-2 Spike 361 375 Spike32 RDISTEIYQAGSKPC 237 SARS-CoV-2 Spike 466 480 Spike33 NGVAGFNCYFPLQSY 256 SARS-CoV-2 Spike 481 495 Spike34 SFQPTNGVGYQPYRV 257 SARS-CoV-2 Spike 496 510 Spike34 GFRPTNGVGYQPYRV 258 SARS-CoV-2 Spike 496 510 Spike34 GFQPTNGVGHQPYRV 259 SARS-CoV-2 Spike 496 510 The percentages and magnitude of these responses were reduced in 92 cancer patients who were mostly under therapy (Tables 2&3) as compared to 187 cancer-free individuals (adjusted p value for differences in percentages of PEPorf p0sitivity=0.016, adjusted p value for differences in IFNy levels upon stimulation with PEP
= wtRBD=0.027, Figure 4H).
The binding affinity of S1-RBD peptides to MHC class I and class II proteins was calculated using the NetMHCpan algorithm. This approach predicted strong binding to MHC class I HLA-A, -B and -C alleles for the RBD epitopes "SPIKE25" (residues 361_375), "SPIKE27" (residues 391-405), "SPIKE31" (residues 451-465). In contrast, "SPIKE33"
(residues 481_495) was estimated to have a low affinity for HLA-B and no affinity for HLA-C alleles (Subtable S13a of Fahrner et al., 2022). Only "SPIKE24", "SPIKE25" and "SPIKE31 were predicted to bind with a high affinity to MHC class 11 HLA-DR
alleles (Subtable S13b of Fahmer et al., 2022) as already reported for the immunodominant 5346-365 region [40]. To investigate potential links between the lack of spontaneous or vaccine-induced S1-RBD-specific TH1 responses and HLA genotypes, we analyzed the distribution of HLA-I and HLA-Il alleles in 101 individuals, 53 vaccinees and 48 cancer patients prior to vaccination, of which 45% presented anti-S1-RBD TH1 responses (Figure 9B-C).
As already reported in severe C0VID19 in an Indian population [45], we found that HLA-DPB1*04:01 was significantly associated with RBD areactivity (Figure 9B-C).
This is in line with the observation that none of the RBD peptides were predicted to be strong binders for this allele (Subtable S13b of Fahrner etal., 2022). Moreover, the HLA-DQA1*01:02 allele paired with the DQB1*05:02 allele was significantly associated with RBD
areactivity (14%
versus 0% in RBD areactive versus reactive respectively, p=0.042, Figure 9B).
Finally, we analyzed T cell responses directed against S1-RBD sequences of the viral variants of concern (VOC) that were recently renamed by WHO as Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2). Indeed, these strains predominantly mutate in the S gene compared with the reference (Wuhan) strain and more precisely within the S1-RBD peptide residues of the "PEPwtRBD" pool.
Therefore, we generated a fourth peptide pool "PEP
= mutRBD" encompassing the 14 mutations described within the S1-RBD sequences of VOC (Table S12 of Fahrner et al., 2022) that we tested in 343 individuals. TH1/Tc1 cell reactivity was higher against PEP
= wtRBD than PEP
- mutRBD in univariate analyses (n=33 positive/48 (68%) vs 18/38 (47%) at D90, p value=0.051, n=43 positive/94 (46%) vs 23/82 (28%) at D180, p value=0.019), coinciding with a drop in the magnitude of IFNy secretion levels in cancer free individuals (Figure 4F, Figure 41). The multivariate analysis indicated that this difference was independent from age, gender and time of sampling (Table 13). The difference of T cell reactivity between PEP
= wtRBD and PEP,,,,,tRBD cannot be ascribed to non mutated peptide residues missing in PEPniõtRBD pool (such as the immunodominant spike 29, which was recognized in <3% of vaccinees when tested separately in this high-throughput screening T cell assay (p=0.4, Figure S8G of Fahrner et al., 2022).

Table 13a. Multivariate analyses for vaccine or infection-induced IFNg release.
PEPorf Multivariate analysis P.value Sampling time -0.001 (-0.003 to 0.000) 0.049 Age (years) 0.003 (-0.001 to 0.006) 0.180 Gender Male -0.117 (-0.213 to -0.019) 0.020 Cancer Yes -0.161 (-0.307 to -0.020) 0.030 No COVID-19 history; 1 round 0.334 (0.209 to 0.460) <0.001 Covid history and vaccine No COVID-19 history ; 2 round 0.685 (0.484 to 0.900) <0.001 rounds Convalescent ; no round 0.411(0.247 to 0.574) <0.001 Convalescent; 1 round 0.875 (0.689 to 1.069) <0.001 Table 13b. Multivariate analyses for vaccine or infection-induced IFNg release.
PEPwtRBD Multivariate analysis P.value Sampling time -0.001 (-0.002 to 0.000) 0.251 Age (years) 0.001 (-0.003 to 0.004) 0.697 Gender Male -0.042 (-0.120 to 0.030) 0.317 Cancer Yes -0.179 (-0.342 to -0.002) 0.028 No COVID-19 history; 1 round 0.101 (-0.004 to 0.215) 0.066 Covid history and vaccine No COVID-19 history ; 2 round 0.310 (0.123 to 0.507) 0.001 rounds Convalescent ; no round -0.028 (-0.163 to 0_109) 0.678 Convalescent; 1 round 0.397 (0.242 to 0.566) <0.001 Table 13c. Multivariate analyses for vaccine or infection-induced IFNg release.
PEPmutRBD versus PEPwtRBD Multivariate analysis P.value PEPmutRBD 0.152 (-0.055 to 0.378) 0.149 Sampling time 0.001 (-0.001 to 0.003) 0.153 Age (years) -0.002 (-0.006 to 0.003) 0.507 Gender Male -0.046 (-0.167 to 0.078) 0.452 Cancer Yes 0.216 (-0.026 to 0.454) 0.065 No COVID-19 history; 1 round -0.104 (-0.260t0 0.042) 0.188 Covid history and vaccine No COVID-19 history ; 2 round -0.336 (-0.620 to -0.037) 0.014 rounds Convalescent ; no round -0.023 (-0.215 to 0.153) 0.812 Convalescent; 1 round -0.358 (-0.617 to -0.151) 0.002 Altogether, these results suggest that defects in the TH1 repertoire affecting the recognition of SARS-CoV-2 S1-RBD are associated with susceptibility to infection or reinfection by SARS-CoV-2 or failure of Spike-based vaccines. T cell responses against S1-RBD from VOCs appear to be reduced in vaccinees as of August 2021, commensurate with the fact that this antigenic region mutates more than other regions of the SARS-CoV-2 orfeome.
5 Discussion Identifying immune correlates of protection from SARS-CoV-2 is critical to predict the efficacy of existing and future vaccines and to follow a potential decay in immune protection imposing repeated immunizations. Thus the titers of neutralizing antibodies that correlate with IgG antibodies against trimeric S or RBD represent a good proxy of protection 10 against breakthrough infections [46,47]. The landscape of prevalence and immunodominance of SARS-CoV-2 T cell epitopes - supposedly associated with protection during the acute phase - has been thoroughly investigated [48]. Using 40-mer peptide pools covering regions of membrane, nucleocapsid, ORF3a, 0RF7/8, and spike proteins, Tan et at. observed a statistically significant correlation between the early appearance of SARS-15 CoV-2 peptide-reactive cells and shorter duration of infection [49].
Here, we unravel the first prospective correlation between preexisting (before the first surge) SARS-CoV-2-specific TH2/Tc2 immune responses and susceptibility to infection with SARS-CoV-2 or reinfection with viral variants, based on 3 independent cohorts and two different methods to monitor TH1/Tc1 and TH2/Tc2 cytokines (ELISA and ELISpot). Both in healthy individuals and 20 cancer subjects, the best immunological correlate for the susceptibility to infection with SARS-CoV-2 was undistinguishably a recall response characterized by a low ratio of TH1/TH2 lymphokines (and more precisely an IL-2/1L-5 ratio <1) secreted upon exposure to the reference SARS-CoV-2 viral strain. The IL-5 memory response coincided with a hole within the TH1/Tc1 cell repertoire affecting the RBD of the spike protein.
Five lines of 25 evidence argue in favor of the clinical significance and protective effect against the infection of TH1/Tc1 immune responses directed against anti-S1-RBD for the current pandemic.
TH1fTc1 responses were undetectable i) in individuals from the pre-vaccine era who are susceptible to infection by SARS-CoV-2, ii) in reinfected persons, and iii) in subjects manifesting breakthrough infections after vaccination, and iv) were somehow reduced 30 against the S1-RBD mutated sequences from VOC in vaccinated HOW.
Finally, given the high rate of mutations residing in the immunologically and clinically relevant sequence of interest (331-525 aminoacid residues of the spike protein), we are tempted to conclude that an immune-driven selection process of viral phylogeny is currently occurring, as already discussed [50,51].

35 Reportedly, CD4+ TH1 and TH2 responses are induced during the primary phase of viral infection, and both TH1 and TH2 can generate an anamnestic response upon rechallenge with the same virus [52]. Survivors from SARS-CoV-1 infection developed polyfunctional T cells producing TH1 cytokines and long-term CD8+ T cell responses as late as 11 years post-infection [9]. The TH1 cytokine IL-2 (which correlated with circulating non-activated TFH cells in convalescent patients in our study) was the pivotal factor distinguishing susceptible from resistant individuals. Signaling via the high-affinity IL-2 receptor (which requires CD25/IL-2Ra expression) favors the generation of T effector cells, and this is associated with TH1 responses sustained by the transcription factor TBX21. Moreover, the development of IFNy producing effector memory T
cells depends upon CD25.15 Accordingly, upon infection with lymphocytic choriomeningitis (LCMV), CD25-deficient CD4+ T cells largely fail to form IFNy producing T
effector cells in secondary lymphoid organs and to generate lung tissue resident memory T cells [53]. In contrast, increased TH2 cytokine release correlated with poor outcome in patients, a finding corroborated in mouse studies of SARS-CoV-1 [54,55] and SARS-CoV-2 [35].
During SARS-CoV-2 infection, TH2-associated blood markers, such as eosinophilia and circulating IL-5, IL-33, eotaxin-2 and eotaxin- 3 correlate with COVI D-19 severity [56].
In fact, Dupilumab, an anti-IL-4Ra antibody blocking IL-13 and IL-4 signaling [57]
protected against inflammatory and severe COVID-19 in two retrospective cohorts [35]. We found that Dupilumab boosts SARS-CoV-2-specific TH1 responses, supporting the rationale of current Phase II trials that evaluate this antibody in the prevention of severe COVID-19 lung infection.
TCR signaling plays a major role in CD4+ polarization and can vary according to the TCR affinity, the amount of peptide/M HC-I1 complexes perceived by a TCR, or the length of time a T cell spends proofreading peptide/MHC-II complexes [15]. Of note, the RBD-specific TH1/Tc1 responses against spike regions 361-375 and 391-405 exhibited robust binding capacities across all MHC class 1 alleles. Several authors reported cross-reactivities between CCC and SARS-CoV-2 [9,20,23,24,33,34,58,59]. However, such cross-reactive T cells may correlate with poor clinical outcome [60-65].
Indeed, according to one report [21], preexisting CCC-specific memory CD4+ T cells exhibit low TCR avidity in almost all unexposed individuals, and are strongly expanded in severe but not mild COVID-19. Moreover, CCC/SARS-CoV-2-cross-reactive T cell clones shared among convalescent and infected individuals harbored lower functional avidity than non-cross-reactive clones, suggesting antigenic imprinting of the TCR repertoire by previous exposure to CCC [26,66].
Of note, these spike-specific cross-reactive CD4+ T cells might not only re-expand during infection but also following vaccination. In line with this possibility, we detected a strong positive correlation between CCC and SARS-CoV-2-specific IL-5 release by memory T cells in unexposed individuals. Moreover, CCC-specific IgG titers were higher in susceptible compared to resistant individuals. Finally, the SARS-CoV-1 and ORF8-specific T
cell repertoire prevailing in the pre-COVI D-19 era failed to be clinically relevant for the avoidance of COVID-19 and such a repertoire was frequently detected in reinfected individuals during their convalescence phase. Of note, we generated S1-RBD-specific IL-4 or IL-5 producing T cell lines and CD4+CD8+ T cell clones from one HCW
presenting a breakthrough infection after vaccination. Hence, we cannot rule out the possibility that a preexisting TH2 immunity, for instance directed against S1-RBD sequences shared by sarbecoviruses9 could increase the susceptibility to, and severity of, SARS-CoV-2 infection [54-56,67].
Our data fuel the theory that i) robust TH1 memory immune responses against RBD might restrain viral infection, thus exerting a selective pressure on the virus, obliging it to generate escape variants by mutation of RBD, ii) preexisting TH2 antiviral responses might not only be incapable of eliminating SARS-CoV-2-infected cells but actually favor (re)infection with SARS-CoV-2, ultimately increasing the viral reservoir, thus favoring the emergence of viral variants. Hence, immunization strategies should aim at triggering TH1/Tc1 (rather than TH2/Tc2) responses against S1-RBD. The efficacy of cellular immune response relies on three components, (i) the antigen, (ii) the adjuvant and (iii) the dynamics of viral evolution [68]. Immunization with inactivated SARS-CoV-1 or with the whole spike (S) protein, caused eosinophilic infiltration following viral re-exposure in mice [69,70]. Unfortunately, the efficacy of the vaccines composed of inactivated virus produced by Sinovac Biotech (CoronaVac) and Sinopharm (BBIBP-CorV) against VOC
have not yet been reported. In contrast, at least in the case of SARS-CoV-1, immunization with RBD induced neutralizing antibodies in the absence of TH2fTc2 responses [71].
Vaccine adjuvants can stimulate TH1/Tc1-favorable innate immunity, as this is the case for multiple viral vectors, virus-like particles and mRNA containing nanoparticles [66,72].
Finally, virus adaptation to the host has to be outcompeted. One might infer from our data that the currently protective immunodominant regions generating a TH1/Tc1 profile may be the focus of the future antigenic drift of SARS-CoV-2, in which case vaccines would have to be updated regularly [73]. Therefore, to win the race against emerging variants, an expedited world-wide vaccination rollout ensuring an immunization en masse against relevant epitopes (and in particular the entire RBD region of the former or current VOCs and Sarbecovirus [67] with vaccine formulations ensuring TH1/Tc1 (rather than TH2/Tc2) responses should outwit the COVI D-19 pandemic. In countries of broad vaccine coverage, it may be advantageous to screen the population for IFI\ly responses against S1-RBD and hence to determine the need of each individual for booster vaccination.
Finally, current efforts to decipher HLA haplotypes associated with maladaptive S1-RBD TH1 responses may open an avenue for personalized vaccine design [74-76].

Example 2: Tumor infiltrating lymphocytes (TIL) as a source to predict tissue resident reactivity to epitopes within viral species that give rise to increased risk to autoimmunity, increased protection or overt, non-productive inflammation.
The clinical characteristics of the patients and multicontact cases from whom the results below are derived are shown in Example 1 (Tables 1, 8) and in Table 14.
Table 14: Clinical characteristics of indexed and contaminated Contaminated Patients characteristics Index (n=54) (n=22) P.value Median 56 54 Age (years) 0.86 [Range] [21-83] [23-82]
ok Male 17 31 11 50 Gender 0.21 Female 37 69 11 50 Yes 54 100 22 100 Malignancy 1.0 No 0 0 0 0 Yes 51 94 7 32 Symptoms No 7 32 0.54 Unknown 3 6 8 36 Day hospital (Mild) 5 72 Hospitalization Clinical 1 14 course (Moderate) <0.001 Admission to ICU

(Severe) ICU: Intensive care unit Peptide selection The final version of the genome of the SARS-CoV-2 virus was released on January 17th 2020 (RefSeq ID MN908947.3). On March 6th 2020 there was no information regarding the immunogenicity of SARS-CoV-2 proteins, from the publicly available sequence data we synthesized peptides covering the entire spike (RefSeq ID
QHD43416.1) and nucleocapsid proteins (RefSeq ID QHD43423.2).
From the membrane protein the peptides were selected to cover 2 potential immunogenic regions of the SARS-CoV-2 membrane protein (RefSeq QH D43419.1); these regions had immunogenic potential because there is a similar region in the SARS-CoV-1 membrane protein.
We also selected peptides covering the entire ORF8 (RefSeq ID QHD43422.1) and (RefSeq ID QHI42199.1) proteins, these peptides were chosen because these two proteins do not exist in the SARS-CoV-1 and might reveal to be interesting immunogenic targets due their uniqueness of being non-shared with SARS-CoV-1, and not to be present in other Coronaviruses. They will also aid to differentiate between vaccination and exposure since they are not shared between other Coronavirus-species.
Other SARS-CoV peptides were peptides found to be immunogenic in previous reported studies (92-99).
In addition, the selected peptides do not have any exact match with the other human coronavi ruses.
Results TIL (tumor infiltrating lymphocytes) are 1-cells, mostly CD4+ and CD8+ 1-cells that home preferentially into malignant tissue. They have a particularly homing mechanism and are believed to derive about 10% from immune cells from peripheral blood and from 90% from tissue-resident immune cells: cells that home into tissues and rarely or never leave the tissue. The reactivity of TIL ¨ that are harvested from tumor lesions during surgery ¨ allows a unique view into tissue-reactive 1-cells. It also allows to examine potential autoimmune reactivity, since ¨ in principle ¨ anti-cancer directed cellular immune responses are in fact very focused auto-immune responses.
TIL reactivity therefore reflects i) an anti-cancer response, and ii) autoimmune response in general.
TIL were expanded ex vivo from tumor specimens from patients with different cancer lesions and tested for reactivity to the 187 peptides derived from the SARS-CoV-2 targets.
Reactivity was determined by IFN-gamma production in 10e4 TIL / peptide species or as IL-17 production! 10e4 TIL / peptide target.
TIL were tested from two different populations: patients who underwent surgery for tumors in the pre-pandemic time, i.e., starting in 2017 till early 2019 in Lisbon, Portugal, and patients during the pandemic time (as shown in Tables 15 and 16). 1-cell reactivity resided in the SARS-CoV-2 Spike protein, in the nucleocapside protein, as well as in viral proteins whose functions are still ill-defined (e.g. ORF8). The SARS-CoV2 peptide selection allowed to identify cross-reactivity with SARS-CoV-1 but not with other circulating Coronaviral species. Cross-reactivity to non-mutant or mutant human 'self proteins' is possible.
1. IFN production.
Table 15: SARS-2016.05.006 (similarity to human proteins and to bacterial species, identified in Table 17), Spike peptide 30 (human tissue proteins, e.g. Tensin which is responsible for driving tissue remodeling in lung tissue and other organs, extracellular matrix formation) and the nucleocapsid 12 (no similarities found) are recognized in TIL
harvested from patients in the pre-pandemic and in the pandemic timeframes.

Reactivity to SARS-2016.05.006, to the spike peptide 30 and nucleocapsid 12 in the pre-pandemic period (e.g. 2017, 2018, early 2019).
Cross-reactivity between human proteins and SARS-CoV are responsible for the recognition defined by IFN production in the pre-pandemic and can also drive the 5 T-cell responses in the pandemic time frame.
The Spike protein 15 is preferentially recognized in the post-pandemic time frame (human proteins and / or bacteria, implying that cross-reactivity does not only pre-exist in the immune repertoire but T-cells can be stimulated and expanded upon exposure to SARS-CoV-2 that also recognize human proteins. The ORF8-9 in the pre-pandemic 10 time frame (similar to human Mycocilin, a protein that is normally secreted into the aqueous humor of the eye), is recognized in the pre-pandemic time frame, yet less in the pandemic, suggesting T-cell anergy or clonal deletion. Exposure to the virus may eliminate these T-cells or keep them non-functional.
2. Other cytoki nes.
15 Not only IFN-gamma (a strongly inflammatory cytokine associated with immune protection and also with overt, i.e. too strong immune responses), yet other cytokines, such as IL-17, that particularly drives autoimmune responses, are detected in the pre-pandemic time frame against peptides that derived from SARS-CoV-2 (Table 16).
For instance peptide ORF8-1 that shares homology to human proteins or bacterial species.
20 Exposure of the immune system to SARS-CoV-2 would allow for activation and expansion of SARS-CoV-2 specific T-cell responses that would also recognize human.
Also ORF8-17 is recognized from 1-cells prior to the pandemic time (in October 2017) in tumor infiltrating T-cells. This peptide does not share homology to human proteins or bacterial species and shows that the human 1-cell receptor repertoire did not delete 25 anti-SARS-CoV-2 directed 1-cell responses during thymic education, i.e.
the individual development of the human immune system. IL-17 productive 1-cells that are pre-existing against SARS-CoV, can augment anti-viral responses and induce overt inflammation or induce autoimmune responses in case of similarities between viral targets and human proteins.
30 3. The spike 30 peptide that represents a target for 1-cells in the pre-pandemic and pandemic time frame defined by IFN gamma production ¨ that would also be able to drive autoimmune response due to the cross-reactivity to the peptide species listed in Table 17 is also affected by mutations in the spike protein. Such cross-reactive T-cells may also be protective or drive overt tissue damaging immune responses.

Potential protection / design of future vaccines Tumor infiltrating T-cells are a source of tissue resident 1-cells that enable to detect autoimmune responses (e.g. reactivity against non-mutant) self proteins that can be screened for reactivity against viral targets. TIL are a superior source as compared to immune cells from blood to screen for potential autoimmunity in viral targets since they are able to invade tissues and since anti-cancer immune responses are a certain form of autoimmune responses.
Positive reactivity against SARS-CoV-2 peptides or viral targets in general in TIL, based on the cytokine production pattern, may indicate i) increased risk for autoimmune diseases upon exposure to the viral pathogen, ii) increased protection (since the virus-reactive T-cells are already present), and/or iii) increased pathogenicity upon viral infection due to an overt immune response (unproductive inflammation in the lung and other organs). Organ-specific damage is therefore not only a bystander effect of the cellular immune response, it is associated with the presence of 1-cells that recognize both the viral pathogen and non-mutant human tissue. The reactivity pattern is quite consistent in TIL from patients in the pre-pandemic time frame.
TIL are therefore a source to predict increased risk for autoimmunity, increased protection or non-productive inflammation. Screening should be made with different cytokines: IFN-gamma indicates inflammation, peptide targets eliciting IL-17 may indicate increased risk for autoimmune responses since IL-17 is in general associated with autoimmunity.
Such peptide species may be eliminated from vaccine candidates.
4 Examples elicitinci IFN-gamma responses:
- Spike15: NLVRDLPQGFSALEP (SEQ ID No: 15) preferentially pandemic period Crossreactivity to tissue and bacteria - Spike30: WNSNNLDSKVGGNYN (SEQ ID No: 30) pre and pandemic periods Crossreactivity to tissue and bacteria - nucleocapsid_12: TLPKGFYAEGSRGGS (SEQ ID No: 97) (SARS-CoV1/2) pre and pandemic periods No hits found - SARS_2016.05.006: LLNKHIDAYKTFP (SEQ ID No: 121) (SARS-CoV1/2) pre and pandemic periods Crossreactivity to tissue and bacteria - ORF8_9: LIELCVDEAGSKSPI (SEQ ID No: 170) preferentially pre-pandemic Cross-reactivity to tissue 4 Examples eliciting IL-17 responses:
- ORF8_1: MKFLVFLGIITTVAA (SEQ ID No: 162) Crossreactivity to tissue and bacteria - ORF8_17: DVRVVLDFI (SEQ ID No: 178) No hits identified n >
o u , r . , "
; = 1 ir 1 :1 Table 15 D1 TILs D11 TILs D13 TILs D1209 k,.) D126 TILs D303 TILs D306 TILs D309 TILs D310 TILs D311 TILs k...) (metastasis (metastasis (metastasis PBMCs (pancreas (rectum (pancreas (pancreas (colon (colon k,.) pancreas pancreas pancreas (pancreas o adenocar adenocar adenocarci adenocar adenocarci adenocar .6.
COVID adenocarci adenocarci adenocarci adenocarci cA
cinoma) cinoma) noma) cinoma) noma) cinoma) PEPTIDES noma noma) noma) INFg pg INFg pg INFg pg INFg pg INFg pg INFg pg noma) INFg pg INFg pg INFg pg 10000 10000 10000 INFg pg cells cells cells cells cells cells cells cells cells cells SARS HLA-0,0 137,00 101,66 54,9 32,3 166,5 5,6 9,3 303,1 0,0 A*02R)1 1 SARS HEA-0,0 0,00 11,48 3,3 19,2 0,0 2,0 5,4 128,9 0,0 A*02:01 2 SARS HEA-0,0 0,00 51,79 2,0 4,5 0,0 4,5 0,0 123,9 0,0 A*0201 3 SARS HEA- 0,0 0,00 0,00 0,2 11,3 0,0 3,6 3,6 134,3 0,0 A*02R11 4 SARS HLA----.1 0,0 0,00 0,00 5,1 0,0 0,0 20,0 0,0 74,1 0,0 w A*0201 5 SARS HEA-0,0 0,00 48,30 32,0 0,9 0,0 3,7 0,0 74,2 0,0 A*02R)1 6 SARS HEA-0,0 0,00 95,26 23,5 2,9 0,0 21,8 7,5 128,1 0,0 A*02R11 7 SARS HEA-0,0 129,08 32,70 69,7 0,4 209,3 6,6 23,0 144,7 0,0 A*02:01 8 SARS HEA-0,0 0,00 0,00 46,6 0,0 0,0 3,0 0,0 157,7 0,0 A*02R11 9 SARS HEA-It 0,0 0,00 0,00 4,5 0,0 0,0 4,9 0,0 96,2 0,0 r) A*02:1711 10 .t.!

tt 0,0 0,00 1,58 147,5 0,0 0,0 1,4 0,0 81,5 0,0 ot A*02:(711 11 r.) SARS HLA-[,.) 0,0 0,00 0,00 0,0 0,0 0,0 1,8 0,0 76,2 0,0 w A*02:T11 12 -O,--o, SARS FILA---, 0,0 0,00 57,80 0,0 0,0 0,0 8,6 0,0 49,4 0,0 =, A*02:E1_13 c.) un a ,-, Is_ ., :1 _______________________________________________________________________________ _____________________________________ 0 SARS HLA-0,0 0,00 18,74 0,0 0,0 0,0 3,7 0,0 97,7 0,0 N
A*02:61 14 SARS H-LA-r.) i=-.) 0,0 0,00 0,00 0,0 0,0 0,0 0,7 0,0 91,0 0,0 A*02:F11 15 r.) z .6.
SARS H-LA-cA
0,0 8,36 14,17 54,3 2,8 0,0 10,2 0,0 137,8 0,0 A*02:01 16 SARS FFLA-0,0 0,00 0,00 9,0 0,9 0,0 10,3 12,2 138,0 0,0 A*02:61 17 SARS FFLA-0,0 0,00 0,00 0,0 0,0 0,0 0,2 0,0 137,4 0,0 A*02:61 18 SARS H-LA-0,0 0,00 0,00 0,0 0,0 0,0 6,7 0,0 56,8 0,0 A*02:61 19 SARS H-LA-0,0 0,00 0,00 0,0 0,0 0,0 2,1 0,0 81,5 0,0 A*02:1711 20 SARS H-LA-0,0 0,00 0,00 0,0 0,0 0,0 0,4 0,0 43,0 0,0 A*02:F11 21 ---.) -i, 0,0 0,00 0,00 0,0 0,0 0,0 1,0 0,0 75,7 0,0 SARS-10.1128 -2 0,0 0,00 56,67 0,0 0,0 0,0 5,7 0,0 90,1 0,0 SARS-10.1128 -3 0,0 0,00 36,61 17,8 0,0 0,0 4,0 0,0 138,9 0,0 SARS-10.1128 -4 0,0 0,00 69,16 7,5 0,9 0,0 8,6 0,0 107,2 0,0 SARS _10.1128 0,0 0,00 0,00 0,0 0,0 0,0 1,7 0,0 83,8 0,0 SARS-10.1128 _ 0,0 0,00 0,00 0,0 0,0 0,0 0,6 0,0 75,4 0,0 It SARS-10.1128 n 0,0 0,00 28,08 0,0 0,0 0,0 0,6 0,0 78,9 0,0 t.J.
7m SARS-10.1128 It r.) -8 0,0 0,00 63,26 0,0 0,0 0,0 3,2 0,0 68,2 0,0 SARi HLA-0,0 0,00 0,00 0,0 0,0 0,0 31,3 0,0 104,6 0,0 a, --, =, SARS HEA-c.) 0,0 0,00 0,00 0,0 0,0 0,0 5,3 0,0 39,7 0,0 un DR0411_2 n >
o u , r . , "
; = 1 ir 1 :1 _______________________________________________________________________________ _____________________________________ 0 SARS HLA-0,0 21,84 10,43 28,7 118,3 0,0 4,3 5,8 130,9 0,0 N

t.) SARS HEA-t...) i=-.) 0,0 5,41 0,00 0,0 0,0 0,0 6,5 3,0 219,3 0,0 t.) z .6.
SARS 37i6.20 cA
0,0 0,00 0,00 5,8 0,0 0,0 9,4 0,0 129,4 0,0 1-05_I
SARS 726.20 a 2 0,0 0,00 0,00 0,0 0,0 0,0 3,8 0,0 109,5 0,0 SARS 5-314.20 0,0 0,00 90,98 0,0 0,0 0,0 0,5 0,0 83,8 0,0 SARS 5-314.20 0,0 0,00 0,00 0,0 0,0 0,0 3,6 0,0 85,8 0,0 0,0 0,00 32,33 1,6 0,0 0,0 3,0 0,0 93,2 0,0 0,0 0,00 151,43 0,0 0,0 0,0 0,0 0,0 83,1 0,0 0,0 0,0 0,00 27,36 14,6 0,0 0,0 3,9 2,9 122,9 X
I i SARS 2016.05--..1 0,0 145,37 179,35 117,6 11,2 261,2 4,9 14,6 322,3 0,0 .006 membrane_1 - 0,0 0,00 0,00 24,0 0,0 0,0 2,7 1,3 169,8 0,0 membrane_2 0,0 0,00 15,32 160,6 0,0 0,0 3,9 0,0 153,6 0,0 membrane_3 0,0 0,00 0,00 166,1 0,0 0,0 2,3 0,0 154,1 0,0 membrane_4 0,0 0,00 0,00 1,9 0,4 0,0 4,0 0,0 157,0 0,0 membrane_5 0,0 0,00 0,00 103,9 0,0 0,0 3,1 0,0 139,0 0,0 membrane_6 0,0 0,00 209,89 128,1 0,0 0,0 4,5 4,5 111,2 0,0 membrane_7 0,0 35,79 155,66 68,6 4,9 16,3 4,5 25,6 276,7 0,0 Spike1 0,0 176,71 0,00 21,8 7,2 0,0 3,0 54,7 327,9 0,0 It r) Spike2 0,0 0,00 0,00 0,0 4,2 0,0 2,0 5,1 125,3 0,0 .t.!
Spike3 0,0 0,00 0,00 0,0 0,0 0,0 5,5 2,6 164,5 0,0 tt ot Spike4 0,0 0,00 0,00 0,0 0,0 0,0 3,7 0,0 160,3 0,0 r.) r.) Spike5 0,0 0,00 0,00 0,0 5,8 0,0 2,5 9,7 122,8 0,0 w O--Spike6 0,0 0,00 0,00 0,0 0,0 0,0 3,1 0,0 137,1 0,0 o, --, Spike7 0,0 0,00 0,00 0,0 10,4 0,0 7,1 0,0 165,4 0,0 =, c.) Spike8 0,0 0,24 0,00 213,8 23,0 21,7 2,8 1,5 285,8 0,0 un n >
o u, r., , ,--u, r., r., o r., ,--N, -.4 _______________________________________________________________________________ _____________________________________ 0 Spike9 0,0 12,96 189,32 0,0 2,6 0,0 21,6 8,4 204,3 0,0 N
Spike10 0,0 0,00 32,66 0,0 0,0 0,0 2,8 0,0 94,2 0,0 o t...) Spike11 0,0 0,00 0,00 0,0 0,0 0,0 0,0 0,0 127,4 0,0 Spike12 0,0 0,00 0,00 0,0 0,0 0,0 0,0 0,0 59,0 0,0 t,.) o .6.
Spike13 0,0 0,00 0,00 0,0 9,0 0,0 3,1 0,0 75,4 0,0 o Spike14 0,0 0,00 0,00 0,0 0,0 0,0 2,8 0,0 69,1 0,0 Spike15 0,0 0,00 0,00 0,0 0,0 0,0 1,2 0,0 L 141,6 j 0,0 - -5pike16 0,0 0,00 0,00 0,0 0,0 0,0 10,4 0,0 176,1 0,0 Spike17 0,0 0,00 0,00 0,0 0,0 0,0 8,9 0,0 241,4 0,0 Spike18 0,0 0,00 0,00 0,0 0,0 0,0 1,8 0,0 69,9 5,0 Spike19 0,0 0,00 0,00 0,0 0,0 0,0 1,3 0,0 87,5 0,0 Spike20 0,0 0,00 0,00 0,0 0,0 0,0 1,5 0,0 79,7 0,0 Spike21 0,0 0,00 0,00 0,0 0,0 0,0 1,1 0,0 114,5 0,0 Spike22 0,0 0,00 0,00 0,0 0,0 0,0 3,4 0,0 82,5 0,0 5p1ke23 0,0 0,00 0,00 0,0 0,0 0,0 4,3 0,0 63,3 0,0 Spike24 0,0 15,63 0,00 0,0 0,0 0,0 4,6 0,0 147,6 0,0 5pike25 0,0 0,00 47,33 0,0 0,0 0,0 2,6 0,0 259,9 0,0 .-.1 o, Spike26 0,0 0,00 0,00 39,7 0,0 0,0 0,0 0,0 127,3 0,0 Spike27 0,0 0,00 0,00 65,1 0,0 0,0 0,5 0,0 57,3 0,0 Spike28 0,0 0,00 0,00 0,0 0,0 0,0 0,7 0,0 131,7 0,0 Spike29 0,0 0,00 158,41 0,0 0,0 0,0 0,0 0,0 83,1 0,0 Spike30 0,0 0,00 69,14 36,8 0,0 0,0 0,9 0,0 131,1 0,0 Spike31 0,0 0,00 0,00 0,0 0,0 0,0 15,0 0,0 61,0 0,0 Spike32 0,0 160,05 21,95 0,0 0,0 25,2 2,3 1,6 167,0 0,0 Spike33 0,0 0,00 0,00 31,9 0,0 0,0 3,0 0,0 201,2 0,0 Spike34 0,0 0,00 0,00 0,0 0,0 0,0 2,9 0,0 104,5 0,0 Spike35 0,0 0,00 0,00 0,0 0,0 2,4 1,1 0,0 101,0 0,0 It 5p1ke36 0,0 0,00 0,00 99,7 0,0 0,0 0,0 0,0 103,4 0,0 r) 17...i Spike37 0,0 0,00 0,00 0,0 0,0 0,0 0,5 0,0 113,0 0,0 tt Spike38 0,0 0,00 0,00 0,0 0,0 0,0 0,0 0,0 165,5 0,0 ot tµ..) Spike39 0,0 0,00 0,00 0,0 0,0 0,0 1,7 0,0 146,5 0,0 o t=-) Spike40 0,0 0,00 0,00 21,0 0,0 0,0 2,0 0,0 205,5 0,0 c-B
o Spike41 0,0 105,07 0,00 55,0 0,0 442,7 3,0 100,6 206,2 0,0 o Spike42 0,0 0,00 0,00 31,9 0,0 0,0 1,9 2,9 164,5 0,0 c.) un, Spike43 0,0 0,00 0,00 6,2 0,0 0,0 0,0 0,0 104,2 0,0 n >
o u , r . , , ; = 1 ir 1 r . , ' ;
' - .8 '= :1 _______________________________________________________________________________ _____________________________________ 0 Spike44 0,0 0,00 0,00 0,0 0,0 26,5 1,4 0,0 158,1 0,0 N
Spike45 0,0 139,74 0,00 1,9 0,0 0,0 21,8 0,0 99,9 0,0 o t...) Spike46 0,0 0,00 0,00 0,0 0,0 0,0 9,7 0,0 103,7 0,0 i=-.) Spike47 0,0 0,00 0,00 29,4 0,0 0,0 0,0 0,1 123,4 0,0 t,.) z .6.
Spike48 0,0 0,00 0,00 45,7 0,0 0,0 2,4 137,3 205,5 0,0 o Spike49 0,0 112,71 27,08 73,0 6,0 30,8 0,2 24,9 261,3 0,0 Spike50 0,0 0,00 0,00 0,0 0,0 0,0 0,7 0,0 144,5 0,0 Spike51 0,0 0,00 11,90 0,0 0,0 0,0 13,9 8,1 154,4 0,0 Spike52 0,0 0,00 13,42 0,0 0,0 0,0 0,0 0,0 122,9 0,0 Spike53 0,0 0,00 0,00 0,0 0,0 0,0 0,0 0,0 89,1 0,0 5pike54 0,0 0,00 0,00 0,0 0,0 0,0 6,1 0,0 149,6 0,0 Spike55 0,0 0,00 0,00 0,0 0,0 0,0 1,7 24,0 66,1 0,0 5pike56 0,0 97,90 15,25 80,9 0,0 200,4 1,9 40,2 247,9 0,0 Spike57 0,0 2,64 0,00 0,0 3,1 0,0 0,6 0,0 230,5 0,0 Spike58 0,0 0,00 0,00 0,0 0,0 0,0 0,0 0,0 102,3 0,0 Spike59 0,0 0,00 0,00 0,0 0,0 0,0 0,0 0,0 165,9 0,0 -..1 Spike60 0,0 0,00 0,00 0,0 0,0 0,0 0,3 0,0 83,8 0,0 Spike61 0,0 0,00 0,00 0,0 0,0 0,0 0,0 0,0 73,1 0,0 Spike62 0,0 0,00 0,00 0,0 0,0 0,0 0,0 0,0 86,3 0,0 5p1ke63 0,0 0,00 0,00 0,0 0,0 0,0 0,0 0,0 66,4 0,0 Spike64 0,0 0,00 0,00 0,0 2,9 0,0 2,2 4,5 169,5 0,0 8pike65 0,0 0,00 337,93 0,0 0,0 0,0 0,5 8,9 190,7 0,0 Spike66 0,0 0,00 186,03 0,0 0,0 0,0 1,5 0,0 145,2 0,0 Spike67 0,0 0,00 160,38 0,0 0,0 0,0 0,0 0,0 83,3 0,0 Spike68 0,0 0,00 0,00 0,0 0,0 0,0 1,0 0,0 72,9 0,0 Spike69 0,0 0,00 411,14 0,0 0,0 0,0 5,7 0,0 83,9 0,0 5p1ke70 0,0 0,00 0,00 0,0 0,0 0,0 0,1 0,0 47,1 0,0 Spike71 0,0 0,00 284,52 0,0 0,0 0,0 0,0 0,0 59,2 0,0 It r) 5p1ke72 0,0 228,65 37,46 0,0 5,6 31,2 0,3 0,5 189,7 0,0 .t.!
tt Spike73 0,0 0,00 39,74 0,0 0,0 0,0 0,2 1,7 182,9 0,0 ot r.) Spike74 0,0 0,00 68,17 0,0 0,0 0,0 9,0 0,0 80,7 0,0 r.) Spike75 0,0 0,00 0,00 0,0 0,0 0,0 12,6 0,0 92,7 0,0 t,.) -O--Spike76 0,0 0,00 0,00 0,0 0,0 0,0 2,9 0,0 125,6 0,0 o --, Spike77 0,0 0,00 0,00 0,0 0,0 0,0 2,4 0,0 97,5 0,0 o c.) un Spike78 0,0 0,00 0,00 0,0 0,0 0,0 0,6 0,0 94,2 0,0 n >
o 1 , r . , , , - . -.' c'P .
:1 Spike79 0,0 0,00 0,00 0,0 0,0 81,3 0,0 N

0,0 N
0,0 0,0 0,0 126,4 t..) 0,0 0,0 0,0 0,0 0,0 20,7 209,7 t..) 0,0 4,0 00 o 0,00 13,7 142,4 .6.
Spike80 0,0 113,50 0,0 0,0 , o 2,9 3,0 0,00 0,0 50,5 0,0 Spike81 0,0 110,22 0,0 0,0 0,0 2,6 142,05 0,0 44,4 0,0 Spike82 0,0 0,00 0,0 0,0 0,0 0,3 0,00 0,0 42,8 0,0 Spike83 0,0 0,00 0,0 0,0 0,0 0,1 171,10 0,0 Spike84 0,0 0,00 12,4 0,0 26,3 ,0 0,00 0,0 Spike85 0,0 0,00 2,0 0,0 0,0 0,0 nucleocapsid_ 0,0 0,00 0,00 nucleocapsid_ 0,0 0,00 0,00 0,0 0,0 0,0 0,4 0,0 63,8 0,0 nucleocapsid_ 0,0 66,40 93,72 180,4 0,0 21,1 67,8 0,0 110,1 4,5 3 -.4 nucleocapsid_ 0,0 1,42 155,76 2,9 0,0 0,0 0,8 13,9 109,7 0,0 0,0 00 nucleocapsid_ 0,0 0,00 155,89 4,5 2,4 0,0 0,6 0,0 111,8 nucleocapsid_ 0,0 0,00 31,01 137,7 0,0 17,7 0,0 2,5 0,0 20,4 6 nucleocapsid_ 0,0 19,39 302,81 11,4 12,9 0,0 11,2 0,0 106,2 0,0 nucleocapsid_ 0,0 0,00 0,00 142,8 0,0 14,9 5,8 0,0 0,0 1,9 8 nucleocapsid_ 0,0 39,72 314,80 3,1 0,0 1,5 0,0 3,8 45,6 0,0 It nucleocapsid_ 0,0 11,71 302,99 22,5 2,2 64,7 6,7 23,2 139,8 0,0 nucleocapsid_ 0,0 0,00 0,00 55,3 0,0 r) 7,8 .t.!
0,0 3,2 0,0 30,1 tt ot 3,2 58,1 235,8 0,0 t..) o r.) 0,0 t..) nucleocapsid_ 0,0 64,45 1 174,67 23,2 24,4 1 e7 o --, o nucleocapsid_ 0,0 0,00 177,14 0,0 24,4 0,0 1,8 14,4 191,3 0,0 ca un 95,6 nucleocapsid_ 0,0 0,00 202,62 0,0 3,0 0,0 9,5 20,4 0,0 n >
o u , r . , , ; = 1 ir 1 :1 _______________________________________________________________________________ _____________________________________ 0 nucleocapsid_ 0,0 0,0 N
0,00 111,54 o 15 69,6 0,0 8,0 19,0 240,4 0,0 t..) t..) nucleocapsid_ 0,0 0,0 i..) 110,92 32,61 t..) 16 24,0 0,0 1,7 0,0 175,3 0,0 z .6.
nucleocapsid_ 0,0 0,0 o 67,01 0,00 17 10,7 0,0 1,7 0,0 120,4 0,0 nucleocapsid_ 0,0 0,0 0,00 269,10 18 45,8 0,0 2,5 0,0 198,4 0,0 nucleocapsid_ 0,0 37,4 25,74 184,16 19 49,7 0,0 9,3 80,0 334,4 0,0 nucleocapsid_ 0,0 0,00 20,79 0,0 0,0 0,0 3,7 4,6 184,4 0,0 20 nucleocapsid_ 0,0 0,00 73,90 0,0 21 0,0 0,0 0,0 0,0 60,2 0,0 nucleocapsid_ 0,0 0,0 0,00 177,89 0,0 22 0,0 0,0 1,8 0,0 125,0 --.1 z, nucleocapsid_ 0,0 0,00 0,00 0,0 23 0,0 0,0 0,3 0,0 92,6 0,0 nucleocapsid_ 0,0 0,00 46,80 0,0 24 0,0 0,0 0,0 0,0 92,5 0,0 nucleocapsid_ 0,0 0,00 0,00 0,0 0,0 0,0 1,1 0,0 75,8 0,0 25 nucleocapsid_ 0,0 0,00 8,29 0,0 0,0 0,0 0,6 0,0 114,8 0,0 26 nucleocapsid_ 0,0 48,34 83,05 0,0 27 0,0 0,0 3,5 0,0 240,9 0,0 nucleocapsid_ 0,0 128,71 0,00 0,0 149,1 0,0 2,3 44,7 195,6 0,0 28 It ORF8_1 0,0 284,71 0,00 0,0 0,0 0,0 1,1 6,2 8,3 0,0 n t. J.
ORF8_2 0,0 0,00 0,00 0,0 0,0 0,0 1,2 0,0 0,0 0,0 tt ORF8_3 0,0 0,00 0,00 0,0 0,0 0,0 6,4 0,0 3,5 0,0 ot ORF8_4 0,0 0,00 76,94 0,0 0,0 0,0 4,0 0,0 1,3 0,0 t..) ORF8_5 0,0 146,76 62,95 0,0 0,0 0,0 0,0 0,0 0,0 0,0 O-o ORF8_6 0,0 204,83 0,00 0,0 0,0 0,0 2,0 0,0 0,0 0,0 --, o ORF8_7 0,0 217,82 94,47 0,0 0,0 0,0 0,0 0,0 0,0 0,0 (,) un n >
o 1. .
r . , "
,11 .j ir 1 ' ' - .8 '= :1 _______________________________________________________________________________ _____________________________________ 0 ORF8_8 0,0 69,59 1 37,50 0,0 0,0 0,0 1,9 4,6 28,1 0,0 N
ORF8 9 0,0 [ 112,66 .I.51,07 9,2 0,0 0,0 1,6 0,0 ___ 1,8 0,0 cc _ .
r..) ORF8_10 0,0 0,00 0,00 0,0 0,0 0,0 0,7 0,0 0,0 0,0 i=-.) ORF8_11 0,0 0,00 0,00 0,0 0,0 0,0 2,8 0,0 0,0 0,0 z .6.
ORF8_12 0,0 0,00 83,89 0,0 0,0 0,0 1,0 0,0 0,0 0,0 1-, ORF8_13 0,0 0,00 19,58 0,0 0,0 0,0 0,0 0,0 0,0 0,0 ORF8_14 0,0 0,00 0,00 0,0 0,0 0,0 0,9 0,0 0,0 0,0 ORF8_15 0,0 0,00 0,00 0,0 0,0 0,0 2,7 0,0 0,0 0,0 ORF8_16 0,0 38,17 100,81 0,0 0,0 0,0 5,6 0,0 0,0 0,0 ORF8 17 0,0 139,79 0,00 89,0 45,1 0,0 1,4 2,5 9,3 0,0 ORF115_1 0,0 41,30 0,00 7,8 8,7 0,0 0,5 0,0 0,0 0,0 co o ORF1 0_2 0,0 45,48 0,00 5,9 21,5 0,0 1,1 0,0 0,0 0,0 ORF1 0_3 0,0 19,81 0,00 0,1 16,3 0,0 1,2 0,0 0,0 0,0 ORF1 0_4 0,0 29,29 0,00 2,2 23,9 0,0 2,7 0,0 0,0 0,0 ORF1 0 5 0,0 30,02 0,00 0,0 21,7 0,0 3,1 0,0 0,0 0,0 ORF8 -A 0,0 48,99 0,00 0,0 15,9 0,0 1,3 0,0 0,0 0,0 ORF8_-BC 0,0 129,49 60,03 46,8 26,6 277,2 2,5 17,3 0,0 0,0 ORF3a_AB 0,0 265,83 0,00 151,3 1,4 133,5 6,2 116,2 6,9 0,0 ORF3a C 0,0 130,79 0,00 14,4 0,0 32,3 16,2 8,9 6,8 0,0 VIRUS (S-ARS-254,69 0,00 CoV-2) No Data 7,6 No Data No Data No Data No Data No Data 0,0 0K13 0,0 28,20 27,76 175,3 24,0 407,6 497,8 320,1 724,7 0,0 PHA 0,0 337,76 0,00 0,0 39,7 113,0 552,2 325,6 64,4 0,0 EBNA 0,0 0,00 0,00 0,0 0,0 0,0 1411,0 3594,0 9,3 1,0 CMV 0,0 0,00 0,00 0,0 9,0 0,0 1207,0 3446,0 19,5 0,0 CMV Pool No Data 140,66 0,00 65,0 No Data No Data No Data No Data No Data 0,0 M1 0,0 166,14 16,49 0,4 1,1 82,4 4,5 0,0 0,0 0,0 It n t.J.
tt It t..) w t..) ,-, =, (,) ui, n >
o u, r., , u, r., r., o r., u, (?.
'i Table 16 t.) t..) Pre Pandemic Post Pandemic t..) =-.) D1 TILs (metastasis 0303 TILs D306 TILs 0309 TILs t..) z 0311 TILs .&.
pancreas (rectum (pancreas (pancreas c, (colon ,--, adenocarcinoma) adenocarcinoma) adenocarcinoma) adenocarcinoma) COVID PEPTIDES
adenocarcinoma) IL17 pg IL17 pg IL17 pg IL17 pg 117 pg 10000 cells cells cells cells cells SARS HLA-0,0 59,4 0,0 0,0 43,3 A*02T01 1 SARS HEA-0,0 77,9 0,0 0,0 16,7 A*02T01 2 SARS HEA-0,0 48,1 0,0 0,0 24,9 A*02T01 3 SARS HEA-0,0 57,3 0,0 0,0 20,9 A*02701 4 SARS HEA-0,0 99,5 0,0 0,0 39,7 A*02701 5 SARS HEA-0,0 30,5 0,0 0,0 20,5 A*027m 6 SARS HEA-0,0 78,1 4,3 0,0 25,9 A*02701 7 SARS HEA-0,0 130,5 12,4 0,0 35,3 A*02701 8 SARS HEA-It 0,0 35,2 0,0 0,0 33,4 r) A*02T01 9 SARS HEA-m 0,0 21,1 0,0 0,0 14,2 ot A*02:51 10 t..) l,) SARS H-LA-t..) 0,0 16,3 0,0 0,0 24,4 O-A*02:51 11 o, ,--, SARS H-LA-=, (,) 0,0 32,3 0,0 0,0 18,7 u, A*02:51_12 n >
o u, r., , ,i r., r., o r., u, (?.
'i SARS HLA-0,0 35,8 0,0 0,0 11,6 t..) A*02:51 13 t..) b.) SARS FILA-=-.) 0,0 22,8 0,0 0,0 12,1 t..) A*02:51 14 z .6.
SARS H-LA-c, ,--, 0,0 24,5 0,0 0,0 15,6 A*02:51 15 SARS H-LA-0,0 49,9 0,0 0,0 22,3 A*02:51 16 SARS H-LA-0,0 40,6 0,0 0,0 27,6 A*02:51 17 SARS H-LA-0,0 18,0 0,0 0,0 12,6 A*02:61 18 SARS H-LA-0,0 13,4 0,0 0,0 16,9 A*02:51 19 SARS H-LA-11,4 0,0 31,1 0,0 0,0 A*02:51 20 SARS H-LA-oo t) 0,0 16,3 0,0 0,0 16,7 A*02:51 21 SARS 10.1-128 1 0,0 27,7 0,0 0,0 14,5 SARS_10.1128_2 0,0 21,9 0,0 0,0 18,9 SARS 10.1128 3 0,0 44,1 0,0 0,0 18,2 SARS_10.1128_4 0,0 36,5 0,0 0,0 28,8 SARS_10.1128_5 0,0 26,6 0,0 0,0 9,7 SARS_10.1128_6 0,0 12,3 0,0 0,0 15,8 SARS_10.1128_7 0,0 18,1 0,0 0,0 11,5 SARS 10.1128_8 0,0 5,3 0,0 0,0 17,9 It r) SAIS HLA-0,0 20,5 0,0 0,0 11,5 m ot t..) SARS HEA-tµJ
0,0 20,2 0,0 0,0 26,7 t..) O-o, SARS HEA---, 0,0 44,4 0,3 0,0 18,1 (,) DROL-101_3 u, n >
o u, r., , ,i ,-.
u, r., r., o r., u, (?.
SARS HLA-DROZO4 0,0 57,5 0,0 0,0 29,9 t.) t..) t..) SARS_3726.-2005_1 0,0 20,2 0,0 0,0 11,5 =-.) t..) SARS_3726.2005 2 0,0 7,2 0,0 0,0 17,3 z .&.
SARS_5314.2004-_1 0,0 24,2 0,0 0,0 16,5 c, ,-, SARS 5314.2004_2 0,0 36,8 0,0 0,0 18,1 SARg_01025-8_1 0,0 27,3 0,0 0,0 12,1 SARS 01025-8 2 0,0 31,4 0,0 0,0 20,2 SARg 01026-X 0,0 58,8 0,0 0,0 16,7 SARS_2-016.05.006 0,0 141,3 38,8 0,0 43,0 membrane_1 0,0 30,7 0,0 0,0 15,0 membrane_2 0,0 40,3 0,0 0,0 21,6 membrane_3 0,0 60,6 15,7 0,0 33,4 membrane_4 0,0 73,7 22,7 0,0 59,6 membrane_5 0,0 65,4 7,1 0,0 26,5 membrane_6 0,0 44,5 0,0 0,0 30,5 membrane_7 0,0 143,4 15,7 0,0 27,7 W
Spike1 0,0 134,7 6,8 0,0 33,5 Spike2 0,0 52,2 0,0 0,0 15,5 Spike3 0,0 38,8 0,0 0,0 17,1 Spike4 0,0 38,4 3,0 0,0 27,0 Spike5 0,0 89,3 14,6 0,0 43,9 Spike6 0,0 69,5 11,4 0,0 42,0 Spike7 0,0 67,6 0,0 0,0 11,1 Spike8 0,0 254,5 17,1 0,0 16,9 It Spike9 0,0 50,9 0,0 0,0 30,4 r) Spike10 0,0 31,0 0,0 0,0 6,3 m ot Spike11 0,0 26,2 0,0 0,0 11,6 t..) Spike12 0,0 28,5 0,0 0,0 17,9 N
N
Spike13 0,0 68,2 9,8 0,0 39,1 O-o, ,-, Spike14 0,0 36,6 0,0 0,0 31,4 =, (,) Spike15 0,0 32,5 0,0 0,0 10,6 u, n >
o u, r., , ,i ,-.
u, r., r., o r., u, (?.
Spike16 0,0 56,7 0,0 0,0 11,6 0 t.) Spike17 0,0 58,3 0,0 0,0 19,7 t..) t..) Spike18 0,0 23,6 0,0 0,0 13,2 =-.) t..) Spike19 0,0 29,7 0,0 0,0 11,6 z .&.
c, Spike20 0,0 27,5 0,0 0,0 8,0 Spike21 0,0 29,4 1,6 0,0 21,7 Spike22 0,0 15,7 0,0 0,0 7,5 Spike23 0,0 27,8 0,0 0,0 6,8 Spike24 0,0 62,4 0,0 0,0 11,8 Spike25 0,0 55,4 0,0 0,0 14,2 Spike26 0,0 23,7 0,0 0,0 5,5 Spike27 0,0 29,6 0,0 0,0 9,0 Spike28 0,0 28,3 0,0 0,0 6,2 Spike29 0,0 31,1 0,0 0,0 7,7 co _i=
Spike30 0,0 26,6 0,0 0,0 15,0 Spike31 0,0 30,0 0,0 0,0 12,2 Spike32 0,0 74,6 0,0 0,0 9,5 Spike33 0,0 98,6 0,8 0,0 20,5 Spike34 0,0 26,5 0,0 0,0 10,3 Spike35 0,0 25,3 0,0 0,0 12,1 Spike36 0,0 30,9 0,0 0,0 12,9 Spike37 0,0 63,0 0,0 0,0 8,8 Spike38 0,0 28,3 0,0 0,0 15,3 Spike39 0,0 31,1 0,0 0,0 9,4 Spike40 0,0 75,6 0,0 0,0 13,4 It Spike41 0,0 118,4 17,8 0,0 37,3 r) Spike42 0,0 44,4 0,0 0,0 15,7 m ot Spike43 0,0 50,0 0,0 0,0 10,3 t..) Spike44 0,0 47,3 0,0 0,0 13,4 N
N
Spike45 0,0 76,4 5,3 0,0 8,9 O-o, ,-, Spike46 0,0 28,9 0,0 0,0 18,8 =, (,) u, Spike47 0,0 61,5 0,0 0,0 12,8 n >
o u, r., , ,i ,-.
u, r., r., o r., u, (?.
Spike48 0,0 62,1 0,0 0,0 16,9 0 t.) Spike49 5,7 121,9 0,0 0,0 37,7 t..) t..) Spike50 0,0 95,3 0,0 0,0 17,7 =-.) t..) Spike51 0,0 66,9 0,0 0,0 22,7 z .&.
c, Spike52 0,0 74,0 12,1 0,0 19,3 Spike53 0,0 96,6 0,0 0,0 17,3 Spike54 0,0 70,9 0,0 0,0 14,8 Spike55 0,0 98,9 0,0 0,0 10,1 Spike56 0,0 149,0 21,3 0,0 31,3 Spike57 0,0 105,2 0,0 0,0 20,3 Spike58 0,0 50,0 0,0 0,0 5,4 Spike59 0,0 17,9 0,0 0,0 17,6 Spike60 0,0 32,5 0,0 0,0 3,8 Spike61 0,0 36,2 0,0 0,0 8,5 Spike62 0,0 49,3 0,0 0,0 8,3 Spike63 0,0 41,3 0,0 0,0 10,8 Spike64 0,0 70,5 0,0 0,0 18,3 00 v, Spike65 0,0 83,5 0,0 0,0 21,6 Spike66 0,0 33,7 0,0 0,0 4,1 Spike67 0,0 26,4 0,0 0,0 12,8 Spike68 0,0 32,9 0,0 0,0 10,9 Spike69 0,0 38,7 0,0 0,0 14,7 Spike70 0,0 31,5 0,0 0,0 11,7 Spike71 0,0 29,8 0,0 0,0 8,7 Spike72 0,0 56,3 0,0 0,0 15,0 It Spike73 0,0 82,5 0,0 0,0 21,8 r) Spike74 0,0 38,8 0,0 0,0 9,0 m ot Spike75 0,0 32,6 5,9 0,0 10,6 t..) Spike76 0,0 26,0 0,0 0,0 7,7 N
N
Spike77 0,0 43,0 0,0 0,0 19,1 O-o, ,-, Spike78 0,0 28,1 0,0 0,0 11,7 =, (,) u, Spike79 0,0 30,9 0,0 0,0 7,3 n >
o u, r., , ,i ,-.
u, r., r., o r., u, (?.

Spike80 0,0 69,0 0,0 0,0 14,1 t.) Spike81 0,0 99,1 0,0 0,0 31,4 t..) t..) Spike82 0,0 45,0 0,0 0,0 5,9 =-.) t..) Spike83 0,0 29,6 0,0 0,0 0,0 z .&.
c, Spike84 0,0 34,6 0,0 0,0 3,6 Spike85 0,0 35,7 0,0 0,0 12,0 nucleocapsid_l 0,0 38,7 0,0 0,0 10,2 nucleocapsid_2 0,0 31,4 0,0 0,0 6,8 nucleocapsid_3 0,0 187,2 0,0 0,0 5,5 nucleocapsid_4 0,0 49,7 0,0 0,0 0,0 nucleocapsid_5 0,0 53,1 0,0 0,0 0,0 nucleocapsid_6 0,0 104,9 0,0 0,0 21,7 nucleocapsid_7 0,0 65,4 0,0 0,0 2,6 nucleocapsid_8 0,0 65,4 0,0 0,0 0,4 00 nucleocapsid 9 0,0 68,3 0,0 0,0 0,0 (:) nucleocapsid -10 0,0 127,7 0,0 0,0 7,1 nucleocapsid_11 0,0 81,9 0,0 0,0 19,5 nucleocapsid_12 69,0 84,7 0,0 0,0 31,4 nucleocapsid_13 0,0 59,6 0,0 0,0 15,2 nucleocapsid_14 0,0 35,8 0,0 0,0 14,0 nucleocapsid_15 51,9 63,6 0,0 0,0 26,2 nucleocapsid_16 0,0 49,8 0,0 0,0 12,2 nucleocapsid_17 0,0 35,1 0,0 0,0 15,2 nucleocapsid_18 0,0 47,8 0,0 0,0 19,8 nucleocapsid_19 37,1 77,5 0,0 0,0 62,3 It nucleocapsid_20 11,6 13,1 0,0 0,0 29,3 r) nucleocapsid_21 0,0 1,1 0,0 0,0 7,9 m ot nucleocapsid_22 0,0 4,8 0,0 0,0 2,4 t..) nucleocapsid_23 0,0 6,1 0,0 0,0 13,4 N
N
nucleocapsid_24 0,0 0,6 0,0 0,0 12,6 O-o, ,-, nuc1e0caps1d_25 0,0 2,4 0,0 0,0 11,7 =, (,) u, nucleocapsid_26 0,0 7,4 0,0 0,0 24,9 n >
o u, r., , u, r., r., o r., u, (?.

nucleocapsid_27 0,0 27,4 0,0 0,0 32,8 t.) nucleocapsid_28 0,0 22,0 0,0 0,0 25,9 t..) t..) I ORF8_1 14,5 I 44,1 1 0,0 0,0 0,0 =-.) t..) z ORF8_2 0,0 0,0 0,0 0,0 0,0 .&.
c, ORF8_3 0,0 5,0 0,0 0,0 0,0 ORF8_4 0,0 5,2 0,0 0,0 0,0 ORF8_5 0,0 10,0 0,0 0,0 0,0 ORF8_6 0,0 5,9 0,0 0,0 0,0 ORF8 7 0,0 11,0 0,0 0,0 0,0 ORF8_8 0,0 30,3 4,7 0,0 0,0 ORF8 9 0,0 79,2 0,0 0,0 1,2 ORF8 -10 0,0 33,9 0,0 0,0 0,0 ORF8_11 0,0 44,3 0,0 0,0 0,0 ORF8_12 0,0 59,3 0,0 0,0 0,0 ORF8_13 0,0 47,7 0,0 0,0 0,0 ORF8 14 0,0 37,7 0,0 0,0 0,0 ORF8_15 0,0 29,5 0,0 0,0 0,0 00 _______________ ORF8 _16 0,0 38,9 0,1 0,0 0,0 --1 ORF8_17 80,7 I 105,2 0,0 0,0 0,0 ORF10_1 0,0 84,2 1,8 0,0 0,0 ORF10 2 0,0 82,2 3,7 0,0 0,0 ORF10_3 0,0 88,4 0,0 0,0 0,0 ORF10_4 0,0 88,0 0,0 0,0 0,0 ORF10 5 0,0 87,3 0,0 0,0 0,0 ORF8 -A 0,0 76,7 0,0 0,0 0,0 It r) ORF8 -BC 0,0 76,9 0,0 0,0 7,4 ORF3a_AB 6,9 55,4 40,9 0,0 0,0 m ot ORF3a C 0,0 67,1 13,4 0,0 0,0 t..) l,) Virus (SARS:CoV-2) No Data No Data No Data No Data No Data t..) O-OKT3 1101,0 17,8 92,5 0,0 205,1 o, ,-, =, OKT3 1186,7 30,3 67,5 0,0 177,7 (,) u, e6ccc co 0 0 0 0 0 Ci 0- 0- 0- 0-s¨

c=4 C) .1- (0 N¨ (0 CD CD

OS RI
(SU CC2- c%1- 003 0 0 ON¨ 0 0 Z Z Z
01 Ct 0 0 w n >
o u , r . , , ; = 1 ir 1 r . , L., '=:1 Table 17 N
IA3:G80L-5 Peptide Virus SEQ Potential SEQ
Protein Name t...) Signature Sequence ID Cross ID
i=-.) Reactive z .6.
Sequence cA

Spike27 No Hits No Hits Spike28 RQIAPGQTG 260 REIAPGLTG 310 Activating molecule in BECN1-regulated autophagy protein 1 domain-containing protein 2 EVRQIAPGQ 261 EVRQAAPEQ 312 Protein translocase subunit SecA Protein translocase subunit SecA [Bacteroides thetaiotaomicron VPI-5482]

Protein translocase subunit SecA [Bacteroides fragilis NCTC 9343]
Spike29 No Hits No Hits Spike30 LDSKVGGNY 262 LKSKHGGNY 313 Tensin-1 cc z NSNNLDSKV 263 NSYNLNSKV 314 Probable cell division protein VVhiA [Clostridium botulinum A str. Hall]
LDSKVGGNY 262 LGSKVGNNY 315 Uridine permease [Saccharomyces cerevisiae S288C]
Spike31 YRLFRKSNL 264 YMLFRKYNL 316 THUMP
domain-containing protein 1 LYRLFRKSN 265 LWRLFRKKN 317 Protein 0-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1 LYRLFRKSN 265 LYNLFTKSN 318 Probable G-protein coupled receptor 82 LYRLFRKSN 265 LYRDFRKEN 319 Zinc finger protein with KRAB and SCAN domains 2 It LYRLFRKSNL 266 LFRLFRHSNL 320 Protein transport protein sec1 [Schizosaccharomyces r) .t.!
pombe 972h-]
tt Spike32 STEIYQAGS 267 STQIYQAVS 321 Phospholipid-transporting ATPase ABCA1 ot r.) o activating kinase [Saccharomyces cerevisiae t-) w 5288C]
-O,--o Formyltetrahydrofolate synthetase [Campylobacter --, o curvus 525.92]
c.) un n >
o u , r . , , ; = 1 ir 1 ' : ' '= :1 Spike33 GFNCYFPLQ 270 GFNIYFPLMS 324 FXNA-like protease [Schizosaccharomyces pombe N
S 972h-]
o w t...) transporter-regulating transcription factor i=-.) [Aspergillus oryzae RIB40]
w o .6.
ORF8_5 No Hits No Hits o nucleocapsid_8 FYYLGTGPE 272 FYYLGSGRE 326 Xyloside xylosyltransferase 1 PRWYFYYLG 273 PRWYFYYLG 327 Human coronavirus 0C43 TGPEA TGPHA
PRWYFYYLG 274 PRWYFYYLG 274 Human coronavirus HKU1 TGP TGP
SARS_2016.05. LLNKHIDAY 275 LLYKAIDAY 328 Voltage-dependent L-type calcium channel subunit 006 alpha-1F

Menaquinone biosynthesis protein MenD ..o [Staphylococcus aureus RF122]
o Methenyltetrahydrofolate cyclohydrolase [Pediococcus pentosaceus ATCC 25745]
Spike2 RTQLPPAYT 277 RTQSPPVYT 331 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 ubiquitin-protein ligase TTC3 Transcription termination/antitermination protein NusG
[Mycoplasma pneumoniae M129]
LTTRTQLPP 280 LVVRTQLPP 334 Quinic acid utilization activator [Neurospora crassa OR74A]
NLTTRTQLP 281 NLTTRIALP 335 RNase Y
[Helicobacter pylori 26695]
Spike3 No Hits No Hits It r) .t.!
Spike15 LVRDLPQGF 282 LVQDLAQGF 336 Tryptophan--tRNA ligase, mitochondrial tt ot LVRDLPQGF 283 LVRDLVTGFS 337 Ull/U12 small nuclear ribonucleoprotein 35 kDa protein r.) o S
t-) w acetylmuramate dehydrogenase [Pseudomonas -O--o fluorescens Pf0-1]
--, o c.) 8pike21 KSFTVEKGI 285 KTFTVQKGI 339 Desmoglein-3 un r =
'=
IL-2 ORF10_4 No Hits No Hits Signature ORF10_5 No Hits No Hits Spike51 NLLLQYGSF 286 NLLLQIGSF 340 DNA
translocase FtsK [[Haemophilus] ducreyi 35000HP]
Spike56 LADAGFIKQ 287 LADRGFIKQ 341 CHS5 SPA2 rescue protein 2 [Saccharomyces cerevisiae S2880]
VTLADAGFI 288 VALQDAGFI 342 MetRS
[Burkholderia lata]
8pike57 LGDIAARDLI 289 LGDIADRDAI 343 SNF-related serinelthreonine-protein kinase LGDIAARDL 290 LGDKAVRDL 344 Tonsoku-like protein LGDIAARDL 290 LGDLAARQL 345 Major membrane protein I [Mycobacterium avium]

[Leptospira borgpetersenii serovar Hardjo-bovis str. JB197]
Ex-Positive Spike84 GCCSCGSCC 291 GCCSGGGCC 347 Late cornified envelope protein 4A
Patients SCGSCCKFD 292 SYGKCCKFD 348 ABN B
[Aspergillus fumigatus A1163]

[Aspergillus fischeri NRRL 181]
Spike85 VLKGVKLHY 293 VLKGSKLHF 349 Kinesin-like protein KIF14 SEPVLKGVK 294 SEAVLDGVK 350 WD repeat-containing protein 87 transporter A component Cbi0 [Salmonella enterica subsp. enterica serovar Typhi]

transporter A component Cloi0 [Salmonella enterica subsp. enterica serovar Paratyphi A str. ATCC
9150]
Non SARS HLA- QFKDNVILL 296 QIKDRVILL 352 Olfactory receptor 52Z1 significant A*02:C1_14 controls AIKLDDKDPQ 297 AIKLDDKAPE 353 TdRPase [Klebsiella pneumoniae subsp. pneumoniae MGH 78578]

Oligopeptide transport ATP-binding protein AppD
[Bacillus subtilis subsp. subtilis str. 168]
r.) DPQFKDNVIL 299 DGQFEDNVIL 355 Alpha-glucosiduronase [Aspergillus flavus NRRL3357]
QFKDNVILL 300 QYKDQVILL 356 Protein SPA2 [Saccharomyces cerevisiae S288C]

n >
o u , r . , , ; = 1 ir 1 r . , L., '=:1 SARS HLA- ETALALLLL 301 DTALDLLLL 357 Sorting nexin-19 N
A*02:C1_15 o t...) GETALALLL 302 GAAALALLL 358 Torsin-1B
i=-.) o Peroxiredoxin-like 2A .6.
o 1--, ETALALLLL 301 ETTPALLLL 359 Protocadherin-16 domain-containing protein 3 ETALALLLL 301 ETALLLFLL 361 Protein Transmembrane protein 176A
ETALALLLL 301 QTALAVLLL 363 Cellulose synthase 2 regulatory subunit [Komagataeibacter xylinus]
ETALALLLL 301 QTALAVLLL 363 Cellulose synthase 3 regulatory subunit [Komagataeibacter xylinus]

dicarboxylate transport sensor protein DctB
[Pseudomonas aeruginosa PA01]
,r) Uncharacterized lipoprotein TP_0449 [Treponema k) pallidum subsp. pallidum str. Nichols]
GETALALLL 302 GETAFAMLL 366 Purine nucleotide synthesis repressor [Yersinia enterocolitica subsp. enterocolitica 8081]
GETALALLL 302 GETAFAMLL 366 Purine nucleotide synthesis repressor [Yersinia pestis Antigua]
GETALALLL 302 GETAFAMLL 366 Purine nucleotide synthesis repressor [Yersinia pestis Pestoides F]
ETALALLLL 301 ETAVALLVL 367 Manganese transporter pdt1 [Schizosaccharomyces pombe 972h-]

Glycoprotein 21 [Human T-Iymphotropic virus 2]
It [Bordetella pertussis Tohama I] r) .t.!

[Bordetella parapertussis 12822] tt ot Uncharacterized transporter C11D3.18C r.) o r.) A*02:C1_16 [Schizosaccharomyces pombe 972h-] t,.) -O--o Glycoprotein 41 [HIV-1 M:F1_VI850] --, o nucleocapsid_12 No Hits No Hits I
c.) un n >
o u , r . , , ; = 1 ir 1 ' : ' '= :1 ORF8_9 IELCVDEAG 305 IDLAVDEAG 372 Myocilin N

ORF8_1 LVFLGIITT 306 LVFLGIVVT 373 Zinc finger protein 90 t...) i=-.) t,.) o .6.
o MKFLVFLGI 308 MKILSFLGI 375 PC1-like 2 protein 1¨

VFLGIITTV 309 VFAGILTTV 376 Fibrinoligase ORF8_17 No Hits No Hits u..) It r) .t.!
tt ot r.) r.) -O,--o --, o c.) un REFERENCES
1. Chen, Z. & John Wherry, E. T cell responses in patients with COVID-19.
Nat Rev Immunol 20, 529-536 (2020).
2. Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med 384, 403-416 (2021).
3. Polack, F. P. et al. Safety and Efficacy of the RNT162b2 mRNA Covid-19 Vaccine.
N Engl J Med 383, 2603-2615 (2020).
4. Walsh, E. E. et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med 383, 2439-2450 (2020).
5. Bilich, T. et al. T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals.
Sci.
Transl. Med. 13, eabf7517 (2021).
6. Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
http://medrxiv. org/lookup/doi/10.1101/2021.02. 14.21251704 (2021) doi:10.1101/2021.02.14.21251704.
7. Moore, J. P. Approaches for Optimal Use of Different COVID-19 Vaccines:
Issues of Viral Variants and Vaccine Efficacy. JAMA 325, 1251 (2021).
8. Channappanavar, R., Fett, C., Zhao, J., Meyerholz, D. K. & Perlman, S.
Vin_is-Specific Memory CD8 T Cells Provide Substantial Protection from Lethal Severe Acute Respiratory Syndrome Coronavirus Infection. Journal of Virology 88, 11044 (2014).
9. Le Bert, N. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584, 457-462 (2020).
10. Ng, 0.-W. et al. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine 34, 2008-2014 (2016).
11. Zhao, J. et al. Airway Memory CD4 + T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. Immunity 44, 1379-1391(2016).
12. Mosmann, T. R. & Coffman, R. L. TH1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties. Annu. Rev.
Immunol.
7, 145-173 (1989).
13. Romagnani, S. Biology of human TH1 and TH2 cells. JClinlmmunol 15, 121-129 (1995).
14. Romagnani, S. & Maggi, E. Thl versus Th2 responses in AIDS. Current Opinion in Immunology 6, 616-622 (1994).
15. Ruterbusch, M., Pruner, K. B., Shehata, L. & Pepper, M. In Vivo CD4 T Cell Differentiation and Function: Revisiting the Th1/Th2 Paradigm. Annu. Rev.
Immunol. 38, 705 725 (2020).
16. Dan, J. M. etal. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371, eabf4063 (2021).
17. Habel, J. R. et al. Suboptimal SARS-CoV-2-specific CD8 T cell response associated with the prominent HLA-A*02:01 phenotype. PTOC Nat! Accd Sci USA
117, 24384-24391 (2020).
18. Oxford Immunology Network Covid-19 Response T cell Consortium et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK
convalescent individuals following COVID-19. Nat Immunol 21, 1336-1345 (2020).
19. Rodda, L. B. etal. Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. Cell 184, 169-183.e17 (2021).

20. Sekine, T. et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell 183, 158-168.e14 (2020).
21. Bacher, P. et al. Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19. Immunity 53, 1258-5 1271.e5 (2020).
22 Lee, J.-S. et al Evidence of Severe Acute Respiratory Syndrome Coronavirus Reinfection After Recovery from Mild Coronavirus Disease 2019. Clinical Infectious Diseases ciaa1421 (2020) doi:10.1093/cid/ciaa1421.
23. Braun, J. et aL SARS-CoV-2-reactive T cells in healthy donors and patients with 10 COVID-19. Nature 587, 270-274 (2020).
24. Grifoni, A. et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell 181, 1489-1501.e15 (2020).
25. Fournier, P.-E. et al. Emergence and ouTcomes of the SARS-CoV-2 'Marseille-4' 15 variant. International Journal of Infectious Diseases 106, 228-236 (2021).
26. Dykema, A. G. et al. Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses. Journal of Clinical Investigation 131, e146922 (2021).
27. Goubet, A.-G. et al. Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia 20 are hallmarks of COVID-I9 in cancer patients with poor prognosis.
http://medrxiv.org/lookup/doi/10.1101/2021.04.26.21250357 (2021) doi:10.1101/2021.04.26.21250357.
28. Andre, F. et al. Malignant effusions and immunogenic tumour-derived exosomes.
The Lancet 360, 295-305 (2002).
25 29.
Besse, B. et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncolitimunology 5, e1071008 (2016).
30. Borg, C. et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK
cell-dependent antitumor effects. J. Clin. Invest. 114, 379-388 (2004).
31. Wemeau, M. et al. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis 1, e104-e104 (2010).
32. Goubet, A.-G. et al. Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. Cell Death Differ (2021) doi:10.1038/s41418-021-00817-9.
35 33.
Mateus, J. et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science 370, 89-94 (2020).
34. Nelde, A. el al. SARS-CoV-2-derived peptides define heterologous and COVID-induced T cell recognition. Nat Immunol 22, 74 85 (2021).
35. Donlan, A. N. et al. IL-13 is a driver of COVID-19 severity. JCI Insight 6, (2021).
40 36.
Cha, E. et al. Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients. Science Translational Medicine 6, 238ra70-238ra70 (2014).
37. Scheper, W. et al. Low and variable tumor reactivity of the intratumoral TCR
repertoire in human cancers. Nat Med 25, 89-94 (2019).
45 38.
Yager, E. J. et al. Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. Journal of Experimental Medicine 205, 711-723 (2008).
39. Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2.
Nature 581, 221-224 (2020).
40. Low, J. S. et at. Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2. Science eabg8985 (2021) doi:10.1126/science.abg8985.
41. Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639-644 (2021) 42. Voysey, M. et at. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOxl nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881-891 (2021).
43. Mouton, W. et at. A novel whole-blood stimulation assay to detect and quantifi) memory T-cells in COVID- 19 patients.
http://medrxiv.org/lookup/doi/10.1101/2021.03.11.21253202 (2021) doi:10.1101/2021.03.11.21253202.
44. Tarke, A. et at. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep Med 2, 100204 (2021).
45. Vishnubhotla, R., Sasikala, M., Ketavarapu, V. & Reddy, D. N. High-resolution HLA genotyping identifies alleles associated with severe COVID-19: A
preliminary study from India. Immun Inflamm Dis (2021) doi:10 1002/iid3 481.
46. Bergwerk, M. et at. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N Engl .1 Med (2021) doi:10.1056/NEJMoa2109072.
47. Hall, V. J. et at. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet 397, 1459-1469 (2021).
48. Tarke, A. et at. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COV1D-19 cases. Cell Reports Medicine 2, 100204 (2021).
49. Tan, A. T. et al. Early induction of functional SARS-CoV-2-specific T
cells associates with rapid viral clearance and mild disease in COVID-19 patients.
Cell Reports 34, 108728 (2021).
50. Hansen, T. H. & Bouvier, M. MiFIC class I antigen presentation: learning from viral evasion strategies. Nature Reviews Immunology 9, 503-513 (2009).
51. Hachim, A. et at. ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection. Nature Immunology 21, 1293-1301 (2020).
52. Whitmire, J. K., Asano, M. S., Murali-Krishna, K., Suresh, M. & Ahmed, R.
Long-Term CD4 Thl and Th2 Memory following Acute Lymphocytic Choriomeningitis Virus Infection. J Virol 72, 8281-8288 (1998).
53. Hondowicz, B. D., Kim, K. S., Ruterbusch, M. J., Keitany, G. J. & Pepper, M. IL-2 is required for the generation of viral-specific CD4 Th 1 tissue-resident memory cells and B cells are essential for maintenance in the lung. Eur. J. Immunol.
48, 80-86 (2018).
54. Li, C. K. et al. T Cell Responses to Whole SARS Coronavirus in Humans. J
Immunol 181, 5490-5500 (2008).
55. Page, C. et at. Induction of Alternatively Activated Macrophages Enhances Pathogenesis during Severe Acute Respiratory Syndrome Coronavirus Infection.
Journal of Virology 86, 13334-13349 (2012).
56. Yale IMPACT Team et at. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463-469 (2020).

57. Le Floc'h, A. et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ra antibody, is required to broadly inhibit type 2 inflammation. Allergy 75,1188-(2020).
58. Meckiff, B. J. el al. Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19. Cell 183, 1340-1353.e16 (2020).
59 Weiskopf, D et al Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Science Immunology 5, eabd2071 (2020).
60. Bacher, P. et al. Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against Candida albicans. Cell 176, 1340-1355.e15 (2019).
61. Greiling, T. M. et al. Commensal orthologs of the human autoantigen Ro60 as triggers of autoimmunity in lupus. Science Translational Medicine 10, eaan2306 (2018).
62. Koutsakos, M. et al. Human CD8+ T cell cross-reactivity across influenza A, B and C viruses. Nature Immunology 20, 613-625 (2019).
63. Sridhar, S. et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nature Medicine 19, 1305-1312 (2013).
64. Welsh, R. M., Che, J. W., Brehm, M. A. & Selin, L. K. Heterologous immunity between viruses: Heterologous immunity between vim ses. Immunological Reviews 235, 244-266 (2010).
65. Woodland, D. L. & Blackman, M. A. Immunity and age: living in the past?
frends in Immunology 27, 303-307 (2006).
66. Saini, S. K. et al. SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8 T cell activation in COVID-19 patients.
Science Immunology 6, eabf7550 (2021).
67. Tan, C.-W. et al. Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors. New England Journal of Medicine 0, null (2021).
68. Iwasaki, A. & Omer, S. B. Why and How Vaccines Work. Cell 183, 290-295 (2020).
69. Bolles, M. et al. A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge. Journal of Virology 85, 12201-12215 (2011).
70. Tseng, C.-T. et al. Immunization with SARS Coronavin.ts Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus. PLoS ONE 7, e35421 (2012).
71. Jiang, S. etal. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Review of Vaccines 11, 1405-1413 (2012).
72. Martins, K. A., Bavari, S. & Salazar, A. M. Vaccine adjuvant uses of poly-IC and derivatives. Expert Review of Vaccines 14, 447-459 (2015).
73. Jo, W. K., Drosten, C. & Drexler, J. F. The evolutionary dynamics of endemic human coron avi ruses . Virus Evolution 7, (2021).
74. Routhu, N. K. et al. SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung. Nat Commun 12, 1-15 (2021).
75. Sun, S. et al. Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. Cell Res (2021) doi:10.1038/s41422-021-00531-8.
76. Parker, R. et at. Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by 1-ILA class II on dendritic cells. Cell Rep 35, 109179 (2021).
77. Chaput, N. et at. Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR NK cell levels correlate with disease ouTcome. Oncohnmutzology 2, e23080 (2013) 78. Jaafar, R. et al. High individual heterogeneity of neutralizing activities against the original 4 strain and 9 different variants of SARS-CoV-2. (2021) doi: 10.21203/rs .3 .rs-783298/v2.
79. de Sousa, E. et at. Mortality in COVID-19 disease patients: Correlating the association of major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants. Int J Irtfect Dis 98, 454-459 (2020).
80. Janice Oh, H.-L., Ken-En Gan, S., Bertoletti, A. & Tan, Y.-J.
Understanding the T
cell immune response in SARS coronavirus infection. Emerg Microbes Infect 1, e23 (2012).
81. Ren, Y. et at. A strategy for searching antigenic regions in the SARS-CoV
spike protein. Genomics Proteomics Bioirtformatics 1, 207-215 (2003).
82. Yang, J. et al. Searching immunodominant epitopes prior to epidemic: HLA
class II-restricted SARS-CoV spike protein epitopes in unexposed individuals. In! hill 21, 63-71 (2009).
83. He, Y., Zhou, Y., Siddiqui, P., Niu, J. & Jiang, S. Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus. J Clin Microbial 43, 3718-3726 (2005).
84. He, Y. et at. Mapping of antigenic sites on the nucleocapsid protein of the severe acute respiratory syndrome coronavirus. J Clin Microbial 42, 5309-5314 (2004).
85. de Sena Brandine, G. & Smith, A. 1). Falco: high-speed FastQC emulation for quality control of sequencing data. F1000Res 8, 1874 (2019).
86. Ewels, P., Magnusson, M., Lundin, S. & Miler, M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics 32, 3048 (2016).
87. Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods 14, (2017).
88. Frankish, A. et al. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res 47, D766-D773 (2019).
89. Soneson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq:
transcript-level estimates improve gene-level inferences. F1000Res 4, 1521 (2015).
90. Koster, J. & Rahmann, S. Snakemake a scalable bioinformatics workflow engine.
Thoinfarmatics 34, 3600-3600 (2018).
91. Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. PNAS 102, 15545-15550 (2005).
92. Zhao J, Zhao J, Mangalam Ashutosh K, Channappanavar R, Fett C, Meyerholz David K, et al. Airway Memory CD4+ T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. Immunity. 2016;44(6): 1379-91.
93. Li CK-f, Wu H, Yan H, Ma S, Wang L, Zhang M, et al. T Cell Responses to Whole SARS Coronavirus in Humans. The Journal of Immunology. 2008;181(8):5490.
94. Janice Oh H-L, Ken-En Gan S, Bertoletti A, Tan Y-J. Understanding the T
cell immune response in SARS coronavirus infection. Emerging Microbes & Infections.

2012;1(1):1-6.
95. Ren Y, Zhou Z, Liu J, Lin L, Li S, Wang H, et al. A Strategy for Searching Antigenic Regions in the SARS-CoV Spike Protein. Genomics, Proteomics & Bioinformatics.
2003;1(3):207-15.
96. Li S, Lin L, Wang H, Yin J, Ren Y, Zhao Z, et al. The Epitope Study on the SARS-CoV
Nucleocapsi d Protein. Gen omi cs, Prc-)teomi cs & Rioinformatics.
2003;1(3):198-206.
97. Yang J, James E, Roti M, Huston L, Gebe JA, Kwok WW. Searching immunodominant epitopes prior to epidemic: HLA class II-restricted SARS-CoV
spike protein epitopes in unexposed individuals. International Immunology.
2009;21(1):63-71.
98. He Y, Zhou Y, Siddiqui P, Niu J, Jiang S. Identification of Immunodominant Epitopes on the Membrane Protein of the Severe Acute Respiratory Syndrome-Associated Coronavirus. Journal of Clinical Microbiology. 2005;43(8):3718.
99. He Y, Zhou Y, Wu H, Kou Z, Liu S. Jiang S. Mapping of Antigenic Sites on the Nucleocapsid Protein of the Severe Acute Respiratory Syndrome Coronavirus.
Journal of Clinical Microbiology. 2004;42(11):5309.
100.Fahmer JE, Lahmar I, Goubet AG, Haddad Y, Carrier A, Mazzenga M, Drubay D, Alves Costa Silva C; Lyon COVID Study Group, de Sousa E, Thelemaque C, Melenotte C, Dubuisson A, Geraud A, Ferrere G, Birebent R, Bigenwald C, Picard M, Cerbone L, Lerias JR, Laparra A, Bernard-Tessier A, Kloeckner B, Gazzano M, Danlos FX, Terrisse S, Pizzato E, Flament C, Ly P, Tartour E, Benhamouda N, Meziani L, Ahmed-Belkacem A, Miyara M, Gorochov G, Barlesi F, Trubert A, Ungar B, Estrada Y, Pradon C, Gallois E, Pommeret F, Colomba E, Lavaud P, Deloger M, Droin N, Deutsch E, Gachot B, Spano JP, Merad M, Scotte F, Marabelle A, Griscelli F, Blay JY, Soria JC, Merad M, Andre F, Villemonteix J, Chevalier ME, Caillat-Zucman S, Fenollar F, Guttman-Yassky E, Launay 0, Kroemer G, La Scola B, Maeurer M, Derosa L, Zitvogel L. The Polarity and Specificity of Antiviral T
Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals. Cancer Discov. 2022 Apr 1;12(4):958-983. doi: 10.1158/2159-8290.CD-21-1441. PMID: 35179201.

Claims (43)

100

1. A method for in vitro determining whether an individual is likely to resist to an infection by SARS-CoV-2, comprising:
(i) generating dendritic cells (DC) from monocytes obtained from said individual;
(ii) loading said DC with a SARS-CoV-2 lysate or SARS-CoV-2 antigens;
(iii) contacting peripheral blood lymphocytes (PBL) from said individual with the DC obtained in step (ii), in appropriate conditions to activate said PBL;
(iv) following the PBL activation, measuring the expression of at least one cytokine secreted by Th1 cells, selected from the group consisting of IL-2, I FNy and TNFa, and measuring the expression of at least one cytokine secreted by Th2 cells, selected from the group consisting of IL-5, IL-4, IL-9, IL-10 and IL-13; and (v) from the results of step (iv), assessing the Th1/Th2 polarization of SARS-CoV-2-specific memory T cell response in said individual, wherein a Th1 polarization indicates that the individual is likely to resist to an infection by SARS-CoV-2, and a Th2 polarization indicates that the individual is susceptible to an infection by SARS-CoV-2.

2. The method of claim 1, wherein in step (iv), the expressions of IL-2 and IL-are measured, and in step (v), the ratiolL2/1L-5 is calculated, wherein IL2/1L5>1 indicates that the individual is likely to resist to an infection by SARS-CoV-2, and 11_2/1L51 indicates that the individual is susceptible to an infection by SARS-CoV-2.

3. A method for in vitro determining whether an individual is likely to resist to an infection by SARS-CoV-2, comprising incubating T lymphocytes from said individual with a mix of antigenic peptides from SARS-CoV-2, under conditions appropriate to stimulate Th1 and/or Th2 lymphocytes specific for said peptides; and (ii) assessing the presence of Thl and/or Th2 lymphocytes;
wherein the presence of Th1 lymphocytes specific for said peptides indicates that the individual is likely to resist to an infection by SARS-CoV-2, and/or the absence of Th1 lymphocytes and/or the presence of Th2 lymphocytes specific for said peptides indicates that the individual is susceptible to an infection by SA RS-CoV-2.

4. The method of claim 3, wherein the mix of antigenic peptides comprises:
- at least five peptides of 9 to 50 aminoacids, preferably 12 to 25 aminoacids, frorn a sequence consisting of aminoacids 331 to 555 of a SARS-CoV-2 spike protein; and - at least one, preferably at least two or at least three peptides of 9 to 50 aminoacids, preferably 12 to 25 aminoacids, from a SARS-CoV-2 nucleocapsid protein.

5. The method of claim 3 or claim 4, wherein the mix of antigenic peptides comprises:
- at least five peptides of 9 to 50 aminoacids, preferably 12 to 25 aminoacids, frorn a sequence consisting of aminoacids 361 to 555 of a SARS-CoV-2 spike protein, wherein at least one or two of said peptides are preferably from a sequence consisting of aminoacids 361 to 495 of a SARS-CoV-2 spike protein and at least one or two of said peptides are preferably from a sequence consisting of aminoacids 466 to 555 of a SARS-CoV-2 spike protein; and - at least two, preferably at least 3 peptides of 9 to 50 aminoacids, preferably 12 to 25 aminoacids, from a sequence consisting of aminoacids 1 to 135 of a SARS-CoV-2 spike protein.

6. The method of any of claims 3 to 5, wherein the mix of antigenic peptides further comprises:
- at least one, preferably at least two or at least three peptides of 9 to 50 aminoacids, preferably 12 to 25 aminoacids, from a sequence consisting of aminoacids 1 to 270 of a SARS-CoV-2 nucleocapsid protein; and/or - at least one, preferably at least two or at least three peptide of 9 to 50 aminoacids, preferably 12 to 25 aminoacids, from a sequence consisting of aminoacids 331 to 419 of a SARS-CoV-2 nucleocapsid protein; and/or - one peptide of 9 to 50 aminoacids, preferably 12 to 25 aminoacids, from a SARS-CoV-2 ORF3a_AB protein, preferably consisting of or encompassing a sequence consisting of aminoacids 244 to 258 of said SARS-CoV-2 ORF3a_AB protein; and/or - at least two peptides of 9 to 50 aminoacids, preferably 12 to 25 aminoacids, frorn a sequence consisting of aminoacids 856 to 1050 of a SARS-CoV-2 spike protein.

7. The method of any of claims 3 to 6, wherein the mix of antigenic peptides further comprises:
- at least one peptide of 9 to 50 aminoacids, preferably 12 to 25 aminoacids, from a sequence consisting of aminoacids 1 to 165 of a SARS-CoV-2 spike protein; and/or - at least one peptide of 9 to 50 aminoacids, preferably 12 to 25 aminoacids, from a SARS-CoV-2 ORF10 protein; preferably from a sequence consisting of aminoacids 1 to 22 of a SARS-CoV-2 ORF10 protein and/or - at least one peptide of 9 to 50 aminoacids, preferably 12 to 25 aminoacids, from a SARS-CoV-2 ORF8 protein, preferably from a sequence consisting of aminoacids 1 to 36 or 99 to 121 of a SARS-CoV-2 ORF8 protein.

8. The method of any of claims 3 to 7, wherein in step (i), T lymphocytes are incubated with the mix of antigenic peptides from SARS-CoV-2 in the presence of IL-2 and IL-15; and in step (ii), the presence of Thl lymphocytes is assessed by measuring the production of IFNy and/or the presence of Th2 lymphocytes is assessed by measuring the production of at least one cytokine selected from IL-5, IL-4, IL-6, IL-9 IL-10 and IL-13.

9. The method of any of claims 3 to 7, wherein in step (i), T lymphocytes are incubated with the mix of antigenic peptides from SARS-CoV-2 in the presence of low doses of IL-2 or IL-15, or PMA/ionomycine, or low dose of anti CD3/anti CD28 antibodies to sensitize the TCR, in addition to IL-4 and/or anti-IL12 antibodies; and in step (ii), the presence of Th2 lymphocytes is assessed by measuring the production of at least one cytokine selected from IL-5, IL-9, IL-10 and IL-13.

10. The method of any of claims 3 to 9, wherein the method is performed in at least one recipient that contains a mix of peptides which are common to all known strains of SARS-CoV-2 or induce cross-reactive immunity.

11. The method of any of claims 3 to 10, wherein the mix of peptides is dispatched in several recipients for performing the method, wherein at least one recipient contains a mix of peptides which are common to all known strains of SARS-CoV-2 or induce cross-reactive immunity, and at least another recipient comprises a mix of peptides which are specific for one or more SARS-CoV-2 variant(s).

12. The method of claim 10 or claim 11, wherein detection of Th1 lymphocytes in said at least one recipient containing a mix of peptides which are common to all known strains of SARS-CoV-2 indicates that the individual is likely to resist to an infection by any SARS-CoV-2 strain.

13. The method of any of claims 3 to 12, for assessing whether an individual is likely to resist to an infection by a variant strain of SARS-CoV-2, wherein the method is performed with a mix of peptides comprising only peptides present in the proteins of said variant strain.

14. A method for monitoring the efficacy of a vaccination against SARS-CoV-2 in an individual, comprising performing the method of any of claims 1 to 13 with a biological sample from said individual.

15. Use of the method according to any one of claims 1 to 14, to monitor the efficacy of a vaccination against SARS-CoV-2 in an individual.

16. An immunogenic composition comprising, in one or several polypeptides, the epitopes present in a sequence corresponding to amino acids 331 to 525 of a SARS-CoV-2 spike protein, as well as the epitopes present in a sequence corresponding to amino acids 1 to 165 of a SARS-CoV-2 spike protein.

17. The imrnunogenic composition of claim 16, comprising a first polypeptide sequence comprising amino acids 331 to 525 of a SARS-CoV-2 spike protein, and a second polypeptide sequence comprising amino acids 1 to 165 of a SARS-CoV-2 spike protein, wherein said first and second polypeptide sequences are in the same polypeptide molecule or in separate polypeptides.

18. The immunogenic composition of claim 17, wherein said first polypeptide sequence consists of amino acids 331 to 525 of a SARS-CoV-2 spike protein, and/or the second polypeptide sequence consists of amino acids 1 to 165 of a SARS-CoV-2 spike protein.

19. The imrnunogenic composition of claim 16 or claim 17, wherein the first polypeptide sequence consists of amino acids 331 to 600 of a SARS-CoV-2 spike protein or a fragment thereof, and/or the second polypeptide sequence consists of amino acids 1 to 270 of a SARS-CoV-2 spike protein or a fragment thereof.

20. The immunogenic composition of any of claims 17 to 19, further comprising a 3rd polypeptide sequence comprising amino acids 1 to 270 of a SARS-CoV-2 nucleocapsid protein, and/or a 4th polypeptide sequence comprising amino acids 244 to 258 of a SARS-CoV-2 ORF3a_AB protein, and/or a 5th polypeptide sequence comprising amino acids 29 to 92 of a SARS-CoV-2 ORF8 protein, and/or a 6th polypeptide sequence comprising amino acids 1 to 36 of a SARS-CoV-2 ORF8 protein, and/or a Ph polypeptide sequence comprising amino acids 22 to 38 of a SARS-CoV-2 ORF10 protein, wherein said 3rd, 4th, 6th, 6th and/or 7th polypeptide sequences are in the same polypeptide molecule as the first and/or second polypeptide sequences or are in one or several separate polypeptide(s).

21. The immunogenic composition of any of claims 16 to 20, which does not comprise the peptide LVRDLPQGFSALE (SEQ ID No: 377).

22. The immunogenic composition of any of claims 16 to 21, which does not comprise the peptide DVRVVLDFI (SEQ ID No: 178).

23. The immunogenic composition of any of claims 16 to 22, which does not comprise the peptide LLNKHIDAY (SEQ ID No:275).

24. The immunogenic composition of any of claims 16 to 23, which does not comprise the peptide IELCVDEAG (SEQ ID No:305).

25. The immunogenic composition of any of claims 16 to 24, which does not comprise the peptide MKFLVFLGIITTV (SEQ ID No: 378).

26. A nucleic acid molecule encoding the polypeptides defined in any of claims to 25.

27. The nucleic acid molecule, which is a RNA molecule.

28. An immunogenic composition comprising the nucleic acid molecule of claim or claim 27.

29. The immunogenic composition of claim 28, comprising a viral vector.

30. A vaccine, comprising the immunogenic composition of any of claims 16 to and 28 to 29, as well as a pharmaceutically acceptable excipient and/or adjuvant.

31. The vaccine of claim 30, comprising at least one adjuvant selected from the group consisting of TLR4 agonists, TLR3 ligands/ agonists, TLR7-8 agonists and TLR9 agonists.

32. The vaccine of claim 30 or 31, comprising at least one adjuvant selected from the group consisting of lipopolysaccharides, MPL: 3-0-desacy1-4'-monophosphoryl lipid A derived from Salmonella minnesotta LPS, poly A :U, poly! :C, IMIQUIMOD, CpG DNA and CpG ODNs.

33. An immunogenic composition comprising a polypeptide comprising the sequence LDSKVGGNY (SEQ ID No: 262), or a nucleic acid encoding the same, for use in the treatment of cancer.

34. The immunogenic composition of claim 33, for use in the treatment of a cancer overexpressing Tensin-1.

35. The immunogenic composition of claim 34, for the use of claim 33 or 34, wherein said cancer is a pancreas adenocarcinoma or a colon adenocarcinoma.

36. The immunogenic composition of claim 33, for the use of claims 33 to 35, wherein said polypeptide comprises the sequence NSNNLDSKVGGNY (SEQ
ID No: 379).

37. The method of any of claims 3 to 13, wherein the Th1 response is assessed using a first mix of peptides comprising at least 3, 4, 5, 6 or more peptides relevant for assessing Th1 response against SARS-CoV-2 and the Th2 response is assessed using a second mix of peptides comprising at least 3, 4, 5, 6 or more peptides relevant for assessing Th2 response against SARS-CoV-2.

38. The method of claim 37, wherein said first and second mixes of peptides are present in separate recipients/tubes.

39. The method of claim 37 or claim 38, wherein in step (ii) of the method, the presence of Thl lymphocytes is assessed by measuring the production of IFNy in the recipient comprising the first mix of peptides and the presence of Th2 lymphocytes is assessed by measuring the production of at least one cytokine selected from IL-5, IL-4, IL-9, IL-10 and IL-13 (preferable IL-5) in the recipient comprising the second mix of peptides.

40. The method of any of claims 3 to 13 and 37 to 39, wherein the absence of Thl after incubation of the T lymphocytes with a mix of peptides covering a sequence comprising amino acids 331 to 525 and/or amino acids 329 to 521 and/or amino acids 391 to 555 of a SARS-CoV-2 spike protein indicates that the individual is susceptible to an infection by SARS-CoV-2 and its variants.

41. The method of any of claims 3 to 13 and 37 to 40, wherein the presence of a Th2 response combined to the absence or weak presence of Th1 after incubation of the T lymphocytes with a mix of peptides covering a sequence comprising amino acids 331 to 525 and/or amino acids 329 to 521 and/or amino acids 391 to 555 of a SARS-CoV-2 spike protein indicates that the individual is susceptible to an infection by SARS-CoV-2 and its variants.

42. The method of any of claims 3 to 13 and 37 to 41, wherein the presence of a Th1 response after incubation of the T lymphocytes with a mix of peptides covering a sequence comprising amino acids 331 to 525 and/or amino acids 329 to 521 and/or amino acids 391 to 555 of a SARS-CoV-2 spike protein indicates that the individual is likely to resist to an infection by SARS-CoV-and its variants.

43. The method of any of claims 3 to 13 and 37 to 42, wherein the presence of a Th1 response after incubation of the T lymphocytes with a mix of peptides comprised in a sequence consisting of amino acids 1 to 135 of a SARS-CoV-2 spike protein indicates that the individual is likely to resist to an infection by SARS-CoV-2 and its variants, only if a Th1 response has also been obtained against another part of the virus, e.g. against peptides of the nucleocapsid.